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The aim of this project was to first investigate the binding preferences of collagen 
binding integrins (α1β1, α2β1, α10β1 and α11β1), and to then assess their role in the 
regulation of endothelial cell (EC) behaviour using human umbilical vein endothelial cells 
(HUVECs). First, quantitative real-time polymerase chain reaction (qPCR) was performed to 
quantify the expression levels of the four integrins. Functional roles of these integrins were 
then investigated using commercially available inhibitors (TC-I-15, Obtustatin and 6F1) to 
modulate integrin function, and small interfering RNA (siRNA) to reduce expression levels.  
qPCR demonstrates that α2 is the most abundant receptor subunit transcript in HUVECs 
followed by α10 and α1; α11 was barely detectable. After integrin inhibition or knockdown, 
functional assays measuring changes in proliferation, apoptosis, adhesion, migration and 
angiogenesis were carried out. 
Synthetic triple helical collagenous peptides (THPs), based on the canonical GFOGER 
amino acid sequence, were used to probe the binding preferences of the integrins. Initially 
recombinant integrin αI-domains were studied, before utilising C2C12 cell lines stably 
expressing the full-length integrin receptors. The four integrins showed very similar, 
overlapping, binding profiles, with α1β1 and α10β1 binding strongly to GLOGEN motifs and 
moderately to GFOGER, and α2β1 and α11β1 binding strongly to GFOGER and moderately to 
GLOGEN.  
The specificities of the inhibitors TC-I-15, Obtustatin, and 6F1, for different integrins 
were characterised using static adhesion assays and real-time xCELLigence adhesion assays. 
TC-I-15 showed cross-reactivity between α1β1 and α2β1 and inhibited both receptors, 
Obtustatin was specific to α1β1 only and 6F1 was specific to α2β1. No cellular toxicity was 
observed for any of these inhibitors. siRNA was optimised to efficiently and selectively target 
each receptor and 90% knockdowns of α1β1, α2β1 and α10β1 mRNA were achieved in 
HUVECs.  
Functional assays were carried out downstream of integrin inhibition or siRNA 
treatment. HUVEC proliferation, measured by cell number quantification and 5-ethynyl-2’-
deoxyuridine (EdU) incorporation analysis, was unaffected by inhibition or siRNA knockdown 
of any integrin receptor. Knockdown or inhibition of α2β1 severely hindered HUVEC 
 
 
attachment and spreading to collagen and THPs, measured by static and real-time adhesion 
assays. Cell migration, in time-lapse microscopy random movement assays, was also impaired 
after either knockdown or inhibition of α2β1. In addition, inhibition of α2β1 using TC-I-15 and 
6F1 impeded angiogenesis in tube formation assays on a Geltrex substrate. However, siRNA 
knockdown of α2β1 had no effect on tube formation. This observation highlights the 
differences in signalling events between inhibiting a receptor that is present and simply lacking 
the receptor altogether. No compensatory upregulation of other α-subunits was observed. 
In conclusion, the inhibition or knockdown of integrin α2β1 has a significant effect on 
the behaviour of HUVECs. In contrast, inhibition or knockdown of α1β1 and α10β1 does not 
significantly affect HUVEC cellular response. Additionally, the results presented here suggest 
that inhibitors and antibodies targeting collagen-binding integrins must be rigorously tested 
for cross-reactivity before use. Finally, these findings show that TC-I-15 could have an 
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1.1 Chapter Summary 
 This chapter aims to give a detailed background understanding and literature review of 
endothelial cell (EC) behaviour and function with an emphasis on the interactions between ECs  
and their extracellular matrix (ECM) and how this relates to  the regulation of EC behaviour. 
The integrin family of adhesion receptors is described in detail with respect to ECs and the 
regulation of EC behaviour.  
1.2 Endothelial Cells 
 The vascular endothelium consists of a thin monolayer of ECs that line all blood vessels 
in the body, from arteries to veins to capillaries (Figure 1.1) and is paramount in regulating 
blood flow and maintaining tissue homeostasis[12]. The endothelium provides a physical barrier 
between the solutes in the blood and the surrounding tissues and has been implicated in the 
regulation of fluid filtration, haemostasis, neutrophil trafficking, hormone trafficking, 
thrombosis and platelet activation. EC dysfunction has been implicated in stroke, heart disease, 
vascular diseases, diabetes, chronic kidney failure, cancer, atherosclerosis and infectious 
diseases[12-14]. ECs interact with macrophages, platelets, monocytes, clotting factors and 
signalling molecules; these interactions are often dynamic and complex. Signal transduction 
Chapter 1 – Introduction 
15 
 
between the Extracellular Matrix (ECM) and EC monolayer is an important regulator of EC 
behaviour in each of these functions[15]. ECs are reactive, multifunctional and highly sensitive 
to physiological conditions. While generally quiescent, ECs can also exist in inflammatory, 
thrombotic or angiogenic phenotypes[9, 16, 17]. 
1.3 Endothelial Cell Development 
The endothelium is critical to the transport of metabolites and the removal of waste 
products from tissues, therefore the vascular circulatory system is the first organ to develop in 
vertebrate embryos by a process termed vasculogenesis[18]. Much of what is known about 
vasculogenesis comes from murine, zebrafish and avian embryonic studies due to the difficulty 
in obtaining ethical approval for studying human embryos. In early mouse embryonic 
development, bone morphogenic protein (Bmp)4 promotes the formation of the mesoderm. 
Endothelial cell precursors are then formed by the differentiation of mesoderm into clusters 
of hemangioblasts, induced by basic fibroblast growth factor (bFGF) and activin A[19-23]. 
Peripheral hemangioblasts differentiate into angioblasts which in turn aggregate, coalesce and 
form endothelial cell tubes with a lumen[18] while central hemangioblasts differentiate into 
hematopoietic stem cells and smooth muscle cells[21]. Shear stress, the physical friction created 
by the flow of blood across the EC surface, is thought to play a role in EC differentiation[21]. In 
mouse embryoid-body derived cells, shear stress induces platelet endothelial cell adhesion 
molecule (PECAM-1, also called CD31) expression in vitro, a key component of intercellular 
junctions in ECs[24]. In mouse embryos shear stress is necessary for the vascular remodelling of 
the yolk sac[25]. In human and murine embryos Bmp4 and Indian hedgehog (IHH) are thought 
to promote endothelial differentiation[26-28]. While in zebrafish, prostaglandin-E2 is thought to 
promote endothelial maturation[29]. Mutations in pathways required for vascular 
development, for example, Notch[30], vascular endothelial growth factor (VEGF)[31-33] and 
Angiopoietin (Ang)/Tie signalling[34], often result in vascular defects that ultimately result in 
embryonic lethality in mice, highlighting the importance of correct vascular development. 
Integrins play major roles in embryonic development and cell differentiation. As a result 
knockout (KO) of the β1 integrin subunit results in embryonic death[35]. 
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1.3 Endothelial Structure and Function 
 ECs can be characterised by the expression of several markers. These include PECAM-
1, Von Willebrand factor (VWF), vascular endothelial-cadherin (VE-Cad), melanoma cell 
adhesion molecule (MCAM, also known as CD146) and vascular endothelial growth factor 
receptor-2 (VEGFR2) (reviewed in[36]). PECAM-1 is a mechanotransducer glycoprotein 
expressed on the surface of ECs, monocytes and platelets. In ECs it regulates vascular 
permeability and transduces mechanical signals inside the cell[37]. VE-Cad is another 
mechanotransducer that also regulates cell-cell adhesion in ECs to modulate monolayer 
permeability[38]. VWF is expressed and stored in secretory vesicles called Weibel-Palade Bodies 
Adapted from ‘Evolving functions of endothelial cells in inflammation’ by Pober et al, 2007[9]. In this 
diagram, a) gives an overview of EC function and vessel structure common to all blood vessels. 
Various signalling molecules relevant to the maintenance of vascular tone are shown. For example 
TFP1 is an inhibitor of platelet activation and thrombus formation. NO is nitric oxide, which is 
synthesised by NOS3 and secreted by endothelial cells to relax smooth muscle cells. VWF is shown 
stored in endothelial cells in WPBs. Anti-thrombin is shown bound to thrombin to inhibit thrombin 
activation of platelets. b) shows the vessel structure in arterioles where ECs release NO to relax 
smooth muscle cells, c) shows capillaries which are the smallest vessels containing just ECs and 
pericytes and d) shows venules where lymphocytes and neutrophils are most active. 
Figure 1.1: Diagram of Vessel Structure. 
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(WPBs) inside ECs. These show up clearly as granular spots in the cytoplasm of ECs in 
fluorescence microscopy when staining for VWF. WPBs can also contain P-Selectin, interleukin 
(IL)-8, angiopeoietin-2 (Ang2), endothelin-1, tissue-type plasminogen activator and CD63, 
suggesting an important role in the regulation of inflammatory pathways[39-45]; they allow the 
rapid release of signalling molecules and cytokines in response to changes in the EC 
microenvironment.  
Endothelial cells are flat, polarised, and will align depending on the direction of blood 
flow. They can also remodel their alignment in response to altered flow direction induced by 
surgical realignment of cells[46]. One important function of ECs is to form a semi-permeable 
monolayer that regulates the controlled transport of metabolites and waste products between 
the blood and the surrounding tissues, contributing to the control of tissue homeostasis[47]. 
ECs control the paracellular transport of metabolites, notably via the opening and closing of 
cell-cell junctions, of which there are three main types; tight junctions (TJs), gap junctions (GJs) 
and adherens junctions (AJs)[48]. Some endothelial cells also utilize specialised vesicle transport 
systems called vesiculo-vacuolar organelles (VVOs)[49], transendothelial channels or caveolae 
(Figure 1.1 C). TJs, AJs and GJs are similar in that they are formed of clusters of transmembrane 
proteins associated with a cytoplasmic plaque comprised of scaffolding proteins, signalling 
molecules and cytoskeleton components[50]. These junctions link the cytoskeleton and the cell 
membrane and can transduce signals to and from the cell.  
TJs consist of tetraspan transmembrane proteins, such as occludins, tricellulin and 
claudins, and single span transmembrane proteins such as junctional adhesion molecules 
(JAMs) -A, -B -C and -D[48]. There are 24 claudins, expressed in a tissue specific manner. Their 
extracellular loop structure creates charge-selective channels that determine the ion 
selectivity of the paracellular barrier[51, 52]. JAMs regulate the leukocyte adhesion and 
transmigration across the endothelium and contribute to the formation of cell polarity[53, 54]. In 
addition to regulating paracellular permeability, TJs also supress proliferation via the 
interaction between ZO-1 and ZONAB and the suppression of Raf-1 signalling by occludin[55, 56]. 
Endothelial AJs contain VE-Cad anchored to the cytoskeleton by β-catenin and plakoglobin[48, 
57], alongside other actin-binding proteins like vinculin and α-actinin[58]. AJs can be destabilised 
by the Proto-oncogene tyrosine-protein kinase (Src)-facilitated phosphorylation and 
subsequent ubiquitin-mediated internalisation of VE-Cad[59, 60], whereas Ang-1 or basic 
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fibroblast growth factor (bFGF) can inhibit VE-Cad internalisation and help maintain vascular 
integrity[61, 62].  
Healthy, resting endothelium secretes basal levels of nitric oxide (NO) continuously[16, 
63]. This NO synthesis and subsequent release from the endothelium is increased in response 
to a variety of molecules, such as, acetylcholine, histamine, thrombin, serotonin, ADP, 
bradykinin or norepinephrine as well as in response to shear stress[16, 64, 65]. ECs generate NO 
from L-arginine and NADPH using the enzyme Endothelial NO Synthase (eNOS) which exists in 
two isoforms: a constitutively active, calcium-dependent isoform and a cytokine-inducible 
Ca2+-independent isoform[63, 66]. NO relaxes vascular tone and maintains vascular homeostasis 
in a variety of ways. For example, NO relaxes vascular smooth muscle by activating guanylate 
cyclase, resulting in increased cGMP, which in turn decreases smooth muscle Ca2+ levels to 
promote vasodilation[64, 67]. NO released into the lumen inhibits platelet activation to maintain 
a quiescent state of anti-coagulation[68, 69]. NO also inhibits the adhesion of leukocytes to the 
vessel wall by modulating the expression or function CD11/CD18 on the surface of 
leukocytes[70]. ECs also secrete prostacyclin which inhibits platelet adhesion to the vessel 
wall[71]. In this relaxed state, ECs facilitate the transport of metabolic molecules across the 
endothelium, regulate vascular tone and contribute to lipid homeostasis, summarised in Figure 
1.1 b and 1.1 d.  
Conversely, Tumor Necrosis Factor-α (TNFα), Lipopolysaccharides (LPS), Histamine, C-
Reactive Protein (CRP), IL-1/-6/-8 and Thrombin all elicit an inflammatory or pro-coagulant 
response from the endothelium where release of p-selectin, VWF and other signalling 
molecules from WPBs results in platelet activation, adhesion and ultimately, thrombosis[12]. 
Because this pro-inflammatory phenotype can be induced by vascular injury, leukocyte 
adhesion is also increased to promote immune function at sites of injury; vascular cell adhesion 
molecule (VCAM) and intercellular adhesion molecule (ICAM) are both leukocyte receptors 
expressed on activated ECs[72]. VWF is a glycoprotein involved in blood clotting; a deficiency in 
VWF causes Von Willebrand Disease (VWD) characterised by delayed clot formation and 
prolonged bleeding[73]. VWF contains collagen binding domains, platelet binding domains and 
multimerization domains[73]. VWF polymerises, head-to-head and tail-to-tail, into long tubular 
structures in WPBs where it is stored until endothelial activation or vessel wall injury. Once 
secreted and under flow, VWF unfolds and the multimers act as a rope that catches and tethers 
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circulating platelets to collagen that is exposed at sites of vascular injury[73, 74]. Platelets are 
anuclear cellular fragments derived from megakaryocytes that aggregate when activated and 
contribute to blood clot formation in the coagulation cascade described below[74]. Platelets are 
activated by their binding to VWF through their platelet glycoprotein 1b (GP1b)-V-IX complex, 
and the binding of platelet α2β1 and glycoprotein VI (GPVI) to collagen. Platelet interaction 
with all three proteins leads to platelet aggregation and thrombus formation[74]. Thromboxane 
and ADP released from damaged ECs also activates platelets[75]. VWF may also contribute to 
the regulation of angiogenesis. siRNA knockdown (KD) of VWF resulted in increased 
angiogenesis in HUVECs, alongside increased angiopoietn-2 and increased VEGF dependent 
proliferation and migration. The same study found increased vascularisation in VWF deficient 
mice[76].  
The coagulation cascade involves a large number of proteins and enzymes called 
clotting factors (f), some of which are named using roman numerals here, for example, factor 
VIIa becomes fVIIa (where the a denotes the activated form). Fibrinogen is also called fI, 
prothrombin is fII and VWF is fXVI. Many of the clotting factors exist as inactive precursors that 
are activated by proteolytic processing and, when activated, exhibit proteolytic function 
themselves[77]. One pathway of the coagulation cascade starts with an inactive integral 
membrane protein called tissue factor (TF) or fIII which associates with fVIIa in blood plasma 
to form an active serine protease enzyme. This enzyme in turn activates coagulation by 
converting fIX to fIXa and fX to fXa[77]. These associate with fVIIIa and fVa respectively, leading 
to the release of thrombin, which processes fibrinogen to fibrin and directly activates 
platelets[77]. Fibrin freely associates to form fibrin clots, which will aggregate platelets and 
contribute to the clot formation[77]. Activated platelets undergo morphological changes, which 
increase their surface area, and release α- and Dense granules[74]. The α-granules contain P-
selectin, fibrinogen, fibronectin, fV, fVIII, PDGF and TGFα. Dense granules contain ATP, ADP, 
calcium, serotonin, histamine and epinephrine[78]. TF is found in the membrane of many cells, 
including cells that surround larger blood vessels and keratinocytes in the skin, to form a 
protective haemostatic layer around blood vessels[79]. The coagulation cascade is only started 
when many conditions are met. fVII must first be proteolytically converted to fVIIa, TF in the 
membrane of non-endothelial cells must then be in contact with blood plasma to pick up fVIIa, 
phospholipids are required for the binding of fIX and fX and damaged cell membranes are more 
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likely to contain the active TF:fVIIa complex (reviewed in[77]). Conversely, tissue factor pathway 
inhibitor (TFPI) is expressed in resting ECs as two isoforms, TFPIα and TFPIβ. TFPIα is secreted 
and TFPIβ is expressed on the cell surface[80]. TFPI potently inhibits fVIIa[81] and fXa[82] and so 
impedes two early stages of coagulation to regulate hemostasis[83].   
Endothelial homeostasis between these pro- and anti-coagulation states is vital to 
maintaining a healthy vasculature; de-regulation of these cell behaviours in EC dysfunction 
contributes to hypertension and atherosclerosis, pathological thrombosis, stroke and 
infarction[14]. One example of EC dysfunction is characterised by unregulated, chronic 
endothelial activation accompanied by a loss of anti-thrombotic signalling, whereby ECs switch 
to a pro-inflammatory or pro-coagulation state unnecessarily[17]. This chronic inflammation, 
like that found in rheumatoid arthritis, can contribute to atherosclerosis. This is a disease of 
blood vessels which is characterised by a build-up of oxidised low-density lipoprotein (oxLDL), 
ECM proteins, oxLDL activated macrophages and ECM-secreting vascular smooth muscle cells 
(VSMCs) in the vessel wall, called an atherosclerotic plaque[84]. The plaque is full of pro-
thrombotic molecules and can facilitate the aggregation of platelets, creating microthrombi. 
The plaque can rupture, releasing ECM proteins and microthrombi into the blood stream which 
can lead to vessel blockages and stroke[84]. EC dysfunction contributes to atherosclerosis by 
upregulating the expression of platelet and leukocyte adhesion molecules on the EC surface[17, 
85]. Additionally, the decrease in NO seen in EC dysfunction results in increased VSMC 
proliferation[86], increased vasoconstriction and increased platelet and leukocyte adhesion to 
vessel walls, further contributing to atherosclerotic plaque build-up in blood vessels and 
reducing blood flow[87]. Inflammatory mediators can also increase EC expression of TF[77], which 
increases the likelihood of the coagulation cascade being triggered and erroneous blood clot 
formation in pathological thrombosis. Sustained chronic inflammation can result in apoptosis 
or detachment of ECs into the blood stream in endothelial dysfunction; high levels of TNFα can 
stimulate apoptosis via decreased p53 and increased p73[88]. These detached Circulating ECs 
(CECs) or EC microparticles released from apoptotic ECs, are elevated in peripheral blood from 
patients with myocardial infarction[89, 90]. CEC quantification can then be used in the 
assessment of EC dysfunction[91-93] or vascular injury[94]. When ECs are activated in 
inflammatory conditions, the surface expression and subsequent release of VCAM1, ICAM1 
and E-selectin is increased, providing another way to determine EC dysfunction[95-97].  
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EC damage can be repaired to an extent by circulating endothelial progenitor cells 
(CEPCs) which have a higher proliferative potential and are derived from bone marrow; CEPCs 
migrate to sites of injury where damaged ECs have detached and proliferate to repair the 
endothelium[98, 99]. CEPCs are distinct from CECs and express immature markers CD34 and 
CD133 whereas CECs and mature ECs express markers of endothelial maturity MCAM and are 
negative for CD133[99-102]. Elevated CECs or CEPCs in peripheral blood have been found in a 
wide range of cancers including lymphoma, melanoma and glioma, in breast, colonic gastric, 
oesophageal, ovarian, testicular and prostate among others[103-107]. These circulating ECs have 
angiogenic potential and could vascularise tumours, helping them to grow. 
Reactive oxygen species (ROS) are highly reactive free radicals such as the superoxide 
anion (O2-·), hydroxyl radical (HO·), nitric oxide radical (NO·) or hydrogen peroxide (H2O2). Low 
levels of ROS are generated normally during respiration and metabolism and they are essential 
signalling molecules[108]. However, increased ROS are produced alongside inflammation and 
injury. When the oxidative potential of ROS outstrips the endogenous anti-oxidant defence 
systems, these molecules become destructive and this is termed oxidative stress. Increased 
ROS concentrations will cause cell injury and eventually cell death[109]. In the endothelium high 
levels of ROS can increase vascular permeability[110, 111] and promote leukocyte adhesion[112, 
113] contributing to endothelial dysfunction. Increased ROS has been shown to decrease eNOS 
expression in bovine ECs[114], which could lead to a decrease in vasodilatory NO secretion and 
a tip towards an inflammatory phenotype. The ROS O2-· converts NO to peroxynitrite (ONOO-
·), another powerful oxidant. This decreases the bioavailability of NO, resulting in a decrease 
of NO signalling which would normally relax vascular tone and promote an anti-inflammatory 
state[115]. Additionally, in response to ROS, a number of proinflammatory genes are 
upregulated, further contributing to a pro-inflammatory and atherogenic phenotype[116]. The 
activation of pro-inflammatory pathways also results in increased ROS production which locks 
the ECs into a cycle of oxidative stress, damage and inflammation resulting in EC dysfunction 
and cardiovascular disease progression. ROS also oxidatively modify other molecules, such as 
lipoproteins and phospholipids, which when oxidised, contribute to atherogenesis[117]. Finally, 
ROS can result in eNOS damage, if the eNOS enzyme becomes dysfunctional it can uncouple 
oxygen reduction from NO synthesis which will result in further ROS production[116]. In 
conclusion, oxidative stress caused by increased ROS promotes an inflammatory phenotype 
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that contributes to atherogenesis, EC dysfunction and ultimately cardiovascular disease. Other 
risk factors that contribute to endothelial dysfunction include smoking, ageing, diabetes, 
hypertension, hypercholesteremia, obesity and chronic infection (reviewed in[118]).  
1.5 Endothelial Heterogeneity 
Endothelial cells are highly specialised and will differ in structure and expression profile 
depending on their source and function. For example arterial ECs will experience higher shear 
stress than venule ECs, large vessel ECs are surrounded by muscle whereas capillaries consist 
of ECs and often pericytes, which help maintain haemostasis and tissue homeostasis[119]. ECs 
convert shear stress into biochemical signals via mechanotransducers such as VEGFR2, PECAM-
1 and VE-Cad[37, 120]. The resulting biochemical signals activate transcription factors that 
maintain cell phenotype. One study[121] found that 285 genes were more abundant in 
Adapted from ‘Organotypic vasculature: From descriptive heterogeneity to functional 
pathophysiology’[1]. Diagram showing EC heterogeneity in capillaries with respect to capillary 
function and vascular permeability. A) shows continuous capillary structure surrounded by the basal 
lamina where vascular permeability is reduced in the presence of TJs. B) shows fenestrated 
capillaries with gaps between the ECs to allow increased vascular permeability. C) shows sinusoidal 
capillaries found in liver where the basal lamina is incomplete allowing for diffusion of molecules. D) 
shows the structure of the endothelium in the Schlemm’s canal where large vacuoles are present to 
allow for the transport of aqueous humor in the eye and E) shows vessel structure in HEVs, which 
are involved in lymphocyte migration. 
Figure 1.2: Diagram of Capillary Structure.  
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saphenous vein ECs (SVECs) than coronary artery ECs (CAECs), and that many of these genes 
were associated with atherosclerosis related pathways. 111 genes were upregulated in CAECs, 
relating to inhibitors of proliferation and lipid metabolism. The same study found that 
stimulation with low-density lipoprotein (LDL) induced greater changes in gene expression in 
CAECs than SVECs, again highlighting differences in functional response between different ECs. 
Additionally, CD36, a glycoprotein involved in the transport of fatty acids into cells, is expressed 
on HDMECs but not HUVECs[122]. 
Capillaries can be described as continuous, fenestrated and sinusoidal (Figure 1.2). 
Continuous capillaries are found ubiquitously including in the brain; they form a barrier that 
allows free diffusion of water, very small molecules and lipid soluble molecules with tightly 
controlled active transcytosis of larger molecules such as glucose (Figure 1.2A). Fenestrated 
capillaries, like those in the intestine, endocrine glands and kidneys, are more permeable and 
are filled with small pores (fenestrations) that allow free transport of larger molecules (Figure 
1.2B). Sinusoidal capillaries that have large gaps between cells and in the associated basal 
lamina which allow the free transport of larger molecules are found in the bone marrow, spleen 
and liver (Figure 1.2C). ECs in the anterior eye chamber acquire a Schelmm’s canal (Figure 1.2D) 
that allows fast transport of aqueous humour from the eye. Also, high endothelial venules 
(Figure 1.2E) found in lymphoid tissues[123] contain specialised cuboid ECs that facilitate 
lymphocyte migration (reviewed in[1]).  
Caveolae are flask-shaped invaginations in the membrane of many cell types, especially 
abundant in ECs, that are rich in cholesterol, glycosphingolipids and caveolins. Caveolae are 
important in cholesterol transport, endocytosis, potocytosis and cell signalling[124]. They are 
thought to be involved in the transportation of molecules across the EC monolayer. It is 
possible that caveolae fuse to form channels through some ECs. Muscle ECs contain many 
caveolae to facilitate the differentiation and transport of molecules to the muscle tissue 
whereas blood brain barrier (BBB) ECs contain very few caveolae as they need to tightly restrict 
the flow of solutes to the brain[125]. Caveolae are also far more prevalent in capillary ECs than 
in artery or vein endothelial cells[126]. It is thought that caveolae can fuse to form VVOs, which 
can form channels through ECs. VVOs are more prevalent in venule ECs[127]. Matrix 
metalloproteinases (MMPs) are a family of zinc-dependent endopeptidases and their 
expression also differs between ECs, HUVECs express higher levels of MMP1, 2 and the MMP 
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inhibitor, TIMP1, than neonatal foreskin ECs (NFECs) but after phorbol 12-myristate 13-acetate 
(PMA) stimulation, NFECs express much higher TIMP1 and MMP9 than HUVECs[128]. Tumour 
microvessels are generally more angiogenic and more permeable than normal blood vessels. 
This increased permeability is partly due to the increased presence of VVOs[129, 130]. ECs from 
the same tissue also show heterogeneity largely because they are adapted to constantly 
respond to temporal changes in the microenvironment, making them susceptible to variation. 
Therefore, it is vital to use the correct ECs to study different endothelial traits, for example 
HUVECs would be unsuitable for studying the BBB and large vessel artery ECs would be 
inappropriate for the study of glomeruli renal EC function. However, there are general traits 
shared by ECs, such as inflammatory response and angiogenic potential, and HUVECs can be 
used to study these. HUVECs are a useful tool for studying ECs due to their well-defined 
characteristics, availability affordability, human origin and robust endothelial phenotype. In 
addition, HUVECs can be obtained as pools from several donors, limiting batch-to-batch 
variability. HUVECs were chosen as model endothelial cells throughout this project[131, 132]. 
It is thought that some of the specialisation and differentiation in ECs is lost once they 
are isolated and cultured in vitro. In one study of rat lung ECs, 41% of plasma membrane 
proteins expressed in vivo are not detectable in vitro[133]. Another study found that 
characteristics specific to high endothelial venule ECs (HEVECs) isolated from tonsils were lost 
just two days after culturing in vitro, specifically, the venule-specific Duffy antigen receptor for 
chemokines (DARC), HEVEC-specific fucosyltransferase Fuc-TVII and type XV collagen[134]. 
Shear stress and haemodynamic forces contribute to the regulation of EC function and 
maintenance of EC phenotype; ECs will behave differently under still or flow conditions. 
Furthermore, ECs are generally quiescent, non-proliferative cells. The process of EC isolation 
and subsequent culture of cells can introduce changes in phenotype. Additionally, expansion 
of cells over multiple passages requires a transformation to a more proliferative phenotype. 
This could lead to some loss of differentiation and specialisation of ECs. Finally, culturing ECs 
alone does not take into account the impact of other cell types such as VSMCs, pericytes, red 
blood cells and immune cells that will all alter the microenvironment of the ECs and initiate 
changes in EC behaviour. All these points highlight important differences between in vitro and 
in vivo systems that must be considered when interpreting and extrapolating data. Despite 
their limitations, in vitro experiments are still a valuable tool when studying isolated pathways 
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and simplified biochemical interactions and are a great starting point. In contrast, in vivo assays 
are generally much longer, more complicated and more expensive but also allow for the study 
of complex systems in a more physiologically relevant system. This project focusses on in vitro 
studies of HUVECs as a starting point to investigating the effects of integrin modulation on 
HUVEC cell behaviour.  
1.6 Integrins 
Integrins are a family of 24 transmembrane cell adhesion receptors that form α/β 
heterodimers from 18-α subunits and 8 β-subunits (Figure 1.3). Their primary function is to 
facilitate adhesion of cells to each other and the ECM. They have an extracellular ‘head’ N-
terminal domain and a cytoplasmic ‘tail’ C-terminal domain, and mediate signal transduction 
between the ECM and the cytoplasm by linking outside signals to the cytoskeleton; they form 
bi-directional signalling hubs capable of integrating signals from multiple pathways[7, 135, 136]. 
Integrins interact and form clusters with co-receptors and other integrins to amplify signals[137]. 
Integrin expression is cell type-dependent, and most integrins bind a selection of ECM or cell-
surface ligands. They play essential roles in embryonic development, cell migration, 
proliferation and angiogenesis, and have been implicated in tumorigenesis and 
inflammation[138]. Figure 1.4 shows the general structure of integrin receptor heterodimers. 
Both α and β subunits have large extracellular domains with multiple subdomains. The α 
subunit has a β-propeller structure at the ‘head’ end, followed by ‘thigh’ and ‘calf’ domains, a 
transmembrane domain and finally a small cytoplasmic domain. The β subunit has a β-I-
domain, a PSI (plexin/semaphoring/integrin) domain, a hybrid domain, four epithelial growth 
factor (EGF) domains and a cystatin-like domain followed by a transmembrane domain and a 
small cytoplasmic tail.  
Nine of the integrin α subunits contain an αI-domain (Figure 1.4), an approximately 200 
amino acid insertion in the β propeller structure, that shares homology with VWF A domains. 
This αI-domain is a Rossman fold with five β sheets surrounded by seven α-helices. It contains 
a metal-ion-dependent adhesion site (MIDAS) that requires co-ordination of Mg2+ for the 
binding of the αI-domains to their ligand[7, 136]. Conformational changes take place in the αI-
domain when Mg2+ is present, allowing the αI-domain to bind to the relevant ligand. In the 
case of α2β1 a C-helix is also present around the MIDAS, creating a groove that can bind to a 
glutamate residue in collagen[8, 139].  The αI-domains show a lot of homology between integrins, 
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but the rest of the subunit is variable[7]. It is thought that cells express an excess of β-subunits 
and the expression of α-subunits determines surface receptor expression[140].  For the integrins 
that have an αI-domain, the α-subunit determines ligand specificity. The β-subunit is 
connected to the cytoskeleton and also contains an I-domain, termed a βI-domain, that 
contains a MIDAS, and a site that is adjacent to the MIDAS called the ADMIDAS[7].  
Integrins exist in active or inactive conformations. For example the platelet integrin 
αIIbβ3 exists in high density on the surface of platelets but in an inactive conformation[141], 
otherwise αIIbβ3 would bind circulating fibrinogen and could lead to unnecessary platelet 
activation, aggregation and thrombosis. Instead, αIIbβ3 is activated from within the platelet, 
allowing subsequent binding to VWF, fibrinogen and fibronectin[142]. A similar mechanism 
works with leukocytes; in resting leukocytes, the β2 subunits are inactive, only becoming 
activated under inflammatory conditions where they adhere to ICAM on the surface of ECs[143].  
Adapted from ‘Integrins’, Barczyk 2010 [7]. This diagram shows the entire mammalian integrin family 
and describes the heterodimers that are made from each class of monomers. The integrins are 
organised here by the ligands that they adhere to, or the cells they are specific to. 
Figure 1.3. Diagram of The Integrin family. 
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There are four known collagen-binding integrins, α1β1, α2β1, α10β1 and α11β1. All are 
thought to be expressed in ECs[7, 136], α1β1 and α2β1 also bind weakly to laminin[144, 145].  The 
range of pathways involving integrins highlights their importance in tissue function and 
homeostasis across a variety of organs, Table 1.1 summarises KO studies of each integrin and 
their effects on embryonic development. Some integrin KOs result in severe, embryonic lethal 
phenotypes (β1, α4, α5, β8, α3, α6, α8, αv, β4), some result in viable embryos with impaired 
leukocyte function (αL, αM, αE, β2, β7), or defects in inflammation (β6), haemostasis (αIIb, β3, 
α2), angiogenesis (α1, β3) or bone remodelling (β3) (reviewed in[120]). Whole organism ablation 
of β1 integrin in mice leads to embryonic fatal phenotype before E5.5[146] and EC specific 
This figure shows the 
structure of integrin 
heterodimers adapted 
from ‘The functional role 
of integrins during intra- 
and extravasation within 
the metastatic 
cascade’[3]. The α-
subunit is shown in blue 
with the β-propeller 
domain in grey. C1 and 
C2 denote the calf 
domains, metal ion 
binding sites are shown 
and labelled with the ion 
they bind to. The β-
subunit is shown in 
green, orange, brown 
and yellow with the 
MIDAS and ADMIDAS 
shown in dark brown 
and pink respectively. 
E1-4 denotes the EGF 
domains and H labels 
the hybrid domain and 
β-T names the β-
tail/transmembrane 
domain. 
Figure 1.4. Diagram of Integrin Structure. 
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ablation of β1 integrin in mice results in severe vascular defects that are lethal around day e9-
11.5[35, 147]. Isolated β1-null ECs showed impaired adhesion to laminin and collagen and 
impaired cell survival[35]. Ablation of α1 or α2 subunits has a much less severe effect, with α1 
null mice producing viable offspring with minor defects in collagen synthesis and 
angiogenesis[148, 149]. α2-null mice show delayed platelet aggregation. However, mice deficient 
in both α2β1 and α11β1 show dwarfism as a result of diminished insulin growth factor (IGF) 
levels[150]. Integrin mediated signalling is essential for cell survival and many cell responses to 
growth factors are dependent on cell adhesion to a substrate via integrins. As a consequence, 
many cell types must be adhered to the matrix through integrins to survive[151, 152].  
Table 1.1 – Effects of Integrin Knockouts in Mice 
Subunit Viability Phenotype 
α1 V, F No obvious developmental defects, reduced tumour vascularization, 
minor defects in collagen synthesis and angiogenesis 
α2 V, F Few obvious developmental defects, delayed platelet aggregation and 
reduced binding to monomeric collagen, reduced mammary gland 
branching 
α3 P Kidney tubule defects, reduced branching morphogenesis in lungs, mild 
skin blistering, lamination defects in neocortex 
α4 E11/14 Defects in placenta (chorioallantoic fusion defect) and heart (epicardium, 
coronary vessels). Chimeras show defects in haematopoiesis 
α5 E10-11 Defects in mesoderm (posterior somites) and vascular development, 
neural crest apoptosis. Chimeras show muscular dystrophy 
α6 P Severe skin blistering, other epithelial tissues also defective. Lamination 
defects in cortex and retina. 
α7 V, F Muscular dystrophy, defective myotendinous junctions 
α8 P Small or absent kidneys, inner ear hair cell defects 
α9 V Die within 10 days of birth, chylothorax due to lymphatic duct defect 
α10  V, F Growth retardation of the long bones, abnormal chondrocyte growth and 
shape[153] 
α11  V, F Reduced granulation tissue formation and impaired wound contraction. 
Dwarfism and impaired incisors [154, 155] 
αv E10/P Two classes: embryonic lethality due to placental defects, perinatal 
lethality with cerebral vascular defects probably due to neuroepithelial 
defects, cleft palate. Most blood vessels develop normally 
αIIb V, F Haemorrhage, no platelet aggregation 
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αL V, F Impaired leukocyte recruitment 
αM V, F Defective phagocytosis and apoptosis of neutrophils, mast cell 
development defects, adipose accumulation. 
αX   Not yet reported 
αD   Not yet reported 
αE V, F Greatly reduced numbers of intraepithelial lymphocytes. 
β1 E6.5 Peri-implantation lethality, ICM deteriorates, embryos fail to gastrulate. 
Extensive analyses of chimeras. 
β2 V, F Leucocytosis, impaired inflammatory responses, skin infections, T cell 
proliferation defects 
β3 V, F Haemorrhage, no platelet aggregation, osteosclerosis, 
hypervascularisation of tumours 
β4 P Severe skin blistering, other epithelial tissues also defective 
β5 V, F No immediately obvious developmental defects 
β6 V, F Inflammation in skin and airways, impaired lung fibrosis—all probably due 
to failure to activate TGFβ 
β7 V Deficits in gut-associated lymphocytes—no Peyer's patches, reduced 
intraepithelial lymphocytes. 
β8 E10/P Two classes: embryonic lethality due to placental defects, perinatal 
lethality with cerebral vascular defects probably due to neuroepithelial 
defects. Most blood vessels develop normally. 
Table 1 adapted from Integrins: Bidirectional, Allosteric Signaling Machines[142] 
Abbreviations – V = Viable, F = Fertile, E = Embryonic lethal, P = Perinatal lethal 
 
Integrins α1β1 and α2β1 are the most defined in ECs and are important in regulating 
angiogenesis and proliferation. Addition of VEGF upregulates α1β1 and α2β1 expression, along 
with cell proliferation, spreading on collagen and angiogenesis[156]. While inhibitors for α1β1 
and α2β1 impede angiogenesis[157-159]. The VEGF dependent interaction of collagen I with α1β1 
and α2β1 induces the activation of the mitogen activated protein kinase (MAPK) pathway, 
which suppresses apoptosis and promotes cell survival[160, 161]. The α1β1 integrin binding to 
collagen also negatively regulates collagen synthesis; in α1-null mice the normal negative 
feedback loop does not exist and so excess dermal collagen is continually synthesised and then 
broken down again[162]. Because α1β1 and α2β1 have been implicated in the regulation of 
proliferation and angiogenesis it is not surprising that they are both implicated in cancer 
progression. The α1β1 integrin is upregulated in colorectal cancer[163] and knockdown of the 
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α1 subunit (noted ITGA1) in tumour xenografts results in reduced tumour progression in HT29 
and T84 cells alongside increased tumour cell necrosis[164]. Additionally, inhibition of α1β1 
integrin results in decreased tumour angiogenesis[165]. Both α1β1 and α2β1 enhance cancer 
cell migration and metastasis, for example, by upregulating MMP synthesis via MAPK 
signalling[166]. The α2β1 integrin also promotes prostate cancer metastasis to the skeleton, 
resulting in a poor prognosis for patients[167]. 
However, little is known about the expression and functions of α10β1 and α11β1 in ECs 
despite α10 being the second most abundant integrin transcript in early passage ECs 
(Haematlas database and Dr Peter Kim, unpublished work). Primarily, α10β1 is expressed in 
chondrocytes[7, 136] and α11β1 is expressed in fibroblasts, mesenchymal cells, skeletal muscle 
and osteoblasts[155, 168]. α10β1 has recently been shown to be upregulated in glioblastoma 
tissues derived from human patients. siRNA knockdown of α10β1 in glioblastoma cells resulted 
in decreased migration and increased cell death, implementing α10β1 in the regulation of 
cancer metastasis[169]. In addition, α10β1 is also upregulated in malignant melanoma cells 
compared to primary melanocytes and knockdown of α10β1 resulted in reduced migration of 
melanoma cells[170]. Integrin α10β1 has also been found to drive tumorigenesis and metastasis 
in sarcoma resulting in much poorer prognosis for patients[171]. 
Integrin α11β1 is a receptor for osteolectin which is involved in the differentiation of 
osteogenic progenitors to mature osteoblasts[172]. KO of the α11 subunit (noted ITGA11) in 
skeletal progenitor cells in mice results in impaired osteogenesis and accelerated bone loss in 
adulthood[172]. Also, α11β1, upregulated by TGFβ, plays a role in cardiac myofibroblast 
differentiation and KO of ITGA11 drastically changes the phenotype of hepatic stellate 
myofibroblast cells [173-176]. Inhibition of the hedgehog pathway decreased ITGA11 expression 
in hepatic stellate cells, in a mouse liver fibrosis model and in human liver slices ex vivo, leading 
to decreased fibrosis[176]. Integrins α11β1 and α2β1 were found to regulate the cell survival of 
mesenchymal stem cells; short hairpin (sh)RNA knockdown of either of these integrins resulted 
in mitochondrial leakage and Bcl-2 protein upregulation[177]. Given the varied roles of these 
integrins in other cells, it can be hypothesised that integrins are present in and have important 
functional roles in ECs. 
Integrins bind collagen via their αI-domain to ‘GxOGEx’ (using the one-letter amino acid 
code, where O is hydroxyproline, a post-translational modification of proline, and x is any 
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natural amino acid) motifs located on the collagen sequence, in a divalent metal ion dependent 
manner[7, 136, 137, 139]. Cryptic binding sites for different integrins could also be revealed in the 
tertiary and quaternary structure of different collagen fibres and mesh networks, and these 
could be important in regulating integrin signalling. For example, one study found that ECs 
cultured on regularly aligned, nano-patterned collagen fibres supported EC populations with 
decreased monocyte adhesion (anti-inflammatory) and increased cell viability compared with 
cells cultured on randomly aligned matrixes[178].  
1.7 Extracellular Matrix and Collagen 
The ECM is a dynamic, acellular compartment present throughout mammalian tissues 
and is specialised for each tissue function. Fibrillar and non-fibrillar collagens are major 
constituents of the blood vessel ECM, which also includes fibrinogens, laminins, heparin 
sulphate, entactin and proteoglycans[179]. The ECM forms a structural surface for organised cell  
attachment that relays signals to and from the endothelium to allow ECs to react to different 
physiological stimuli[12]. The ECM plays an important role in regulating EC behaviour and ECs 
themselves modify the composition of the ECM[180]. ECs maintain and remodel their local niche 
by secreting ECM components including MMPs which degrade collagen, and α1β1 and α2β1 
have been implicated in the regulation of both collagen and MMP synthesis[162, 181, 182]. 
Fragments created upon collagen cleavage can act as differential signalling molecules on a 
range of pathways[10]. For instance, a C-terminal fragment of the non-collagenous domain of 
collagen XVIII, termed endostatin, inhibits VEGF-induced EC migration[183]. Arresten, a 
proteolytic fragment of collagen IV, binds to integrin α1β1, resulting in the inhibition of MAPK 
induced cell proliferation and anti-apoptotic Bcl expression, enhancing apoptosis in ECs[184, 185]. 
Growth factors and other signalling molecules are also sequestered in the ECM and are 
released upon collagen degradation. Therefore, it is relevant to study the interactions between 
ECs and their surrounding matrix. 
Collagen is the most abundant protein in the human body and is the main constituent 
of the ECM. It gives tensile strength to skin, bone, cartilage and blood vessel walls. Collagens 
are characterised by their triple-helical domains (THDs) (Figure 1.5),  formed from 3 
polypeptide α-chains containing repeating (G-X-Y) sequences where G is Glycine, X is often 
proline and Y is often hydroxyproline[6, 10]. The formation of the triple helix conformation is 
driven by a network of hydrogen bonds perpendicular to the helix axis[186], resulting in a one 
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amino acid stagger between α-chains. This unique triple helix conformation is essential for the 
collagen assembly in fibrils which is required for the structural role of collagen within the 
extracellular matrix. The triple helix conformation is also necessary for the recognition of 
collagen-binding cell-surface receptors and cell-secreted proteins and is crucial to its biological 
function. Members of the collagen family form a diverse family of 28 proteins. Figure 1.6 
summarises the different α-chains of the collagen family and how they are structured to give 
an idea of the diversity of the collagen family. Collagens are organised into tertiary structures 
and form networks in the ECM; collagens II and III are fibrillar homotrimeric proteins, whereas 
collagens I, IV and XI are heterotrimeric[10, 187]. The α-chains of collagens I, II, III, V, VIII and X 
are almost entirely triple helical, whereas a helical structure makes up only 10% of collagen 
XII[10] and collagen VI α-chains contain mostly VWF A-domains that participate in protein-
protein interactions. Collagen IV is a major protein constituent of the endothelial ECM, 
alongside laminin, and has been shown to influence EC behaviour and proliferation[180]. Other 
collagens found in the basal lamina include: collagen I, III, IV, V, VI, VIII[84]. The structure of 
collagen IV is interesting in that the long THD is peppered with non-helical regions, allowing for   
Adapted from ‘Collagen Structure: new tricks from a very old dog’ Bella 2016[6]. The middle diagram 
shows how the side chains of each peptide residue are arranged, while the other two show the general 
shape of the helix  
Figure 1.5. Structural Representations of the Triple Helical Domains of Collagen. 








Adapted from ‘The Collagen Family’, Ricard-Blum 2011[10]. This diagram shows the different 
domains and different structures of all the members of the collagen family in depth. The fibril 
forming collagens are mostly triple helical whereas the fibril associated collagens are more varied 
containing plenty of non-collagenous interruptions in the THP domains. 
Figure 1.6: Representations of the Collagen Family α-Chains 




Figure 1.6 continued: Adapted from ‘The Collagen Family’, Ricard-Blum 2011[10]. This diagram 
illustrates the variety in the collagen family. The α-chains of collagens XI, XII, XXVI and XXVIII contain 
mostly VWF A-domains whereas the network forming collagen IV is almost entirely THD interrupted 
with lots of short non-collagenous domains and the membrane collagens contain a unique 
membrane domain.  
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flexible sections that can crosslink other matrix proteins. Collagens XIII, XVII, XXIII and XXV are 
transmembrane collagens[188, 189] which could play a role in signal transduction from the ECM. 
Collagen XVII has a long cytoplasmic non-collagenous domain whereas XIII, XXIII and XXV have 
much shorter intracellular domain. Induction of collagen XIII expression in ECs can mediate 
transmigration of monocytes along the EC monolayer in renal fibrosis[190].  
Collagens form fibrils and networks with other collagens, and the supramolecular 
structure depends on collagen composition. For example, collagens II, III, XI and IX will associate 
to form fibrillar structures whereas collagen IV will form networks, collagen VI will form beaded 
filaments and collagens VIII and X form hexagonal structures[10]. Fibril-associated collagens will 
then associate with collagen fibrils, adding additional functional domains for protein-protein 
interactions. Collagens are degraded by MMPs in many physiological processes related to cell 
migration, development and tissue repair. However, these functions can be highjacked in 
pathological processes such as tumour metastasis[166, 191]. In this project, soluble collagen I was 
mainly used as it is found ubiquitously in the ECM, is commercially available at a reasonable 
cost and is made almost entirely of THD structure. Collagen I also contains several known 
integrin binding sites and so proved valuable for studying integrins in ECs. Collagen IV was 
tested alongside collagen I in preliminary experiments but since no advantage was seen using 
the much more expensive collagen IV, it was decided that collagen I would suffice for the 
majority of studies here. Geltrex™ (LDEV-free reduced growth factor basement membrane 
matrix), the Thermo equivalent of Matrigel, was used for all assays analysing tube formation. 
Geltrex™, like Matrigel, is a basement membrane matrix extracted from murine Engelbreth-
Holm-Swarm tumours, containing mostly collagen IV, laminin, entactin and heparin sulphate 
proteoglycans along with some growth factors and cytokines in low levels[192, 193]. 
1.8 The Regulation of Migration in Endothelial Cells 
 Cell migration is a tightly controlled process involved in development, wound healing, 
immune response and angiogenesis[194] but can also be pathological when deregulated, for 
example when cancer cells become highly motile and metastasise[194] and in chronic 
inflammatory diseases, vascular diseases, multiple sclerosis, osteoporosis and mental 
retardation[194]. ECs are generally non-migratory in stable blood vessels but can be stimulated 
to migrate during wound healing or angiogenesis. For directional migration to occur the ECs 
must polarise in response to a chemoattractant such as VEGF so that a leading and trailing 
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edge are established[161, 195]. The leading edge sends out membrane protrusions called 
filopodia that adhere to the ECM ahead of the cell. The filopodia are driven by cytoskeletal 
actin polymerisation[194, 196, 197]. The adhesion of filopodia to the ECM will stabilise the 
protrusions and link the cytoskeleton to the ECM. This creates traction between the ECM and 
the cell cytoskeleton, pulling the cell forward. The trailing edge must then detach from the 
ECM to allow the whole cell to migrate[194]. Each stage of cell migration must be carefully 
regulated from cell polarisation to filopodia protrusions to cell attachment and de-adhesion. 
Integrins are adhesion receptors and so play an important role in each of these stages[197]. 
Strong adhesions in the filopodia will enhance cell migration whereas strong adhesions in the 
trailing edge will slow down migration and so it’s imperative that localised regulation of 
processes takes place.  Both α1β1 and α2β1 have been implicated in VEGF mediated EC 
migration[160] and α10β1 has been implicated in the regulation of glioblastoma migration and 
so could also play a novel role in EC migration here[169]. 
1.9 The Regulation of Angiogenesis in Endothelial Cells 
Angiogenesis, the process of forming new blood vessels from pre-existing vasculature, 
is tightly regulated and complex. The ECM provides both a physical scaffold and a signalling 
platform for ECs. In a concerted response to pro-angiogenic signals, the ECs must remodel the 
ECM, breaking cell-cell and cell-matrix adhesions, change their morphology, invade 
surrounding tissue, migrate to a new position and then re-form cell-cell and cell-matrix 
contacts[18, 179, 198]. Many signalling molecules and pathways are involved, for example VEGF 
and bFGF are known to enhance angiogenesis by stimulating ECs to secrete MMPs[166, 199]. 
Resulting degradation of the ECM also releases ECM-bound cytokines and growth factors, like 
VEGF, which further stimulates cell proliferation and angiogenesis. Once ECs have sprouted 
and started to form a new branch of blood vessel, other cells like pericytes must be recruited 
to stabilise the mature blood vessel[179, 180, 200]. Hypoxia, a main driver of angiogenesis, will 
induce VEGF expression in many tissues, including the endothelium, to stimulate angiogenesis 
in tissues that are not receiving enough oxygen. Hypoxia is detected by transcription factors 
called hypoxia-inducible factors (HIFs). In the presence of oxygen HIFs are hydroxylated, then 
ubiquitinylated and targeted for degradation by HIF-prolyl hydroxylases (HIF-PHs). In hypoxia, 
the HIF-PHs cannot hydroxylate HIFs and they are not subsequently ubiquitinylated resulting 
in a build-up of HIFs and the subsequent transcription of HIF-targeted genes like VEGF[201, 202]. 
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Pathogenic deregulation of angiogenesis is associated with wound healing defects, 
rheumatoid arthritis, diabetic microvascular disease, macular degeneration, ischemia and 
inflammation[179]. Angiogenesis is upregulated in many cancers and is essential in supplying 
tumour blood supply. ECs isolated from tumours have been found to express higher levels of 
collagens I and III than ECs from surrounding healthy tissue[203]. The role of collagen-binding 
integrins in regulating angiogenesis has been partly investigated. For instance, a range of 
studies have shown that VEGF mediates integrin α1β1 and α2β1 up-regulation in migrating 
ECs, and inhibition of these integrins blocks angiogenesis without effect on existing 
vasculature[157]. As a corollary, inhibiting synthesis of collagen I and IV, the primary ligands for 
11 and 21, inhibits capillary formation[198]. Specific inhibition of α1β1 by Obtustatin 
inhibits angiogenesis in a CAM assay and Lewis lung carcinoma syngeneic model[204].  In 
conclusion it is been demonstrated that VEGF upregulates angiogenesis in a α1β1- and α2β1- 
dependent manner; these integrins are established as regulators of angiogenesis. However, 
the roles of α10β1, relatively abundant in HUVECs, and α11β1 in angiogenesis have not yet 
been explored. 
1.10 Other Endothelial Collagen Receptors 
 ECs may also express some other collagen binding proteins, for example platelet-
glycoprotein VI (GPVI), discoidin domain receptor (DDR)1, DDR2, secreted protein acidic and 
rich in cysteine (SPARC), osteoclast-associated immunoglobulin-like receptor (OSCAR), 
leukocyte-associated immunoglobulin-like receptor 1 (LAIR-1) and G-protein-coupled receptor 
56 (GPR56). 
 SPARC is a macromolecule secreted in the ECM that modulates cell-matrix interactions, 
SPARC binds collagen but has no adhesive properties for cells. SPARC is anti-proliferative and 
de-adhesive in vitro[205, 206], it binds to and inhibits platelet derived growth factor (PDGF) and 
VEGF[206] and it mediates the disassembly of focal adhesions in ECs leading to cell rounding[207]. 
There are conflicting studies for the role of SPARC in cancer progression. On the one hand, 
SPARC seems to be generally anti-tumorigenic as solid tumours implanted in SPARC-null mice 
grow much larger than in control mice with no change in angiogenic growth factor 
expression[208]. The same study also found alterations in collagen synthesis resulting in smaller, 
less mature collagen fibres suggesting a role for SPARC in modulating the ECM[208]. Additionally, 
SPARC also regulates the secretion of the ECM proteins fibronectin and laminin[209]. In glioma 
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and neuroblastoma SPARC expression impairs tumour growth and angiogenesis[205]. However, 
SPARC has also been shown to promote metastasis and invasion of cancer cells in melanoma, 
glioma, and carcinomas in breast and pancreas (reviewed in[205]). SPARC is expressed in 
microvascular ECs in response to VEGF[210, 211] and it is thought to regulate EC shape and barrier 
function by increasing vascular permeability[211, 212]. SPARC contributes to the regulation of the 
BBB permeability[210]. SPARC is also upregulated during blood vessel development and after 
vascular injury, suggesting a role in angiogenesis and wound healing[213].  
 DDR1 and DDR2 are collagen-binding, transmembrane, receptor tyrosine kinases RTKs 
that adhere to, and are activated by, several types of collagen[214]. They contain a collagen-
binding discoidin-domain alongside transmembrane, and tyrosine kinase domains[215]. DDR1 
and DDR2 are proposed to bind to a GVMGFO motif found in collagen I, II and III. Interestingly, 
this is the same sequence proposed to bind to VWF and SPARC[216]. DDR1 is expressed in 
epithelial cells and immune cells such as T-cells whereas DDR2 is expressed in mesenchymal 
cells, fibroblasts, chondrocytes and neutrophils[215]. DDR1 and DDR2 are both expressed in de-
differentiated epithelial cancers and fibrosarcoma cells[215]. DDRs shed their ectodomains after 
collagen binding via a disintegrin and metalloproteinase (ADAM10) mediated proteolysis, that 
terminates DDR signalling[217]. DDRs are involved in the regulation of cell migration, which is 
unsurprising given their role in cell adhesion. DDR1 expression increases migration in 
squamous cell carcinoma cells, T-cells, THP-1 human monocytic cells and glioma cells, possibly 
due to the DDR-mediated upregulation of MMP expression (reviewed in[215]). DDR2 has been 
shown to regulate fibroblast migration through Matrigel[218] and VSMC migration in hypoxic 
conditions[219]. Both DDRs interact with integrins resulting in increased integrin activation and 
increased integrin-mediated cell adhesion in human embryonic kidney (HEK293) cells[220]. It 
has been proposed that DDRs are microenvironment sensors that detect damaged collagen 
fibres because the binding sites for DDRs are obscured in larger, highly ordered fibrils but 
exposed in newly formed or damaged fibrils[215]. DDRs have not been studied in ECs but are 
shown to interact with α2β1 and α1β1, to upregulate integrin-mediated cell adhesion. Studying 
DDRs in ECs is therefore also relevant to this project. 
OSCAR is a collagen binding receptor found in osteoclasts, monocytes, granulocytes, 
macrophages, and monocyte-derived dendritic cells[221, 222]. OSCAR regulates osteoclast 
differentiation and dendritic cell migration and survival and has been implicated in the 
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regulation of the osteoimmune system[221]. OSCAR promotes immune cell activation, 
maturation and survival and promotes proinflammatory signalling. Ligation of OSCAR triggers 
intracellular Ca2+ release and secretion of interleukin (IL)-8 which is a cytokine associated with 
chemotaxis, cell adhesion and angiogenesis[221, 223]. OSCAR has been detected, but not well 
characterised, in ECs[221]. OSCAR has been found in the membrane fraction of ECs and is 
thought to promote EC survival in HUVECs[224]. Expression of OSCAR is upregulated by ox-LDL 
in HCAECs[224]. 
LAIR-1 is a transmembrane glycoprotein collagen receptor that inhibits immune cells, 
presumably to downregulate unnecessary immune response[225]. LAIR-1 is expressed on almost 
all immune cells including T-cells, B-cells, monocytes, monocyte derived dendritic cells, 
eosinophils, basophils and mast cells[226]. LAIR-1 is also found on CD34+ haematopoietic 
progenitor cells, peripheral blood cells and thymus lymphocytes[226]. Crosslinking of LAIR-1 on 
natural killer immune cells using antibodies inhibits their function in lysing targeted cells and 
LAIR-1 can also inhibit T-cell mediated cytotoxicity[227]. LAIR-1 KO mice developed normally and 
appeared healthy in a pathogen-free environment but show a higher frequency of activated T-
cells.[225] 
Finally, GPVI is a platelet collagen receptor that regulates platelet aggregation[228]. GPVI 
adheres to GPO repeats in the collagen triple helix and forms dimers that cluster together on 
the platelet surface to amplify platelet activation[228]. GPVI binding to collagen is a prerequisite 
for platelet integrin α2β1 activation and subsequent thrombus formation[229]. Previous 
unpublished work by Dr Peter Kim in Professor Farndale’s group found that ECs adhered to 
GPO repeats and it was hypothesised that ECs express GPVI. However, no further studies were 
carried out to clarify this observation.  
1.11 Aims of the project 
 As described in this introduction, ECs and their surrounding ECM are ubiquitous 
throughout all organs of the body. ECs help regulate vascular tone, tissue homeostasis and 
inflammatory response and as a result they have important roles in many diseases[230]. EC 
dysfunction and the switch from a quiescent to pro-inflammatory and pro-coagulant state 
contributes to a range of cardiovascular diseases, including atherosclerosis and stroke[12]. EC 
dysfunction and associated cardiovascular disease can be caused by smoking, poor diet, 
obesity, age and inactivity and is a leading cause of mortality in the UK[12, 68, 91, 230]. The 
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endothelium is surrounded by a biologically active matrix of scaffolding and signalling proteins 
that help regulate EC behaviour and the continuous signalling between ECs and their ECM 
could yield novel therapeutics for EC dysfunction and associated cardiovascular disease. The 
work presented here aims to study ECs and their surrounding ECM to further understand the 
causes and progression of cardiovascular disease with intent to treat cardiovascular diseases 
more efficiently. Additionally, angiogenesis is paramount to tumour progression and again, the 
study of ECs and their ECM in the context of angiogenesis is essential to finding new 
therapeutic targets for the inhibition of tumour angiogenesis to help treat cancers.  
This project aims to study the expression and function of the four collagen-binding 
integrins in HUVECs. It builds upon work undertaken by a previous PhD student in the Farndale 
group, Dr Peter Kim. HUVECs were chosen as model ECs as they are well characterised, human 
in origin and easily available. HUVECs are suitable for this project as this work does not aim to 
investigate a particular endothelial phenotype specific to a subset of endothelial cells. Rather 
the project aims to looks at EC behaviour generally. HUVECs show an endothelial phenotype in 
vitro but cannot be passaged in excess of 5 times as they may lose their endothelial 
phenotype[134]. 
 First, commercially available HUVECs will be validated and characterised by their 
expression of EC markers such as VEGFR2, VE-Cad, MCAM, PECAM-1 and VWF using flow 
cytometry. Next, qPCR will be used to check for the presence and relative expression levels of 
these integrins in activated and non-activated states, alongside VWF, SPARC and DDR1 and 2. 
 Synthetic collagen II and III and XIII peptide Toolkits, synthesised in the Farndale group, 
contain overlapping sequences that map the triple helical domains (THDs) of these three 
collagens. Collagen THDs are made of three chains, each composed of Gx1x2 repeats where x1 
is often Proline and x2 is often a 4R-hydroxyproline (a post-translational modification of the 
proline side chain, noted O in the one-letter amino acid code)[231]. The formation of the triple 
helix is driven by a network of hydrogen bonds perpendicular to the helix axis[186], resulting in 
a one amino acid stagger between peptide strands. This unique conformation is essential for 
the collagen assembly in fibrils which is required for the structural role of collagen within the 
extracellular matrix. The triple helix conformation is also necessary for the recognition of 
collagen-binding cell-surface receptors and cell-secreted proteins and is crucial to its biological 
function. These toolkit triple helical peptides (THPs) are designed to mimic the native structure 
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of collagen and have been used to pinpoint the binding site of VWF A3 in Collagen III [139, 232-
235], and by inference, the partially conserved site in Collagens I and II. In solution, these peptide 
strands spontaneously bundle together to form a triple helix. In addition, GPC triplets were 
added in the N-terminal and C-terminal end of peptide strands to enable THP linkage to tissue 
culture plates. In addition to toolkit peptides, shorter THPs (SPs) have been synthesised 
containing 5 GPP repeats at each end and a central short integrin-targeting host sequence 
designed from variations of GFOGER or GLOGEN found in different collagens. A list of these 
peptides can be found in Chapter 4.2 and the host sequences found in different collagens is 
summarised in Chapter 4, table 4.1. 
The THPs containing integrin binding motifs loosely based on GFOGER, named SPs, will 
also be used to study the adhesion of the four integrins to collagen. First recombinant integrin 
I-domains will be tested before moving on to study the full length heterodimeric receptor using 
C2C12 cell lines that have been stably transfected to express one of the four collagen binding 
integrins[236]. Static adhesion assays and real-time adhesion studies using the xCELLigence 
electrical impedance system will be used to investigate differences in binding specificity. 
Ultimately these differences will be exploited using peptides to ligate specific integrin 
receptors, if possible. Adhesion experiments will then be repeated in HUVECs to compare the 
binding profile of HUVECs to C2C12s with respect to integrin expression.  
 Inhibitors, siRNA and CRISPR will be explored as methods to modulate integrin 
signalling and the downstream effects of receptor inhibition or knockdown on HUVEC function 
will be assessed. Changes in proliferation, apoptosis, angiogenic capability and migration will 
be quantified in each condition. To study proliferation cell number quantification assays and 
EdU incorporation microscopy assays will be used downstream of integrin KO or inhibition. To 
quantify apoptosis, fluorescent Annexin V will be used in microscopy and flow cytometry 
assays. Additionally, a lactate dehydrogenase (LDH) detection cytotoxicity kit will be used to 
quantify necrosis. Time lapse migration assays will be used downstream of inhibition and siRNA 
to determine the effects on cell movement in random walk conditions. Lastly, tube formation 
assays using Geltrex will be used to quantify the effects of integrin KD or inhibition on tube 
formation. 
 Throughout this dissertation the nomenclature “α1β1” refers to the full-length integrin 
heterodimer whereas “ITGA1” refers to the α-subunit. 
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2.1 Chapter Summary 
 This chapter aims to introduce all the reagents, materials and protocols used to carry 
out all the experiments described in this project. 
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2.2 List of Materials and Reagents 
Table 2.1: List of all materials and reagents used 
Name Company/Source Catalogue Number 
µ-Slide 4 Well Ph+ Ibidi 80446 
Angiogenesis µ-slides Ibidi 81506 
Annexin V-PE Biolegend 640947 
BSA GE Healthcare - 
C2C12 cells Samir Hamaia - 
Cell Proliferation Kit III (EdU-488; FC) Promocell PK-CA724-488FC 
Chemotaxis µ-slides Collagen coated Ibidi 80322 
Chemotaxis µ-slides Ibidi-treat Ibidi 80326 
CLICK PLUS EDU 488 FLOW KIT Thermo C10633 




Collagen IV Sigma C5533 
cOmplete™ Mini Protease Inhibitor Sigma 11836153001 
Cryo-SFM for cryopreservation Promocell C-29910 
Cytotoxicity Detection Kit (LDH) Roche 11644793001 
DharmaFECT 1 Dharmacon T-2001-01 
DharmaFECT 2 Dharmacon T-2002-01 
DharmaFECT 3 Dharmacon T-2003-02 
DharmaFECT 4 Dharmacon T-2004-01 
DMEM Thermo 41966-029 
Endothelial Basal Medium 2 (EBM2) Promocell C-22211 
Endothelial Growth Medium 2 (EGM2) Promocell C-22111 
FBS Thermo C-22211 
Fibronectin Sigma FC010-1MG 
G418 Thermo 11811031 
Geltrex™ (Matrigel) Thermo A1413202 
Helix NIR Biolegend 425301 
Hoechst 33342 Thermo H1399 
Human E-Selectin DuoSet ELISA R&D systems DY724 
Human ICAM-1/CD54 DuoSet ELISA R&D systems DY720-05 
Human VCAM-1/CD106 DuoSet ELISA R&D systems DY809 
HUVECs, cryopreserved Promocell 
C-12208  
Lot Numbers and genders: 
416Z042 m/m/f/f newborn 
426Z006 m/m/f/m newborn 
426Z007 f/f/m/f newborn 
420Z015.2  f/m/f/m newborn 
Interleukin (IL)-1α Miltenyi Biotech 130-093-894 
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Keratinocyte-SFM (1X) Thermo 17005042 
Laminin Sigma L6274-.5MG 
Lipofectamine LTX Thermo 15338100 
Lipofectamine RNAiMAX Thermo 13778075 
Lipopolysaccharides from E.coli Sigma L4391-1MG 
M3 Protein Fragment Samir Hamaia N/A 
Nunc Tissue Culture Flasks 75cm2 Thermo 156499 
Obtustatin R&D systems 4664/100U 
Odyssey Blocking buffer PBS Licor 927-40000 
OptiMEM Thermo 31985070 
PCR Mycoplasma Test Kit I/C Promocell PK-CA91-1024 
Penicillin-Streptomycin Solution Sigma P4333-100ML  
Phorbol12-myristate13-acetate (PMA) Abcam ab120297 
Pierce™ TMB Substrate Kit Thermo 34021 
Plasmid Plus Maxi Kit Qiagen 12963 
pMDG.2 (Gift from Dr Frank 
McCaughan) Addgene  12259 
Polybrene Sigma TR-1003-G 
PromoFectin Promocell PK-CT-2000-HUV 
Propidium Iodide Sigma P4170-25MG 
psPAX2 (Gift from Dr Frank 
McCaughan) Addgene  12260 
Puromycin Sigma P8833-25MG 
px458 (Gift from Dr Frank McCaughan) Addgene  48138 
Rezasurin Promocell PK-CA707-10054 
Rhodamine Phalloidin Thermo R415 
Rneasy Plus RNA extraction kit Qiagen 74134 
siGLO Green Transfection Indicator Dharmacon D-001630-01-05 
Silencer Select Negative Control #2 Thermo 4390846 
Silencer Select ITGA1  Thermo 4390825 - s7534, s7532 
Silencer Select ITGA10 Thermo 4392421 - s16180, s16181 
Silencer Select ITGA11 Thermo 4390825/242,4392421/240 
Silencer Select ITGA2 Thermo 4399666/s541358, s541359 
Silencer Select GAPDH Thermo 4390850 
Silencer Select Negative Control #1 Thermo 4390844 
TaqMan DDR1 Assay Thermo 4331182, Hs01058430_m1 
TaqMan DDR2 Assay Thermo 4351372, Hs01025956_m1 
TaqMan GAPDH Assay Thermo 4331182, Hs99999905_m1 
TaqMan ANGPT2 Thermo Hs01048042_m1 
TaqMan TIE1  Thermo Hs00892698_m1 
TaqMan Gene Expression Master Mix Thermo 4369016 
TaqMan HPRT1 Assay Thermo 4448490, Hs02800695_m1 
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TaqMan ITGA1 Assay Thermo 4331182, Hs00235006_m1 
TaqMan ITGA10 Assay Thermo 4351372, Hs01006921_m1 
TaqMan ITGA11 Assay Thermo 4331182, Hs01012939_m1 
TaqMan ITGA2 Assay Thermo 4331182, Hs00158127_m1 
TaqMan Reverse Transcription Kit Thermo N8080234 
TaqMan SPARC Assay Thermo 4331182, Hs00234160_m1 
TaqMan vWF assay Thermo 4331182 - Hs01109453_m1 
TC-I-15 R&D systems 4527/10 
Tumour Necrosis Factor (TNF)α Thermo PHC3015 
TransfeX™ Transfection Reagent ATCC® ACS-4005 
tRFP CRISPR Lentiviral Plasmid Addgene  57819 
TryplE Thermo 12604021 
Trypsin-EDTA Sigma T4174-100ML 
VEGF-165, human Promocell C-64420 
Vitronectin Sigma 5051-0.1MG 
 
2.3 List of Antibodies 
A list of antibodies used in this project is detailed in table 2.2. 
Target and conjugate Application Company Product Number 
GST HRP conjugated ELISA Sigma GERPN1236 
CD144 (VE-Cadherin), human, FITC FC Miltenyi Biotech 130-100-713 
CD146, human, Alexa Fluor® 488 FC Biolegend 342007 
CD309/VEGFR2, human, Alexa Fluor® 
488   
FC Biolegend 359913 
CD31-FITC, human (clone: AC128) FC Miltenyi Biotech 130-098-171 
CD45, human, APC  FC Biolegend 368511 
CD49a, ITGA1, Alexa Fluor 488 FC Thermo PA5-46887 
GAPDH WB Abcam ab9484 
IRDye® 680LT Goat anti-Rat IgG 
Secondary Antibody 
WB Licor 926-68029 
ITG1/CD49a  (639508) WB R&D systems MAB5676-SP 
ITGA2 - 6F1 Inh/WB Professor Barry Coller of the 
Rockefeller University, New York. 
ITGA2/CD49b  WB R&D systems MAB12331 
Mouse IgG H&L Alexa Fluor® 488 
isotype control 
FC Abcam ab150113 
α-Tubulin Loading control WB Abcam ab4074 
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2.4 Cell culture 
Pooled HUVECs were cultured in endothelial growth media 2 (EGM2) unless stated 
otherwise. C2C12s, HT1080s, HEK293T were grown in DMEM/10% FBS and 1% 
penicillin/streptomycin. Immortalised Bronchial Epithelial (BE) cells were a gift from Dr Frank 
McCaughan, University of Cambridge, and were grown in Keratinocyte-SFM (1X). All cells were 
maintained at 37°C, 5% CO2. All cells were stored in liquid nitrogen or at -80°C and defrosted 
in a 37°C water bath before being placed directly into media pre-warmed to 37°C. HUVECs 
were seeded at 500,000 per 75cm2 flask and passaged at 70% confluence using TryplE to 
detach the cells at room temperature. 10% FBS in PBS was added to counteract the TryplE. All 
other cells were passaged using Trypsin/EDTA at 37°C for 5 minutes and DMEM with 10% FBS 
to quench the trypsin.  
All experiments using cells were carried out under sterile conditions. Cells were 
counted using a haemocytometer. Thermo, Nunc tissue culture plates and flasks were used for 
all cells. HUVECs were used at passage three, four or five. Low passage cells were 
cryopreserved in Promocell Cryo SFM cell freezing media and stored at -80°C for later use.  
2.5 Media and Buffers 
Table 2.3 – List of Buffers and Media used 
Buffer/Media Recipe 
TBS 50nM TRIS, 150mM NaCl, pH 7.4, 1L H2O 
Lysis buffer for ELISAs 1 % TRITON X100 in TBS 
Blocking buffer PBS 3 % BSA in PBS 
Blocking buffer TBS 3 % BSA in TBS 
TBS-T TBS + 0.05% Tween-20 
PBS-T PBS + 0.05% Tween-20 
AV Buffer 10mM HEPES, 140mM NaCl, 2.5mM CaCl 
Laemmli Buffer 
4% SDS, 20% Glycerol, 125mM TRIS, 10% β-mercaptoethanol, 
0.02% Bromophenol blue 
 
2.6 Protein Expression – VWF A domains and αI-domains 
The αI-domains of all four integrins and VWF A1 and A3 domains were cloned by Dr S. 
Hamaia (Department of Biochemistry, University of Cambridge) and expressed as glutathione 
S-transferase (GST)-tagged constructs. SHuffle® cells were transformed and grown on 
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100μg/ml Ampicillin plates. Resulting colonies were grown in LBE media containing 100μg/ml 
Ampicillin. Once the bacterial suspension reached 0.5 optical density (OD), the temperature 
was lowered to 30°C and expression was induced with the addition of 0.5M IPTG. After 
overnight incubation, the protein was extracted using Triton™ X100, sonication, centrifugation 
and glutathione-agarose beads in a purification column. Several different preparations were 
used for these experiments. Each condition was performed in triplicate and at least three 
independent repeats of the experiment were carried out. 
2.7 Immunofluorescence Imaging of EC Markers 
 HUVECs were cultured on tissue culture plastic in EGM2 at varying densities. After 24 
hours, cells were washed with PBS fixed with 4%PFA in H2O. Fixed cells were blocked with 3% 
BSA in PBS for 1 hour at room temperature (RT) before adding primary antibodies in 1% BSA in 
PBS overnight at 4°C. Wells were washed with 1%BSA in PBS 3 times before adding secondary 
antibodies and Hoechst in 1% BSA in PBS for one hour at RT protected from light. Wells were 
washed three times with PBS and left in PBS for imaging on the Leica DM6000 microscope. 
Images were analysed using ImageJ 1.51 (National Institute of Health). The presence of EC 
markers were tested in each batch of pooled HUVECs used. 
2.8 DuoSet ELISAs after HUVEC Activation 
Nunc tissue culture plates were coated with collagen I EZ-Gel at 10μg/ml. HUVECs were 
cultured on collagen I coated surfaces overnight in EGM2. The following day 20ng/ml TNFα, 
10ng/ml IL-1α or 1μg/ml LPS was added to the cells and left overnight for 16 hours. The 
following day, the media was aspirated, spun at 1000 xG and stored at -80°C. The cells were 
lysed on ice in PBS containing 1% Triton X-100 and 1 cOmplete Mini Protease inhibitor cocktail 
tablet per 10ml Lysis buffer. Cells were scraped in lysis buffer and the lysates were incubated 
on ice for 30 minutes before centrifuging at 13000 X G for 20 minutes. Supernatants were 
stored at -80°C and pellets were discarded. 
All reagents, antibodies and standards from the DuoSet ELISA kits were made following 
manufacturers recommendations. Immulon 2HB plates were coated with either VCAM, ICAM 
or E-selectin capture antibodies overnight in PBS at the manufacturers recommended 
concentration. The next morning plates were washed three times with 200μl PBS and blocked 
with 1% BSA in PBS for one hour. VCAM, ICAM or E-Selectin standard curves, HUVEC cell lysates 
(diluted 1:10 with 1% BSA) or media from HUVEC cultures were added to the blocked wells for 
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1 hour. After three washes with 200μl PBS-T, VCAM, ICAM or E-Selectin capture antibodies 
(biotin conjugated) were added, in 1% BSA in PBS for one hour. After three washes with PBS-T 
streptavidin-HRP was added for 20 minutes protected from light. After 4 washes with PBS-T, 
the Roche TMB substrate kit was added (1:1 ratio, 100μl/well) and the colour was allowed to 
develop until the blue was clearly visible. The reaction was quenched with 2M H2SO4 and the 
plate was read in a SpectraMax plate reader at 450nm.  
Each condition was performed in triplicate and at least three independent experiments 
were carried out, each with a different batch of pooled HUVECs. 
2.9 Lentiviral CRISPR/Cas-9 
 Plasmids, protocols and technical advice were kindly provided by Dr Frank McCaughan, 
Department of Biochemistry, Cambridge. The packaging plasmids used were psPAX-2 (Figure 
2.1) and pMDG.2 (Figure 2.2) while guide RNA’s were cloned into Addgene 57819 plasmid 
(Figure 2.3). Guide RNA sequences were obtained using the CRISPR design program at: 
http://crispr.mit.edu/ and integrin DNA sequence information on the Ensembl gene browser.  
Guide RNA primers (3 sets for each target) were ordered from Sigma and annealed 
(boiled at 95°C for 3min before cooling down at 0.1°C/s to 22°C in a thermocycler) to create 
small inserts with Bbsm1 compatible sticky ends. Addgene 57819 plasmid was digested with 
Bbsm1 and the guide RNA sequences were inserted using T4 ligase. DH5α cells were 
transformed and grown on ampicillin plates, colonies were collected and grown in 2XTY media, 
Qiagen miniprep kits were used to extract the plasmids and these were sent for sequencing 
using the U6 promoter. Plasmids with the correct guide sequences (sgRNA plasmids) were 
amplified in bacterial systems and extracted using Qiagen endo-free plasmid maxi kits.  
Packaging plasmids and lentiviral CRISPR guide RNA plasmids were transfected into 
HEK293T cells. HEK293T cells were seeded at 4 million per 10cm dish in DMEM + 10% FBS with 
no antibiotics and the following day these HEK293T cells were transfected with 1.5μg pMD2.G 
: 4.5μg psPAX2 : 6μg sgRNA plasmid using lipofectamine™ diluted in OptiMEM® media. After 
24 hours DMEM was replaced with DMEM +20% FBS to remove transfection reagents. After 
another 48 hours the supernatant containing viral particles was harvested, filtered through a 
45μM filter and aliquoted into 200μl viral samples and stored at -80°C.  
BE or HUVECs were grown in complete media until 70% confluent in a 6-well plate. 
Media was changed to basal EBM or DMEM + 8μg/ml polybrene. 50μl of the viral particle 
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solution was added to the cells and incubated for 6 hours. The media was replaced with 
complete media and cells were incubated for 24 hours. Cells were checked each day for red 
fluorescence on a Leica DM6000 microscope, and eventually a MoFlo Astrios cell sorter was 
used to separate red cells from the rest, which were analysed for expression of the target 
protein. 
2.10 Knockdown using siRNA 
Reverse siRNA transfection protocols were used. Two Silencer Select siRNAs for each 
target were pooled as described the materials table, except where siGLO was used to optimise 
transfection reagent concentration. The pooled siRNA was used as below (Table 2.4): 
Table 2.4 – siRNA concentrations used 
Condition Target siRNA Negative control siRNA Final [siRNA] 
ITGA1 50nM 100nM 150nM 
ITGA2 50nM 100nM 150nM 
ITGA10 50nM 100nM 150nM 
All 50nM + 50nM + 50nM - 150nM 
Negative control - 150nM 150nM 
The siRNA was diluted with OptiMEM in the tissue culture vessel, 250μl per well for a 
6-well plate. DharmaFECT4 (D4) was mixed with OptiMEM in a sterile tube at 1:50 ratio and 
incubated for 5 minutes, 250μl per well for a 6-well plate. The diluted D4 was then added to 
the diluted siRNA in the wells and incubated for 20 minutes. Cells were then added in 2ml of 
EGM2 without Heparin per well at 60,000/ml, and incubated for 8 hours at 37°C, 5% CO2. After 
8 hours the media was replaced with pre-warmed complete EGM2. The cells were passaged 
after 24-48 hours. All experiments were carried out after 48-72 hours siRNA.  
2.11 RNA Extraction, cDNA synthesis and qPCR 
 For quantitative real-time polymerase chain reaction (qPCR), the Qiagen RNeasy Plus 
Mini Kit was used to extract total RNA from cells, in a Qiacube automated machine with 30μl 
elution volume, as per manufacturer’s instructions. β-mercaptoethanol was added to the RLT 
lysis buffer at 10μl/ml and genomic DNA removal columns were used. A corresponding cDNA 
library was created using the TaqMan reverse transcription reagents as follows (Table 2.5): 
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Table 2.5 – Reverse Transcription Volumes 
Reagent Volume Final Concentration 
H2O Variable – make up to 50μl - 
10x Reverse transcription buffer 5μl 1X 
MgCl2 3.5μl 1.75mM 
dNTP mix (2.5mM each) 10μl 0.5mM each 
RNase Inhibitor 2.5μl 1.0U/μl 
Random Hexamers 2.5μl 2.5μM 
Multiscribe reverse transcriptase 2.5μl 2.5U/μl 
RNA, in H2O Variable  <1μg 
Total 50μl - 
 The Reverse transcription reaction was placed in a thermocycler using the 
recommended protocol (10min at 25°C, 30min at 37°C, 5min at 95°C, 10min at 4°C). RNA was 
either used straight away for qPCR or stored at -20°C until use. The qPCR reaction was set up 
as below and the reaction was run on an Applied Biosystems 7300 Real-Time PCR System as 
per manufacturer’s instructions. TaqMan predesigned primer and probe sets were used, the 
sequences for these are not available but the product information is listed in the table of 
reagents (Table 2.6).  
Table 2.6 – qPCR Volumes 
Reagent Volume for 1 reaction 
H2O Variable – make up to 20μl 
Taqman Gene Expression Master Mix 10μl 
20x Target assay 1μl 




 To quantify changes in mRNA expression, the HPRT1 CT value was subtracted from each 
experimental CT value (in triplicate), giving a ΔCT number. These ΔCTs were averaged and the 
fold change was calculated by the equation 2-ΔCT. Where siRNA was used, the ΔCT value for the 
control condition was subtracted from the ΔCT value for the siRNA KD condition and the 
resulting ΔΔCT value was used to calculate percentage expression using 2-ΔΔCT. Three technical 
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repeats were carried out with each batch of cDNA and at least three separate knockdown 
experiments were performed using different batches of pooled HUVECs. 
2.12 Western Blots 
 Cells were grown in 12-well plates, seeded at 50,000-100,000 per well in EGM2. After 
24 hours cells were lysed directly with 150μl of Laemmli buffer and scraped into screw top 
Eppendorf tubes. Lysates were vortexed and then boiled for 5 minutes and stored at -20°C or 
used straight away. Lysates were loaded in NuPage gels and run using the NuPage Gel 
Electrophoresis system at 200V for 45 minutes. Gels were washed and blotted onto 
Immobilon-FL PVDF membranes using the BioRad TransBlot® Turbo™ Semi-Dry transfer system 
in blotting buffer using the “High MW” protocol for 11 minutes. Membranes were then washed 
in PBS and blocked using the Odyssey PBS blocking buffer for one hour. Primary antibodies 
were added in Odyssey blocking buffer at 4°C overnight. After 3x 10min washes in PBS-T, the 
Licor secondary antibodies were added at 1:10,000 in Odyssey blocking buffer protected from 
light for 1 hour. After 3x 10min washes with PBS-T and 2x 10minute washes with PBS the 
membranes were visualised using a Licor Odyssey CLx Western Blot imaging system and 
associated software. Western blots were carried out using lysates from three separate siRNA 
knockdown experiments using different batches of pooled HUVECs. 
2.13 Cellular Static Adhesion Assays  
Immulon 2HB 96-well plates were coated with 100μl per well of peptides at 10μg/ml in 
0.01M acetic acid or with proteins/antibodies at concentrations stated) overnight at 4°C. After 
3x 200μl/well washes with PBS, plates were blocked with 200μl/well filtered 3% BSA in PBS at 
room temperature for one hour. Plates were washed again, and 100μl per well of cells were 
added at 10, 15 or 20k cells per well at RT for one hour. Unbound cells were washed away with 
3x washes of 200μl per well of PBS. Remaining cells were lysed with 50μl per well of 2% TRITON 
X-100 in double-distilled water for one hour at room temperature. Cells were detected using 
50μl per well of the Roche cytotoxicity LDH kit. The catalyst and substrate solutions of the kit 
were mixed at a ratio of 1:45 and 50μl was added to the wells to detect LDH in the cell lysate. 
Absorbance was read at 490nm on a SpectraMax 190 microplate reader. Each condition was 
performed in triplicate and each experiment was repeated at least three times using different 
batches of pooled HUVECs. 
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2.14 Protein Static Adhesion Assays  
Immulon 2HB 96-well plates were coated with 100μl per well of peptides at 10μg/ml in 
0.01M acetic acid or with proteins/antibodies at concentrations stated overnight at 4°C. After 
3x 200μl per well washes with washing buffer (1mg/ml BSA in TBS), plates were blocked with 
200μl per well of filtered 3% BSA in TBS for one hour. αI-domains and other proteins were 
added at 10μg/ml washing buffer for one hour. After 3x washes with washing buffer, detection 
antibodies (HRP conjugated anti-GST or anti-His followed by anti-mouse HRP conjugate) were 
added for one hour. Plates were washed 4x with 200μl per well of washing buffer and bound 
protein was quantified using the Pierce™ TMB Substrate Kit. The colorimetric reaction was 
stopped with an equal volume of 1M H2SO4 and absorbance was read at 450nm on a 
SpectraMax 190 microplate reader. Each condition was performed in triplicate and each 
experiment was repeated at least three times using several batches of proteins unless stated 
otherwise. 
2.15 Migration Random Walk Assays 
 Ibidi μ-slide 4-well Ph+ chamber slides were coated with 100μl per well of peptides at 
10μg/ml in 0.01M acetic acid or with proteins/antibodies at concentrations stated in PBS 
overnight at 4°C, before blocking with 3% BSA in PBS for one hour at room temperature. After 
3 washes with PBS, 700μl per well of cells were added at 14,000 cells/ml and left for 4 hours 
to attach. After 4 hours, phase images were taken every 5 minutes for 9 hours using an 
automated Leica DM6000 microscope in a humidified incubated chamber, 37°C, 5% CO2. The 
TrackMate plugin in ImageJ was used to quantify migration as average distance moved by one 
cell. Cells visible for over 80 frames were counted, cells that died or left the field of view were 
not analysed. 10 fields of view, all from a single well, were analysed for each condition and 
three independent experimental repeats were carried out using different batches of pooled 
HUVECs.  
2.16 Real-Time Adhesion Assays Using xCELLigence 
 A real-time xCELLigence RTCA SP electrical impedance system was used to measure cell 
adhesion and spreading in real time. xCELLigence plates were coated with peptides or proteins 
as described above for one hour at room temperature or overnight at 4°C and blocked with 3% 
BSA in PBS for one hour. Wells were washed with PBS and equilibrated with 50μl of serum-free 
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media (DMEM or EBM) at 37°C. A baseline reading was taken before adding 15,000 or 20,000 
cells per well in 50μl of EGM for HUVECs and serum-free DMEM for all other cell types. 
Electrical impedance readings were taken automatically every 5 minutes for 4 hours at 37°C, 
5% CO2. Each condition was performed in triplicate and three independent experiments were 
carried out. 
2.17 Tube Formation Assays 
10μl of Geltrex was added to each well of an Ibidi angiogenesis μ-slide and incubated 
at 37°C for 1 hour. HUVECs were detached, counted and added at 4000 per well (in 50μl) in 
EGM2 with or without inhibitors, or 48 hours post-siRNA. Slides for tube formation assays were 
incubated at 37°C for 24 hours. Phase images were taken at 6- and 24-hour time points. The 
Angiogenesis Analyzer plugin by Giles Carpentier, (Faculte des Sciences et Technologie, 
Universite Paris Est Creteil Val-de-Marne, France) was used to analyse and quantify images. 
(Gilles Carpentier, Contribution: Angiogenesis Analyzer. ImageJ News, 5 October 2012). Each 
condition was performed in triplicate and at least three independent experiments were carried 
out using different batches of pooled HUVECs. 
2.18 EdU Proliferation Microscopy Assay 
 The Click-iT EdU proliferation assay Alexa Fluor 488 kit from Thermo Fisher Scientific 
was used to quantify proliferation. Cells were cultured on collagen coated surfaces in a 24-well 
plate at 20,000 per well. After addition of siRNA or inhibitors, cells were incubated for 24 hours 
in EGM2. EdU was then added at 20μM for 2 hours, cells were fixed with 4% PFA in H2O, washed 
3x with PBS and permeabilised with 0.1% Triton X100 in PBS for 5 minutes. After 3 washes the 
Click-iT reaction cocktail was added for 30 minutes, as per the manufacturer’s instructions. 
Cells were finally stained using Hoechst and images for 10 randomly selected fields of view in 
each well were taken, each field of view typically contained around 200 cells. An ImageJ macro 
was created to count EdU positive (green nucleus) vs all cells (blue nucleus) and the percentage 
of green cells was calculated. The ImageJ macro involved the following ImageJ functions in 
order:  
• “Subtract background” to remove any anomalies introduced from the surface coating 
• “Colour threshold” to set a intensity threshold for the presence of a nucleus 
• “Convert to mask” to make the image binary based on the colour thresholding 
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• “Fill holes” to ensure that one nucleus is not mistaken for several 
• “Watershed” to separate two adjacent nuclei so that both are counted 
• “Analyse particles” to count the number of particles (nuclei) in each image. This 
function also measures the size, area and position of each particle but for counting 
nuclei only the number of particles is needed.  
Each condition was performed in triplicate and at least three independent experiments 
were carried out using different batches of pooled HUVECs. 
2.19 Cell Spreading Assay – Microscopy 
 Cells were cultured on collagen I coated surfaces in a 24-well plate at 20,000 
per well. After addition of siRNA or inhibitors, cells were incubated for 1 hour in EGM2 at 37°C. 
Cells were then fixed with 4% PFA in H2O, washed 3x with PBS and permeabilised with 0.1% 
Triton X100 in PBS for 5 minutes. After 3 washes with PBS, rhodamine phalloidin and Hoechst 
were added for one hour in PBS with 1% BSA. After three washes cells were imaged in PBS 
using the Leica microscope described above, with 10 fields of view per well. An ImageJ macro 
was created, as before, to count the number of cells per field of view and the area covered by 
cells, per field of view. The area per cell was calculated from these measurements. The ImageJ 
macro was the same as described in 2.18 except the colour threshold parameters differed 
slightly to ensure an accurate measurement of cell area. Each condition was performed in 
triplicate and three independent experiments were carried out using different batches of 
pooled HUVECs. 
2.20 Annexin V Apoptosis Assay – Microscopy  
 Wells of a 24-well plate were coated with collagen or peptides as described 
above. Cells were seeded in EGM2 at 20,000 cells/well and left for 4 hours to attach. The media 
was then changed to EBM + 0.2% FBS + 20ng/ml TNFα. After 6, 24 or 48 hours, cells were 
washed with AV Buffer and incubated in AV buffer plus Annexin V PE and Hoechst for 15 
minutes. After 3 washes with AV buffer, cells were visualised using a Leica DM6000 microscope 
in AV buffer. 5 randomly selected fields of view for each well were acquired. ImageJ was used 
to quantify the average amount of PE fluorescence per cell. The fluorescence intensity was 
measured using the ImageJ function and this was divided by the number of nuclei, counted 
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using the macro above. Each condition was performed in triplicate and at least three 
independent experiments were carried out using different batches of pooled HUVECs. 
2.21 Annexin V Apoptosis Assay – Flow Cytometry 
Wells of a 12-well plate were coated with collagen or peptides as before. Cells were 
seeded in EGM2 at 50,000 cells/well and left for 4 hours to attach. The media was then changed 
to EBM + 0.2% FBS + 20ng/ml TNFα. After 6, 24 or 48 hours, cells were detached using TryplE 
as above and washed with AV Buffer, then resuspended 100μl of AV Buffer +2.5μl Annexin V-
PE and Helix NIR dye for 15 minutes. The cells were then diluted with 500μl of AV Buffer and 
immediately run on an Accuri C6 flow cytometer. Unstained and FMO controls were used to 
gate Annexin V/Helix NIR positive vs negative cells and percentages were calculated. One well 
was analysed per condition and at least three independent experiments were carried out using 
different batches of pooled HUVECs. 
2.22 Cytotoxicity Assay – LDH 
 Cells were grown in 12 or 24-well plates, coated as before with collagen or peptides. 
After 24 hours of treatment (siRNA, serum starving, TNFα or treatment as stated), media was 
collected and stored at 4°C until detection. Stored media was aliquoted into a 96-well plate 
(100μl per well) in triplicate. The Roche cytotoxicity kit was used to quantify LDH released by 
necrotic cells in the media: the catalyst and substrate solutions were mixed at a ratio of 1:45 
and 50μl was added to the wells. Once the red colour had developed, absorbance was read 
using a SpectraMax 190 microplate reader at 490nm. A standard curve was created by lysing a 
known number of cells with 2% Triton X100 for comparison. Each condition was performed in 
triplicate and at least three independent experiments were carried out using different batches 
of pooled HUVECs. 
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2.23 – Diagrams of Plasmids Used in Lentiviral CRISPR 
 
  
An illustration of the psPAX2 packaging plasmid used to create lentiviral particles for the integrin 
knockouts. Figure taken from the Addgene website: https://www.addgene.org/12260/ 
Figure 2.1. Diagram of psPAX2.  
 











An illustration of the pMD2.G packaging plasmid used to create lentiviral particles for the integrin 
knockouts. Figure taken from the Addgene website: https://www.addgene.org/12259/ 
Figure 2.2. Diagram of pMD2.G.  
 




2.24 Toolkit Peptides 
 Toolkit peptides and derivatives were synthesised in-house (by Dr JD Malcor and Dr 
Arkadiusz Bonna, Department of Biochemistry, University of Cambridge) as triple helical 
homotrimers. Peptide strands were assembled using solid phase peptide chemistry on an 
automated microwave-assisted synthesiser to enable rapid, cost-effective and efficient 
synthesis. Peptides were then cleaved from the resin beads, purified by preparative reverse-
phase high performance liquid chromatography, freeze dried and characterized by mass 
spectrometry. Peptides were dissolved at 5 mg/ml in 0.01 M acetic acid, heated to 70°C for 5 
An illustration of the CRISPR plasmid used to create lentiviral particles for the integrin knockouts. 
Figure taken from the Addgene website: https://www.addgene.org/57819/ 
Figure 2.3. Diagram of 57819.  
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min and let to cool down overnight to enable triple helix folding. Peptides were diluted from 
this stock solution to 10 µg/ml in 0.01M acetic acid for the coating of empty tissue culture wells 
prior to experiments. The sequences of the toolkit peptides are listed below (using the one 
letter amino acid code, where O is hydroxyproline. 
Toolkit II Sequences:         
1 GPC(GPP)5- GPMGPMGPRGPOGPAGAOGPQGFQGNO-(GPP)5GPC 
2 GPC(GPP)5- GPQGFQGNOGEOGEOGVSGPMGPRGPO-(GPP)5GPC 
3 GPC(GPP)5- GPMGPRGPOGPOGKOGDDGEAGKOGKA-(GPP)5GPC 
4 GPC(GPP)5- GEAGKOGKAGERGPOGPQGARGFOGTO-(GPP)5GPC 
5 GPC(GPP)5- GARGFOGTOGLOGVKGHRGYOGLDGAK-(GPP)5GPC 
6 GPC(GPP)5- GYOGLDGAKGEAGAOGVKGESGSOGEN-(GPP)5GPC 
7 GPC(GPP)5- GESGSOGENGSOGPMGPRGLOGERGRT-(GPP)5GPC 
8 GPC(GPP)5- GLOGERGRTGPAGAAGARGNDGQOGPA-(GPP)5GPC 
9 GPC(GPP)5- GNDGQOGPAGPOGPVGPAGGOGFOGAO-(GPP)5GPC 
10 GPC(GPP)5- GGOGFOGAOGAKGEAGPTGARGPEGAQ-(GPP)5GPC 
11 GPC(GPP)5- GARGPEGAQGPRGEOGTOGSOGPAGAS-(GPP)5GPC 
12 GPC(GPP)5- GSOGPAGASGNOGTDGIOGAKGSAGAO-(GPP)5GPC 
13 GPC(GPP)5- GAKGSAGAOGIAGAOGFOGPRGPOGPQ-(GPP)5GPC 
14 GPC(GPP)5- GPRGPOGPQGATGPLGPKGQTGEOGIA-(GPP)5GPC 
15 GPC(GPP)5- GQTGEOGIAGFKGEQGPKGEOGPAGPQ-(GPP)5GPC 
16 GPC(GPP)5- GEOGPAGPQGAOGPAGEEGKRGARGEO-(GPP)5GPC 
17 GPC(GPP)5- GKRGARGEOGGVGPIGPOGERGAOGNR-(GPP)5GPC 
18 GPC(GPP)5- GERGAOGNRGFOGQDGLAGPKGAOGER-(GPP)5GPC 
19 GPC(GPP)5- GPKGAOGERGPSGLAGPKGANGDOGRO-(GPP)5GPC 
20 GPC(GPP)5- GANGDOGROGEOGLOGARGLTGROGDA-(GPP)5GPC 
21 GPC(GPP)5- GLTGROGDAGPQGKVGPSGAOGEDGRO-(GPP)5GPC 
22 GPC(GPP)5- GAOGEDGROGPOGPQGARGQOGVMGFO-(GPP)5GPC 
23 GPC(GPP)5- GQOGVMGFOGPKGANGEOGKAGEKGLO-(GPP)5GPC 
24 GPC(GPP)5- GKAGEKGLOGAOGLRGLOGKDGETGAA-(GPP)5GPC 
25 GPC(GPP)5- GKDGETGAAGPOGPAGPAGERGEQGAO-(GPP)5GPC 
26 GPC(GPP)5- GERGEQGAOGPSGFQGLOGPOGPOGEG-(GPP)5GPC 
27 GPC(GPP)5- GPOGPOGEGGKOGDQGVOGEAGAOGLV-(GPP)5GPC 
28 GPC(GPP)5- GEAGAOGLVGPRGERGFOGERGSOGAQ-(GPP)5GPC 
29 GPC(GPP)5- GERGSOGAQGLQGPRGLOGTOGTDGPK-(GPP)5GPC 
30 GPC(GPP)5- GTOGTDGPKGASGPAGPOGAQGPOGLQ-(GPP)5GPC 
31 GPC(GPP)5- GAQGPOGLQGMOGERGAAGIAGPKGDR-(GPP)5GPC 
32 GPC(GPP)5- GIAGPKGDRGDVGEKGPEGAOGKDGGR-(GPP)5GPC 
33 GPC(GPP)5- GAOGKDGGRGLTGPIGPOGPAGANGEK-(GPP)5GPC 
34 GPC(GPP)5- GPAGANGEKGEVGPOGPAGSAGARGAO-(GPP)5GPC 
35 GPC(GPP)5- GSAGARGAOGERGETGPOGPAGFAGPO-(GPP)5GPC 
36 GPC(GPP)5- GPAGFAGPOGADGQOGAKGEQGEAGQK-(GPP)5GPC 
37 GPC(GPP)5- GEQGEAGQKGDAGAOGPQGPSGAOGPQ-(GPP)5GPC 
38 GPC(GPP)5- GPSGAOGPQGPTGVTGPKGARGAQGPO-(GPP)5GPC 
39 GPC(GPP)5- GARGAQGPOGATGFOGAAGRVGPOGSN-(GPP)5GPC 
40 GPC(GPP)5- GRVGPOGSNGNOGPOGPOGPSGKDGPK-(GPP)5GPC 
41 GPC(GPP)5- GPSGKDGPKGARGDSGPOGRAGEOGLQ-(GPP)5GPC 
42 GPC(GPP)5- GRAGEOGLQGPAGPOGEKGEOGDDGPS-(GPP)5GPC 
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43 GPC(GPP)5- GEOGDDGPSGAEGPOGPQGLAGQRGIV-(GPP)5GPC 
44 GPC(GPP)5- GLAGQRGIVGLOGQRGERGFOGLOGPS-(GPP)5GPC 
45 GPC(GPP)5- GFOGLOGPSGEOGKQGAOGASGDRGPO-(GPP)5GPC 
46 GPC(GPP)5- GASGDRGPOGPVGPOGLTGPAGEOGRE-(GPP)5GPC 
47 GPC(GPP)5- GPAGEOGREGSOGADGPOGRDGAAGVK-(GPP)5GPC 
48 GPC(GPP)5- GRDGAAGVKGDRGETGAVGAOGAOGPO-(GPP)5GPC 
49 GPC(GPP)5- GAOGAOGPOGSOGPAGPTGKQGDRGEA-(GPP)5GPC 
50 GPC(GPP)5- GKQGDRGEAGAQGPMGPSGPAGARGIQ-(GPP)5GPC 
51 GPC(GPP)5- GPAGARGIQGPQGPRGDKGEAGEOGER-(GPP)5GPC 
52 GPC(GPP)5- GEAGEOGERGLKGHRGFTGLQGLOGPO-(GPP)5GPC 
53 GPC(GPP)5- GLQGLOGPOGPSGDQGASGPAGPSGPR-(GPP)5GPC 
54 GPC(GPP)5- GPAGPSGPRGPOGPVGPSGKDGANGIO-(GPP)5GPC 
55 GPC(GPP)5- GKDGANGIOGPIGPOGPRGRSGETGPA-(GPP)5GPC 
56 GPC(GPP)5- GPRGRSGETGPAGPOGNOGPOGPOGPO-(GPP)5GPC 
 
 
Toolkit III Sequences: 
 
1 GPC(GPP)5- GLAGYOGPAGPOGPOGPOGTSGHOGSO-(GPP)5GPC 
2 GPC(GPP)5- GTSGHOGSOGSOGYQGPOGEOGQAGPS-(GPP)5GPC 
3 GPC(GPP)5- GEOGQAGPSGPOGPOGAIGPSGPAGKD-(GPP)5GPC 
4 GPC(GPP)5- GPSGPAGKDGESGROGROGERGLOGPO-(GPP)5GPC 
5 GPC(GPP)5- GERGLOGPOGIKGPAGIOGFOGMKGHR-(GPP)5GPC 
6 GPC(GPP)5- GFOGMKGHRGFDGRNGEKGETGAOGLK-(GPP)5GPC 
7 GPC(GPP)5- GETGAOGLKGENGLOGENGAOGPMGPR-(GPP)5GPC 
8 GPC(GPP)5- GAOGPMGPRGAOGERGROGLOGAAGAR-(GPP)5GPC 
9 GPC(GPP)5- GLOGAAGARGNDGARGSDGQOGPOGPO-(GPP)5GPC 
10 GPC(GPP)5- GQOGPOGPOGTAGFOGSOGAKGEVGPA-(GPP)5GPC 
11 GPC(GPP)5- GAKGEVGPAGSOGSNGAOGQRGEOGPQ-(GPP)5GPC 
12 GPC(GPP)5- GQRGEOGPQGHAGAQGPOGPOGINGSO-(GPP)5GPC 
13 GPC(GPP)5- GPOGINGSOGGKGEMGPAGIOGAOGLM-(GPP)5GPC 
14 GPC(GPP)5- GIOGAOGLMGARGPOGPAGANGAOGLR-(GPP)5GPC 
15 GPC(GPP)5- GANGAOGLRGGAGEOGKNGAKGEOGPR-(GPP)5GPC 
16 GPC(GPP)5- GAKGEOGPRGERGEAGIOGVOGAKGED-(GPP)5GPC 
17 GPC(GPP)5- GVOGAKGEDGKDGSOGEOGANGLOGAA-(GPP)5GPC 
18 GPC(GPP)5- GANGLOGAAGERGAOGFRGPAGPNGIO-(GPP)5GPC 
19 GPC(GPP)5- GPAGPNGIOGEKGPAGERGAOGPAGPR-(GPP)5GPC 
20 GPC(GPP)5- GAOGPAGPRGAAGEOGRDGVOGGOGMR-(GPP)5GPC 
21 GPC(GPP)5- GVOGGOGMRGMOGSOGGOGSDGKOGPO-(GPP)5GPC 
22 GPC(GPP)5- GSDGKOGPOGSQGESGROGPOGPSGPR-(GPP)5GPC 
23 GPC(GPP)5- GPOGPSGPRGQOGVMGFOGPKGNDGAO-(GPP)5GPC 
24 GPC(GPP)5- GPKGNDGAOGKNGERGGOGGOGPQGPO-(GPP)5GPC 
25 GPC(GPP)5- GGOGPQGPOGKNGETGPQGPOGPTGPG-(GPP)5GPC 
26 GPC(GPP)5- GPOGPTGPGGDKGDTGPOGPQGLQGLO-(GPP)5GPC 
27 GPC(GPP)5- GPQGLQGLOGTGGPOGENGKOGEOGPK-(GPP)5GPC 
28 GPC(GPP)5- GKOGEOGPKGDAGAOGAOGGKGDAGAO-(GPP)5GPC 
29 GPC(GPP)5- GGKGDAGAOGERGPOGLAGAOGLRGGA-(GPP)5GPC 
30 GPC(GPP)5- GAOGLRGGAGPOGPEGGKGAAGPOGPO-(GPP)5GPC 
31 GPC(GPP)5- GAAGPOGPOGAAGTOGLQGMOGERGGL-(GPP)5GPC 
32 GPC(GPP)5- GMOGERGGLGSOGPKGDKGEOGGOGAD-(GPP)5GPC 
33 GPC(GPP)5- GEOGGOGADGVOGKDGPRGPTGPIGPO-(GPP)5GPC 
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34 GPC(GPP)5- GPTGPIGPOGPAGQOGDKGEGGAOGLO-(GPP)5GPC 
35 GPC(GPP)5- GEGGAOGLOGIAGPRGSOGERGETGPO-(GPP)5GPC 
36 GPC(GPP)5- GERGETGPOGPAGFOGAOGQNGEOGGK-(GPP)5GPC 
37 GPC(GPP)5- GQNGEOGGKGERGAOGEKGEGGPOGVA-(GPP)5GPC 
38 GPC(GPP)5- GEGGPOGVAGPOGGSGPAGPOGPQGVK-(GPP)5GPC 
39 GPC(GPP)5- GPOGPQGVKGERGSOGGOGAAGFOGAR-(GPP)5GPC 
40 GPC(GPP)5- GAAGFOGARGLOGPOGSNGNOGPOGPS-(GPP)5GPC 
41 GPC(GPP)5- GNOGPOGPSGSOGKDGPOGPAGNTGAO-(GPP)5GPC 
42 GPC(GPP)5- GPAGNTGAOGSOGVSGPKGDAGQOGEK-(GPP)5GPC 
43 GPC(GPP)5- GDAGQOGEKGSOGAQGPOGAOGPLGIA-(GPP)5GPC 
44 GPC(GPP)5- GAOGPLGIAGITGARGLAGPOGMOGPR-(GPP)5GPC 
45 GPC(GPP)5- GPOGMOGPRGSOGPQGVKGESGKOGAN-(GPP)5GPC 
46 GPC(GPP)5- GESGKOGANGLSGERGPOGPQGLOGLA-(GPP)5GPC 
47 GPC(GPP)5- GPQGLOGLAGTAGEOGRDGNOGSDGLO-(GPP)5GPC 
48 GPC(GPP)5- GNOGSDGLOGRDGSOGGKGDRGENGSO-(GPP)5GPC 
49 GPC(GPP)5- GDRGENGSOGAOGAOGHOGPOGPVGPA-(GPP)5GPC 
50 GPC(GPP)5- GPOGPVGPAGKSGDRGESGPAGPAGAO-(GPP)5GPC 
51 GPC(GPP)5- GPAGPAGAOGPAGSRGAOGPQGPRGDK-(GPP)5GPC 
52 GPC(GPP)5- GPQGPRGDKGETGERGAAGIKGHRGFO-(GPP)5GPC 
53 GPC(GPP)5- GIKGHRGFOGNOGAOGSOGPAGQQGAI-(GPP)5GPC 
54 GPC(GPP)5- GPAGQQGAIGSOGPAGPRGPVGPSGPO-(GPP)5GPC 
55 GPC(GPP)5- GPVGPSGPOGKDGTSGHOGPIGPOGPR-(GPP)5GPC 
56 GPC(GPP)5- GPIGPOGPRGNRGERGSEGSOGHOGQO-(GPP)5GPC 
57 GPC(GPP)5- GERGSEGSOGHOGQOGPOGPOGAOGPC-(GPP)5GPC 
 


































2.25 Statistical Analysis 
 PRISM GraphPad 8.2.1 was used for all statistical tests. Where siRNA is used, the mean 
value for each condition is compared to the mean value for the control condition using ordinary 
one-way ANOVA and Dunnett’s multiple comparisons test unless otherwise stated. Dunnett’s 
multiple comparisons test was used here because each siRNA condition was compared to the 
negative control siRNA condition and Dunnett’s test was the most appropriate test for this 
comparison. Dunnett’s test was also recommended by the PRISM GraphPad software for this 
application. Where inhibitors or activators are used, ordinary one-way ANOVA analysis is used 
with Sidak’s multiple comparisons test and the mean for each condition is compared with the 
mean for the appropriate control condition. TC-I-15 is compared with the TC-I-15 vehicle 
control (NaOH) and everything else is compared to the control, both using Sidak’s multiple 
comparison test or T-tests where stated. Sidak’s test was used here because it is a relatively 
stringent test and each condition was compared to the relevant control condition rather than 
an overall control for the experiment. The test results are included in the text and P values that 
indicate statistical significance are highlighted in bold. If a Student’s T-test is used, it is stated 
and described in the text. The Student’s T-test is used to compare pairs of data sets only, with 
no multiple comparisons. Two-way ANOVA and Tukey’s multiple comparisons tests are used 
for some of the static adhesion assays and some qPCR expression data and this is stated in the 
text. Tukey’s multiple comparisons test is used to compare each condition to all other 
conditions in the experiment, rather than comparing each condition to a control condition.  
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3.1 – Chapter Summary 
 This chapter focusses on using THPs synthesised in the Farndale Group to probe 
integrin binding preferences with the aim of determining specific peptides ligands targeting 
specific integrins. In the first instance, binding of integrin αI-domains to THPs containing 
proposed integrin-binding motifs was assessed. To verify the data produced in this work, 
further experiments were performed using C2C12 cells that were stably transfected to express 
full-length integrin receptors. The mRNA expression profiles of the four collagen-binding 
integrins was determined in HUVECs alongside other collagen receptors and the EC marker 
VWF. HUVECs were validated for expression of endothelial markers such as VWF, PECAM-1, 
VEGFR2, and MCAM. Finally, the integrin THP binding profiles determined using C2C12 cells 
was compared with the adhesion profiles of HUVECs on the same THPs. In this chapter, and 
indeed the rest of the thesis, α2β1 refers to the full-length integrin heterodimer whereas ITGA2 
refers to the α-subunit alone. 
3.2 –  Introduction  
 Integrins are primarily a group of adhesion receptors that anchor cells to the ECM, or 
to other cells, before activating a wide range of downstream signalling pathways. These 
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depend on the cell type and presence of other integrin-associated proteins. For example 
platelet αIIBβ3 adhesion to fibrinogen leads to platelet aggregation[141] and α2β1 adhesion to 
collagen in leukocytes promotes T-cell survival through a MAPK/ERK pathway[237]. The ligands 
vary between the 24 integrins and the main ligands are summarised below[238] in Table 3.1. 
However, there are many other protein-protein interactions not listed here: 
 
Table 3.1 – Different Integrin Ligands 
Ligand Found in Integrins 
RGD motif 
Fibronectin, vitronectin, laminin, 
fibrinogen, VWF 
αVβ1, αVβ3, αVβ5, αVβ6, αVβ8, α5β1, α8β1, 
αIIbβ3 
LDV motif Fibronectin, VCAM1, CD45 α4β1, α4β7, α9β1, αLβ2 αMβ2 αXβ2 αDβ2, αEβ7 
GFOGER motif Collagens α1β1, α2β1, α10β1, α11β1 
Laminin Laminin α3β1, α6β1, α7β1, α6β4 
adapted from: ‘Crystal 
Structure of the I Domain 
from Integrin α2β1’ by 
Jonas Emsley et al. J. Biol. 
Chem. 1997[8] 
The coordinated Mg2+ ion 
(M) with associated water 
molecules (ω). Loops in 
grey, helices in green. Side 
chains of the MIDAS are 
shown, alongside the side 
chain from the C-Helix, 
which regulates ITGA2 αI-
domain adhesion. 
Figure 3.1: Diagram of the Structure of the MIDAS From ITGA2 αI-domain 
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Each integrin will recognise a different motif, or set of motifs, and the differences in 
binding affinities could play a role in regulating cell function by targeting a specific integrin to 
trigger subsequent signalling pathways. An enrichment of α1β1 specific motifs in the ECM 
could upregulate α1β1 adhesion and could lead to increased α1β1-dependent downstream 
signalling events. Crystal structures have been obtained for the α1β1 and α2β1 αI-domains[8, 
239]. They are proposed to bind collagen in a similar way as the MIDAS is strictly conserved. 
However, there could be subtle differences that infer selective binding preferences in different 
collagens. For the ITGA2 αI-domain, the MIDAS is made up from D151, S153, S155, T221, D254 
from the Rossman fold structure and Y285 from the C-helix[8] (Figure 3.1) creating a groove. An 
E residue from the collagen motif would coordinate the Mg2+ ion in the MIDAS to facilitate 
binding in the groove created by the C-helix (Figure 3.2). The C-helix groove is thought to be 
25Å x 20Å in dimension, containing the prominent Y285. In this model from Emsley et al[8] 
(Figure 3.1 and 3.2), substituting the E residue in collagen for a shorter D residue would annul 
binding due to steric clashes. Other residues predicted to be involved in binding are D219, 
Adapted from ‘Crystal Structure of the I Domain from Integrin α2β1’ Emsley et al 1997[8] showing the 
electron density map of integrin α2β1 αI-domain binding to a THP. A glutamate residue fits into the groove 
created by the MIDAS and the C-helix. Blue = positive charge, red = negative charge and white = neutral. 
Collagen is shown as a backbone triple helix.  
Figure 3.2: Diagram of the I-domain of α2β1 Binding to Collagen. 
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L220, E256, H258, Y285, N289, L291, N295, K298. The MIDAS, C-helix and groove are 
conserved between the ITGA1 and ITGA2 αI-domains[239], however the C-helix differs in that 
the Y285 is replaced with a S, and L286 becomes Y in ITGA1. An activating mutation in ITGA1 
(E317A) causes the C-helix to unwind, changing the position of Y285 and moving the helix into 
an open conformation which upregulates activity[240]. 
Previous work in the Prof Farndale group established that GFOGER and GLOGEN are 
strong ligands for all four collagen binding integrins, with GFOGER targeting preferentially α2β1 
and α11β1 while GLOGEN targets preferentially α1β1 and α10β1[235, 241] and so this was taken 
as a starting point for exploring other motifs. Collagen protein sequences were probed for any 
potential integrin binding sites that resembled the GFOGER or GLOGEN motifs already 
established. THPs, described in Chapter 2.23, containing these motifs were synthesised. THPs 
are homotrimeric peptide sequences that readily form triple helices due to their GPC(GPP)5 
repeats at both the N and C terminus surrounding the central integrin-motif sequence[232, 234]. 
These THPs mimic the natural triple helical structure of the triple helical domains (THDs) of 
collagen but they are short and contain functional sequences. Table 3.2 summarises the motifs 
that synthesised and tested, referred to from now on as Short Peptides (SPs). To probe the 
different binding preferences of the 4 collagen-binding integrins, α1β1, α2β1, α10β1, α11β1, 
static adhesion assays were employed using these collagen mimetic SPs. Two motifs, GHDGDK 
and GFSGER, from the SPs are not present in any human collagen THDs but were included to 
test the effect of changing E to D in GHDGEK, and a change from A to F in GASGER. 
GPP10, a THP composed only of 10 GPP triplets and GPC triplets on both the N- and C- 
terminal, was synthesised to serve as a negative control. This was used to check that any 
activity is due to the inserted GFOGER-like motif rather than the general triple helical structure 
imposed by GPP triplets, or the GPP repeats themselves. While GPP10 is an inert negative 
control, it is important to note that the helical structure is likely to be tighter in the repeated 
GPP repeats seen in GPP10 than in native collagen. This change in conformation could affect 
integrin binding as well. Integrins with a MIDAS require metal ions to function[8] (Figure 3.1), 
so for each experiment either Mg2+ was added to facilitate binding or a metal ion chelator, 
ethylenediaminetetraacetic acid (EDTA), was added to sequester metal ions. If binding was 
observed in the presence of EDTA it can be assumed to be non-specific, as the MIDAS in the 
αI-domain will not be able to function without Mg2+. 
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GΑOGER  Α1x2 Α1x2 Α2  
Α1 
Α3 
Α1x2  Α3              
GΑSGER Α1                 Α1     
GFOGDR     Α1                  
GFOGEK    Α6  Α3    Α1             





  Α1    
Α1 
Α2 
           
GFQGEK    Α6                   
GFSGER                       
GHDGDK                       
GHDGEK            Α1           
GKOGER Α2         Α1             
GLKGEN   Α1                    





  Α1   Α1         Α1    








A1   A2  A2            




Α1     Α1x2                
GLOGEΑ    Α4       Α1          Α1  
GLSGER   Α1                    
GMOGER Α1 Α1 Α1  Α2    Α3              
GNOGER     Α1            Α1  Α1    
GNRGER   Α1         Α1           
GPKGER    Α6 Α1  Α1    Α1 Α1 Α1 Α1x2 Α1  Α1   Α1   
GQKGEI        Α1    Α1    Α1       




 Α1    Α1   Α1             
GRSGET  Α1                     
GSOGEK    Α1 Α3       Α1x2           
GSQGEK                       
GVOGER        A2              A1 
GVOGEΑ  Α1                     
Table 3.2. List of integrin-binding peptide motifs in THPs. showing the distribution of collagen motifs in the COL 
(triple helical) domains of different human collagens. Α1 = THD alpha 1 chain. Α1x2 means the motif is found 
twice in that domain. GHDGDK and GFSGER are not found anywhere in the COL domains of human collagens. 
GHDGDK was created to test the effects of E to D mutation in GHDGEK whereas GFSGER is a mutation of the 
GΑSGER found in collagen I. 
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Simplified systems using recombinant αI-domains were used as a starting point to study 
the interactions between integrins and collagens. The αI-domains contain the binding sites for 
collagen[8]. These αI-domains were cloned by Dr Samir Hamaia and expressed in bacterial 
systems as GST-tagged constructs. These were used in static adhesion assays alongside the SPs 
described above. In order to study integrins in a simplified cellular set-up, C2C12 that are stably 
transfected to express one of the four collagen-binding integrins were used in adhesion studies 
to assess the behaviour of the full-length heterodimer integrin in the hope of finding peptides 
that are specific for each of the four integrins. C2C12 cells were stably transfected by Dr Samir 
Hamaia to express one of the four α-subunits, which then associates with the mouse β1 subunit 
inside the cell to form the full-length functional receptor. C2C12 cells are an immortalised 
mouse myoblast cell line that were chosen because they do not naturally express any collagen-
binding integrins and so any positive binding observed in the transfected cells that is absent in 
the non-transfected (C2C12 control) cells can be assumed to be a result of the transfected 
human α-subunit, as described in[242].  
3.3 Binding of Recombinant αI-domains to Short Peptides  
First, GST-tagged αI-domains were expressed in bacteria, extracted and purified using 
anti-GST affinity columns. The αI-domains for ITGA1 and ITGA2 were straightforward to 
express and both were functional showing high affinity specific binding when tested with 
collagen and GFOGER. However, ITGA10 and ITGA11 proved much more difficult to express 
and while GST-tagged proteins were recovered in abundance, they were not functional. This 
may be due to differences in folding between the αI-domains. It is possible a regulatory protein 
that aids αI-domain folding in ITGA10 and ITGA11 is missing or that the conditions required for 
successful protein folding and function are simply not met. The β1-subunit could also be 
necessary for proper function or folding of these integrins and the αI-domain alone may not 
be enough to bind in these conditions. Immulon 2HB plates were coated with peptides 
overnight in 0.01M AcOH and blocked with BSA before integrin αI-domains were added and 
left to adhere. After stringent wash steps, an anti-GST HRP conjugated antibody was used to 
detect remaining bound αI-domain using a TMB substrate colourimetric assay. Integrin αI-
domain binding is shown in Figure 3.3 as a function of absorbance. Binding took place in a 
cation-dependent manner, with no binding in the presence of EDTA. This suggests that there 
were no non-specific adhesion and that the detected absorbance was due to binding through 
Chapter 3 – Integrin Adhesion Studies 
71 
 
integrins. This was confirmed by the absence of binding on BSA-coated wells. The absence of 
adhesion on GPP10 further implied that no non-specific binding to the triple helix structure of 
peptides occurred. Table 3.3 and 3.4 show a summary of the statistical analysis of the Mg2+ 
values for each peptide using Dunnett’s multiple comparison test comparing each value to that 
of GPP10, P values are adjusted for multiple comparisons.  
 
 
Figure 3.3: Integrin αI-Domain Adhesion to Short Peptides 
Graph showing the binding of recombinant ITGA1 and ITGA2 αI-domains to SPs as a function of as 
absorbance at 450nm, at a 1hr time point. Black bars represent the presence of Mg2+ and grey bars 
represent the presence of EDTA, as thus show non-specific binding. The mean absorbance from 
three separate repeats is plotted with the error bars indicating SD 
A 
B 
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Table 3.3 – Statistical analysis for ITGA1 αI-domain 
Peptide Mean SD P Peptide Mean SD P 
GAOGER 0.3023 0.019 0.9323 GLOGER 3.284 0.102 <0.0001 
GASGER 0.1274 0.027 0.9991 GLSGER 3.314 0.063 <0.0001 
GFOGDR 0.2105 0.053 0.9996 GMOGER 0.6356 0.121 <0.0001 
GFOGEK 3.395 0.246 <0.0001 GNOGER 3.519 0.092 <0.0001 
GFOGER 3.341 0.133 <0.0001 GNRGER 0.2798 0.066 0.9864 
GFQGEK 3.025 0.084 <0.0001 GPKGER 0.2932 0.218 0.9677 
GFSGER 3.288 0.143 <0.0001 GQKGEI 0.4217 0.361 0.1175 
GHDGDK 0.1287 0.053 0.9991 GQRGER 0.1067 0.015 0.9986 
GHDGEK 0.1325 0.042 0.9992 GROGER 2.218 0.533 <0.0001 
GKOGER 2.818 0.591 <0.0001 GRSGET 3.274 0.177 <0.0001 
GLKGEN 2.629 0.459 <0.0001 GSOGEK 0.4139 0.195 0.1447 
GLKGER 0.8004 0.226 <0.0001 GSQGEK 0.1482 0.047 0.9995 
GLOGEA 3.403 0.235 <0.0001 GVOGEA 0.1798 0.023 >0.9999 
GLOGEN 3.319 0.145 <0.0001 BSA 0.09458 0.055 0.9937 
Analysis of mean absorbance values compared to the GPP10 control mean. P values were obtained 
using Dunnett’s Multiple comparison test, adjusted for multiple comparisons 
 
Table 3.4 – Statistics analysis for ITGA2 αI-domain 
 
Peptide Mean SD P Peptide Mean SD P 
GAOGER 0.1505 0.009 0.3926 GLOGER 0.6888 0.047 <0.0001 
GASGER 0.1469 0.013 0.3445 GLSGER 0.4835 0.113 <0.0001 
GFOGDR 0.1585 0.006 0.5142 GMOGER 0.1352 0.007 0.2127 
GFOGEK 3.312 0.166 <0.0001 GNOGER 0.5523 0.450 <0.0001 
GFOGER 2.779 0.135 <0.0001 GNRGER 0.1744 0.025 0.7792 
GFQGEK 0.6320 0.180 <0.0001 GPKGER 0.1178 0.016 0.0921 
GFSGER 2.291 0.229 <0.0001 GQKGEI 0.3258 0.091 0.8073 
GHDGDK 0.1354 0.041 0.2149 GQRGER 0.1477 0.010 0.3543 
GHDGEK 0.1245 0.020 0.1292 GROGER 0.8139 0.042 <0.0001 
GKOGER 0.3974 0.096 0.0442 GRSGET 0.4683 0.104 0.0002 
GLKGEN 0.1734 0.038 0.7624 GSOGEK 0.3108 0.051 0.9657 
GLKGER 0.1493 0.012 0.3755 GSQGEK 0.1471 0.016 0.3462 
GLOGEA 0.3689 0.032 0.1942 GVOGEA 0.1576 0.007 0.5005 
GLOGEN 0.1729 0.026 0.7556 BSA 0.1261 0.022 0.1402 
Analysis of mean absorbance values compared to the GPP10 control mean. P values were obtained 
using Dunnett’s Multiple comparison test, adjusted for multiple comparisons 
 
The binding profiles of the two integrins were markedly different. ITGA1 αI-domain 
showed strong binding to most peptides tested whereas the ITGA2 counterpart was much less 
active, binding to only 3 motifs. Whilst previous work indicates that α1β1 preferentially binds 
GLOGEN over GFOGER, here strong binding to both ligands was observed. The αI-domain binds 
motifs from several collagen sequences with a high specificity; out of the collagen IV motifs. 
ITGA1 bound to GFQGEK, GFOGEK, GLOGEA and GFOGER and moderate binding affinity to 
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GROGER was observed. Numerous peptides which were specific for ITGA1 did not bind ITGA2. 
The differential affinities of the integrins for peptide sequences indicates that peptides could 
be used as a tool to probe ITGA1 function in ECs. Whilst no clear conclusive consensus 
sequence for ITGA1 αI-domain was determined, analysis of the ITGA1 binding motifs raises 
some important points which are summarised below with bullet points for simplicity:  
• GLKGEN supported moderate binding whilst GLKGER does not. did not. However, the 
GER motif supported binding in many other peptides. This suggests that the overall 
change in shape or charge conferred by a mutation from N to R in the presence of GLK 
impedes binding. 
• GNOGER but not GMOGER supported binding. No other peptides have methionine in 
the 2nd position in the consensus sequence, but other THPs that have hydrophobic side 
chains (GLOGEN, GLOGER) and larger side chains (GFOGER) showed strong binding.  
• GLOGER and GLOGEN showed similar binding profiles , suggesting that an R  (positively 
charged) to N (polar neutral) mutation does not impede binding at this position. 
• GFQGEK supported binding whilst GSQGEK did not, suggesting a F (hydrophobic) to S 
(polar neutral) in the 2nd position blocks binding. 
• GLOGEA supported high binding but GVOGEA did not. Both L and V have hydrophobic 
aliphatic side chains, but V is one carbon shorter. 
• GFOGER and GFOGEK both supported high binding. Both R and K have basic side chains, 
but many peptides with N in the 6th position also show high binding, so this is not a 
requirement. 
• GLOGEN and GLKGEN both show high binding suggesting the 3rd position can be basic 
or polar neutral. There are no tight restrictions on the 3rd position. 
• Changing the 5th position from E to D abolishes binding in GFOGER as predicted by 
Emsley et al[8] for ITGA2 αI-domain. 
The binding profile of the αI-domain of ITGA1 suggests that there are no restrictions on 
the 2nd, 3rd and 6th positions of the recognition motif and that it may be the overall shape 
and confirmation of the helix rather than the specific residues that confers specificity. The 
groove in the I-domain contains a mixture of positive, negative and neutral side chains, thus 
the variability of the recognition sequence may stem from this[8]. 
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The binding profile of ITGA2 αI-domain was much less active, binding only GFOGER 
(collagen type I, II, IV, VII, XI), GFOGEK (collagen type IV, VI, X) and GFSGER. This suggests that 
GFx3GEx6, where x3 is neutral, x6 is basic and the 5th position is a glutamate, is necessary for 
binding. The absence of binding to other SPs could be due to missing regulatory elements in 
the β-subunit. Alternatively, the αI-domain could be in a less active confirmation when 
expressed as an αI-domain recombinant protein alone, without the rest of the β-propeller from 
the α-subunit or the rest of the α-subunit itself. There are no peptides specific for the ITGA2 
αI-domain. 
3.4 Binding of integrin expressing C2C12 cells to Short Peptides 
 Adhesion of recombinant proteins of αI-domains is a good starting point for studying 
integrins, but this approach is limited as only one domain of the receptor is present and there 
are no functional αI-domains for ITGA10 and ITGA11. The β1 subunit and the rest of the α-
subunit could play a role in the regulation of integrin function, as the β-subunit has its own I-
domain, so it is important to validate any findings using full length receptors. Also, protein 
adhesion assays here only study the simple interactions between the αI-domain and the 
peptide whereas in a physiological setting there are several other receptors and signalling 
molecules that would associate and interact with integrins on the cell surface. It is therefore 
necessary to validate the αI-domain assays in whole cells.  
 Static adhesion assays using SPs, as above, were carried out under sterile conditions. 
After blocking, C2C12 cells expressing collagen binding integrins were added at 20,000/well in 
serum-free DMEM and left at RT for one hour to adhere to coated peptides. After three gentle 
washes the remaining cells were lysed in 50μl of 2% Triton x100. The Roche cytotoxicity LDH 
kit was used to quantify the number of cells still attached to the peptides after washing as a 
function of LDH activity in a colorimetric assay. Results are shown in Figure 3.4. 
 The binding profiles of the four integrins were very similar. The α2β1 receptor showed 
the more active profile, indicated by binding to a large number of peptides, whereas the α1β1 
(and α10β1, α11β1) showed a less active binding profile compared to experiments using αI-
domain recombinant proteins. This is possibly due to the absence of the regulatory function of 
the β1 subunit and the rest of the α-subunit in the recombinant proteins. Binding of the αI-
domain to GNOGER, GKOGER, GLOGER, GORGER and GMOGER was lost in the full length α1β1 
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receptor whereas the full length α2β1 adhered to more THPs than the ITGA2 αI-domain. The 
β1-subunit could potentially interact with each α-subunit differently. For example, the β1-
subunit could stabilise a less active confirmation of the ITGA1 αI-domain but could encourage 
a more active confirmation of the ITGA2 αI-domain. Further studies are needed to confirm this 
hypothesis. It is possible that other co-receptors are present in C2C12 cells that subtly 
influence the activity of the integrin heterodimers, explaining the differences seen between 
isolated αI-domains and full-length receptors. The data presented from the C2C12 cell 
adhesion assays is more physiologically relevant as it takes place in a cellular setting with full-
length receptors rather than isolated αI-domains. 
 
Table 3.5 – List of peptide specificity 
 
Peptides that bind all integrins Peptides specific for α2β1  
Motif Collagen Type Motif  Collagen Type 
GFOGEK IV, VI and X GAOGER II, III, IV, VI, VII, IX 
GFOGER I, II, IV, VII and XI GKOGER I and X 
GFSGER not found in human collagens GMOGER I, II, III, V, IX 
GLOGEK IV, V, VI, IX and XI GNOGER V, XXII and XXIV 
GLOGEN III XXI and XXII GNRGER III and XIII 
GLOGER I II and VII GSOGEK IV, V, XIII 
Other peptide specificities 
Motif Collagen Type Integrin specificity 
GFQGEK IV α1β1 and α2β1 only 
GLKGER IV VII and X α2β1 and α10β1 only 
GLOGEA IV XI and XXVII Not α11β1 
GLKGEN III Not α11β1 
GLSGER III Not α11β1 
GRSGET II α1β1, α2β1 only 
GROGER I, III, VII, X Not α10β1 
 
   




Adhesion is shown as absorbance at 490nm after cell lysis and quantification with the LDH 
colorimetric cytotoxicity assay. The black bars indicate Mg2+ dependent adhesion while the grey 
bars indicate addition of the metal ion chelator EDTA. SPs are shown in alphabetical order, GPP10 
is a negative control peptide. BSA represents empty wells coated with BSA without THPs.  
Figure 3.4 Adhesion of Integrin Expressing C2C12 to Short Peptides  
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The C2C12 control cells showed no binding both with Mg2+ and EDTA. Therefore, the 
binding seen with the transfected C2C12 cells is assumed to be due to the transfected human 
α-subunit. None of the cell lines showed binding in the EDTA condition (grey bars) meaning 
that all adhesion was metal ion dependent, suggesting again that any binding seen in the 
presence of Mg2+ is due to the transfected integrins. Table 3.5 summarises the peptides that 
have specific integrin binding patterns. Unfortunately, only α2β1 shows binding to specific 
peptides. As a consequence, binding to α2β1 will mask adhesion of other integrins when more 
than one type of integrin is present. Tables 3.6 to 3.9 summarise the statistical analyses. 
This comprehensive study of collagenous integrin binding motifs types suggests that 
there are multiple, varied binding sites for all four collagen-binding integrins across the entire 
human collagen family. However, it also shows that peptides alone cannot be used to ligate 
single integrins in ECs as there is considerable overlap of binding motifs across the four 
receptors. In addition, the more active binding profile of α2β1 masks the attachment to other 
integrins and prevents us from determining the specific effect of each integrin on cellular 
response using THPs. Generally, the consensus binding motif among all four integrins is 
Gx2x3GEx6, where x2 is F or L, x3 is O or S and x6 is K, N or R, in agreement with our previous 
publication[243]; an R at x2 will rule out binding of α10β1 due to a clash between positively 
charged R215 in the αI-domain and the R at x2. These results also suggest that A or K at x3 
attenuate binding of α11β1. 
Table 3.6: Statistical analysis of C2C12-ITGA1 adhesion to THPs.  
Peptide Mean 
absorbance 
SD n P Peptide Mean 
absorbance 
SD n P 
GAOGER 0.141 0.054 4 0.9993 GLOGER 0.493 0.143 4 <0.0001 
GASGER 0.194 0.064 4 0.9994 GLSGER 1.049 0.257 4 <0.0001 
GFOGDR 0.128 0.045 4 0.9989 GMOGER 0.098 0.027 4 0.9482 
GFOGEK 0.937 0.067 4 <0.0001 GNOGER 0.192 0.083 4 0.9994 
GFOGER 1.342 0.085 4 <0.0001 GNRGER 0.118 0.044 4 0.9943 
GFQGEK 0.522 0.058 4 <0.0001 GPKGER 0.132 0.064 4 0.9990 
GFSGER 1.502 0.143 4 <0.0001 GQKGEI 0.168 0.099 4 >0.9999 
GHDGDK 0.114 0.049 4 0.9935 GQRGER 0.137 0.059 4 0.9992 
GHDGEK 0.110 0.037 4 0.9926 GROGER 0.402 0.087 4 0.0005 
GKOGER 0.204 0.023 4 0.9991 GRSGET 1.016 0.080 4 <0.0001 
GLKGEN 0.461 0.097 4 <0.0001 GSOGEK 0.183 0.061 4 0.9997 
GLKGER 0.321 0.029 2 0.2742 GSQGEK 0.131 0.066 4 0.9990 
GLOGEA 1.149 0.272 4 <0.0001 GVOGEA 0.166 0.026 4 >0.9999 
GLOGEK 0.871 0.013 2 <0.0001 BSA 0.317 0.069 2 0.3106 
GLOGEN 2.116 0.090 4 <0.0001 GPP10 0.169 0.083 4  
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Mean absorbances are compared to the mean absorbance of GPP10 using two-way ANOVA and 
Dunnett’s multiple comparisons test. 
 
Table 3.7: Statistical analysis C2C12-ITGA2 adhesion to THPs 
Peptide Mean 
absorbance 
SD n P Peptide Mean 
absorbance 
SD n P 
GAOGER 0.504 0.144 4 0.0147 GLOGER 2.054 0.229 4 <0.0001 
GASGER 0.373 0.085 4 0.2764 GLSGER 1.767 0.474 4 <0.0001 
GFOGDR 0.102 0.050 4 >0.9999 GMOGER 0.592 0.065 4 0.0010 
GFOGEK 2.097 0.260 4 <0.0001 GNOGER 1.362 0.443 4 <0.0001 
GFOGER 2.238 0.182 4 <0.0001 GNRGER 1.498 0.147 4 <0.0001 
GFQGEK 1.922 0.240 4 <0.0001 GPKGER 0.144 0.084 4 0.9995 
GFSGER 2.059 0.148 3 <0.0001 GQKGEI 0.337 0.159 3 0.5962 
GHDGDK 0.174 0.111 4 0.9991 GQRGER 0.143 0.070 4 0.9995 
GHDGEK 0.121 0.090 4 0.9998 GROGER 2.237 0.191 4 <0.0001 
GKOGER 1.812 0.173 3 <0.0001 GRSGET 1.326 0.445 3 <0.0001 
GLKGEN 1.354 0.334 4 <0.0001 GSOGEK 0.621 0.272 3 0.0014 
GLKGER 1.202 0.222 3 <0.0001 GSQGEK 0.226 0.071 4 0.9929 
GLOGEA 1.756 0.248 4 <0.0001 GVOGEA 0.163 0.085 4 0.9993 
GLOGEK 1.882 0.000 1 <0.0001 BSA 1.297 0.000 1 <0.0001 
GLOGEN 1.782 0.148 4 <0.0001 GPP10 0.099 0.056 4  
Mean absorbances are compared to the mean absorbance of GPP10 using two-way ANOVA and 
Dunnett’s multiple comparisons test. 
 
Table 3.8 Statistical analysis C2C12-ITGA10 adhesion to THPs 
Peptide Mean 
absorbance 
SD n P Peptide Mean 
absorbance 
SD n P 
GAOGER 0.139 0.073 4 0.9993 GLOGER 1.704 0.335 4 <0.0001 
GASGER 0.153 0.075 4 0.9990 GLSGER 1.453 0.338 4 <0.0001 
GFOGDR 0.109 0.039 4 0.9999 GMOGER 0.158 0.090 4 0.9989 
GFOGEK 1.056 0.209 4 <0.0001 GNOGER 0.145 0.060 4 0.9992 
GFOGER 1.437 0.176 4 <0.0001 GNRGER 0.096 0.063 4 >0.9999 
GFQGEK 0.289 0.046 4 0.2219 GPKGER 0.118 0.099 4 0.9997 
GFSGER 0.593 0.134 4 <0.0001 GQKGEI 0.107 0.071 4 0.9999 
GHDGDK 0.102 0.074 4 >0.9999 GQRGER 0.125 0.073 4 0.9996 
GHDGEK 0.098 0.070 4 >0.9999 GROGER 0.214 0.129 4 0.8926 
GKOGER 0.162 0.016 4 0.9988 GRSGET 0.113 0.050 4 0.9998 
GLKGEN 0.910 0.338 4 <0.0001 GSOGEK 0.119 0.043 4 0.9997 
GLKGER 1.102 0.129 2 <0.0001 GSQGEK 0.126 0.110 4 0.9996 
GLOGEA 1.618 0.348 4 <0.0001 GVOGEA 0.186 0.066 4 0.9925 
GLOGEK 1.758 0.008 2 <0.0001 BSA 0.353 0.108 2 0.1339 
GLOGEN 2.135 0.106 4 <0.0001 GPP10 0.100 0.051 4  
Mean absorbances are compared to the mean absorbance of GPP10 using two-way ANOVA and 
Dunnett’s multiple comparisons test. 
 
Table 3.9: Statistical analysis C2C12-ITGA11 adhesion to THPs 
Peptide Mean 
absorbance 
SD n P Peptide Mean 
absorbance 
SD n P 
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GAOGER 0.186 0.072 4 0.9996 GLOGER 1.805 0.381 4 <0.0001 
GASGER 0.160 0.078 4 >0.9999 GLSGER 0.529 0.275 4 0.0067 
GFOGDR 0.144 0.076 4 >0.9999 GMOGER 0.214 0.093 4 0.9991 
GFOGEK 2.002 0.226 4 <0.0001 GNOGER 0.181 0.054 4 0.9996 
GFOGER 1.917 0.386 4 <0.0001 GNRGER 0.150 0.078 4 >0.9999 
GFQGEK 0.346 0.184 4 0.5635 GPKGER 0.146 0.069 4 >0.9999 
GFSGER 1.276 0.363 4 <0.0001 GQKGEI 0.164 0.064 4 0.9999 
GHDGDK 0.137 0.056 4 0.9998 GQRGER 0.193 0.119 4 0.9995 
GHDGEK 0.129 0.049 4 0.9997 GROGER 1.376 0.408 4 <0.0001 
GKOGER 0.257 0.068 4 0.9933 GRSGET 0.305 0.137 4 0.8675 
GLKGEN 0.389 0.169 4 0.2771 GSOGEK 0.161 0.063 4 0.9999 
GLKGER 0.231 0.000 1 0.9993 GSQGEK 0.164 0.076 4 0.9999 
GLOGEA 0.349 0.149 4 0.5447 GVOGEA 0.203 0.103 4 0.9993 
GLOGEK 2.212 0.202 3 <0.0001 BSA 0.360 0.124 3 0.5752 
GLOGEN 1.064 0.418 4 <0.0001 GPP10 0.151583 0.076204 4  
Mean absorbances are compared to the absorbance of GPP10 using two-way ANOVA and 
Dunnett’s multiple comparisons test. 
 
3.5 Collagen Receptor Expression in HUVECs 
 As this project focuses on studying the collagen binding integrins and their role in 
HUVECs, the expression levels of each receptor were first characterised. qPCR was used to 
detect the mRNA expression levels of each integrin in HUVECs. The mRNA expression of the EC 
Graph showing the CT 
values for each 
endogenous control after 
activation with various 
cytokines. 20ng/ml TNFα, 
10ng/ml IL-1α, 0.2% FBS, 
200μM TC-I-15, 20μM 
Obtustatin or 1μl of 
lipofectamine was added 
to cell cultures in 12 well 
plates and incubated at 
37°C overnight. The 
expression levels of each 
control were remarkably 
stable across these 
conditions 
Figure 3.5. Comparison of Endogenous Controls For Use in qPCR. 
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marker VWF was also evaluated, together with the three other collagen-binding proteins that 
share the common binding motif with VWF, DDR1, DDR2 and SPARC, for comparison. TaqMan 
primers and probes were used to detect integrin transcripts. To control for differences in cDNA 
concentration in each assay, a TaqMan primer/probe set was used to detect an endogenous 
housekeeping transcript for normalisation. The mRNA transcripts for HPRT1, GAPDH and 
YWHAZ were all tested for their suitability as an endogenous control transcript in HUVECS. 
HUVECs were cultured for 24 hours in EGM2 with the addition of cytokines, integrin inhibitors, 
or serum starvation. qPCR was used to detect the transcript levels of each endogenous control 
over these conditions. Figure 3.5 shows the comparison of the cycle threshold (CT) values of 
each endogenous control tested. The values were remarkably consistent across three repeats. 
siRNA targeting GAPDH was used in experiments described in chapter 5 to optimise siRNA KD, 
which was characterised using qPCR. Therefore, GAPDH cannot be used as an endogenous 
control for the quantification of GAPDH KD. Both YWHAZ and HPRT1 would be suitable but 
YWHAZ is expressed at higher levels, so HPRT1 was chosen for all subsequent studies. 
Graphs showing the relative expression levels of several collagen receptor mRNA transcripts shown 
as fold change relative to HPRT1. Note the difference in scale between A) and B), with SPARC at 100 
and VWF at around 50. Table 3.8 (below) summarises the one-way ANOVA, Tukey’s multiple 
comparisons statistical analysis. VWF and SPARC were compared separately using an unpaired T-
test. 
Figure 3.6: Comparison of Collagen Receptor Expression in HUVECs.  
A B 
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To characterise the integrin expression patterns in HUVECs using qPCR, HUVECs were 
cultured in tissue culture plates in EGM2 media before total mRNA extraction using Qiagen 
RNeasy Plus RNA extraction kits. Total RNA was reverse transcribed into cDNA using TaqMan 
reverse transcription reagents with random hexamers. Predesigned TaqMan gene expression 
assays were used to quantify the expression of different collagen receptors at the mRNA level. 
All experiments were repeated using cDNA libraries derived from at least 3 pools of HUVECs 
and qPCR was carried out in triplicate. The ΔΔCT method was used to normalise CT values to 
the endogenous control and expression data is shown in Figure 3.6 as fold change relative to 
HPRT1. ITGA1, ITGA2, ITGA10 and ITGA11 refer to the detection of the mRNA transcript of the 
integrin α1, α2, α10 and α11 subunits respectively. Figure 3.6 shows the expression data as the 
mean with error bars showing SD. Table 3.10 summarises the statistical analysis of this data 
using one-way ANOVA and Tukey’s multiple comparison’s test for all receptors except VWF 
and SPARC which were compared using a students’ T-Test. The means of the fold-changes 
relative to HPRT1 are shown with SD, n and P values for the multiple comparisons. 
Table 3.10 – Statistical analysis of receptor expression  
 Mean fold 
change 
SD n P = vs 
ITGA1 
P = vs 
ITGA2 
P = vs 
ITGA10 
P = vs 
ITGA11 
P = vs 
DDR1 
P = vs 
DDR2 
ITGA1 0.5048 0.265 11  <0.0001 0.0042 0.8782 0.1373 <0.0001 
ITGA2 5.886 1.288 11 <0.0001  <0.0001 <0.0001 <0.0001 >0.9999 
ITGA10 1.815 0.411 11 0.0042 <0.0001  0.0038 >0.9999 <0.0001 
ITGA11 0.0054 0.004 11 0.8782 <0.0001 0.0038  0.0491 <0.0001 
DDR1 1.794 0.704 3 0.1373 <0.0001 >0.9999 0.0491  <0.0001 
DDR2 5.806 1.095 3 <0.0001 >0.9999 <0.0001 <0.0001 <0.0001  
Mean fold change values for each condition are compared to the mean fold change values for all other 
conditions using one-way ANOVA and Tukey’s multiple comparison test. A students T-test was used 
to compare VWF and SPARC 
          
VWF 43.31 7.592 3  SPARC vs VWF *P=0.0149 
SPARC 101.7 23.49 3  
  
 VWF is an endothelial marker that shows relatively high (50x fold change compared to 
HPRT1) expression levels. This contributes to validating the endothelial phenotype of the cells. 
Of the four collagen-binding integrins, ITGA2 was found to be the most abundant integrin 
(5.886 x fold change compared to HPRT1, ****P<0.0001 compared to all the other integrins 
Figure 3.6), followed by ITGA10 (1.815 x fold change compared to HPRT1) and then ITGA1 
(0.5048 x fold change compared to HPRT1), whereas ITGA11 was barely detectable (0.0054 x 
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fold change compared to HPRT1). There was no significant difference between ITGA1 and 
ITGA11 expression. This agrees with unpublished work by Dr Peter Kim (personal 
communication) Expression of ITGA2 has been characterised in a variety of ECs including 
HUVECs whereas ITGA1 is well defined in microvascular ECs[157, 158]. Both are upregulated by 
VEGF[160], which is included in the EGM2 media at low levels (0.5ng/ml). It is possible that 
addition of more VEGF will upregulate the ITGA1 subunit. The ITGA10 subunit has not been 
characterised in ECs but is present at the mRNA level according to these experiments. 
Therefore, one of the main objectives of this project was to characterise the expression and 
role of α10β1 integrin in HUVECs.  
Collagen receptors DDR1 (1.794-fold increase compared to HPRT1) and DDR-2 (5.806-
fold increase compared to HPRT1) were both detected in HUVECs. DDR-2 is seen at similar 
levels to ITGA2 and DDR-1 is found at similar levels to ITGA10. These receptors have not been 
well characterised in ECs but some studies suggest DDR2 is upregulated in activated ECs[244]. It 
is therefore possible that higher levels would be seen after addition of TNFα, LPS or ILs. One 
study found that DDR2 is also expressed in high levels in ECs in human tumours, and the loss 
of DDR2 supresses tumour metastasis[245]. The same study also found that induced 
overexpression of DDR2 in HUVECs has been found to increase proliferation, migration and 
angiogenesis. DDR1 has been detected, but not characterised, in brain microvascular cells[246]. 
DDR1 interacts with the integrin β1 subunit and DDR1 overexpression in human fibroblasts and 
3T3 cells, results in increased activated β1, increased β1 adhesion to collagen and increased 
β1 glycosylation which affects integrin function[247, 248] This suggests a regulating role for DDR1 
in β1 function[249]. The same study found that α2β1 expression almost doubled in DDR1 
overexpression and decreased after DDR1 KO[249]. Interestingly, SPARC is expressed in relatively 
high levels (101.7 x fold change compared to HPRT1) and twice as abundant as the EC marker 
VWF (43.31 x fold change compared to HPRT1, *P=0.0149). SPARC is thought to regulate EC 
barrier function by inducing cell-shape changes resulting in increased barrier permeability in 
pulmonary artery, bovine microvascular and bovine aortic ECs[210, 212]. Elevated SPARC 
expression in tumours results in a VCAM dependent increase of vascular permeability and 
contributes to cancer cell metastasis[250]. SPARC is a de-adhesive protein that promotes cell de-
attachment[205, 206] whereas integrins promote strong cell adhesion to collagen. Hence, while it 
Chapter 3 – Integrin Adhesion Studies 
83 
 
is outside the scope of this project, it would be interesting to further characterise SPARC 
functions in HUVECs, given its high levels of mRNA expression. 
 In conclusion, the mRNA for the ITGA2 subunit was detected in much higher amounts 
than the other three integrins, with ITGA10 being the second most abundant transcript, 
followed by ITGA1, while ITGA11 was undetectable. There is a pool of β1 subunit in the cell 
that pair up with the α-subunits to form the heterodimer[140]. The protein expression of these 
integrins is therefore determined by the expression of the α-subunits. 
3.6 Characterisation of pooled HUVECs 
 Before carrying out any further integrin studies in HUVECs, experiments were 
performed to characterise their endothelial phenotype. There are several markers for EC 
phenotype, VWF being the most commonly used marker as many commercially available 
antibodies have been thoroughly validated for use in ECs and VWF is easily visualised in WBPs 
as rod-shaped granules in the cytoplasm[132]. VE-Cad is an EC marker expressed on the cell 
surface as an adhesion molecule, it controls cell-cell junction adhesion and blood vessel 
formation, and contributes to the regulation of proliferation and apoptosis[38]. CD45 is a marker 
for hematopoietic lineage, it is expressed in EC progenitor cells and should be largely absent in 
mature ECs. CD45 is also express in leukocytes and lymphocytes. CD31 is a common marker 
for EC phenotype that is highly expressed on the surface of ECs. It is also expressed on platelets, 
monocytes, neutrophils and is important in leukocyte migration. MCAM is another membrane 
EC marker, binding to laminin. Finally, VEGFR2, a receptor for VEGF that mediates 
angiogenesis, is expressed mainly in ECs but can also be detected in a number of other cells 
including endometrial epithelium, hematopoietic stem cells, liver sinusoidal ECs, Sertoli cells 
and Leydig cells, platelets and megakaryocytes, sensory and autonomic neurons, Schwann 
cells, Muller glial cells, retinal progenitors, and osteoblasts (EC markers are reviewed in[36]). 
HUVECs will be tested for the presence of these markers by immunofluorescence and flow 
cytometry. VWF has been detected at the mRNA level in Figure 3.6. 
Pooled HUVECs were purchased from Promocell. They are marketed as positive for 
VWF and CD31. EC markers VWF and CD31 were detected by immunofluorescence in HUVECs 
cultured to passage 5 in EGM2 media.  Cells were fixed in 4% PFA before staining in 1% BSA in  
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PBS and image acquisition by microscopy. A representative field of view for PECAM-1 is shown 
in Figure 3.7 with Hoechst nuclear staining. VWF staining in sparse and confluent cells is shown 
in Figure 3.8 alongside rhodamine phalloidin actin staining and Hoechst nuclear staining.  
 
 
A: immunofluorescence staining for CD31 (green) and Hoechst (blue). B: flow cytometry staining for 
various HUVEC cell markers. For flow cytometry assays, the darker green/red shows isotype control 
stained cells whereas the lighter colour shows the marker stained cells. Experiments were repeated 
with unstained cells and the curves were comparable to isotype controls, not shown here for 
simplicity.  
PECAM-1 PECAM-1 
Figure 3.7: Expression of Endothelial Markers in HUVECs. 
MCAM 
A B 




Immunofluorescence images showing Hoechst (blue), VWF (green) and actin (red), on 4% PFA fixed 
HUVECs at passage 5. Sparsely populated (left) and densely populated (right) cells are shown. WBPs 
are clearly visible as VWF+ rod shaped granules in the cytoplasm. VWF staining is variable, possibly 
due to heterogeneity in the HUVEC population, cells are pooled from 4 donors 
Figure 3.8: VWF staining in HUVECs.  
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All cells exhibited positive staining for the EC marker PECAM-1 in both 
immunofluorescence and flow cytometry, suggesting an EC phenotype (Figure 3.7). Positive 
staining for PECAM-1, VE-Cad, VWF, and MCAM was also observed using flow cytometry 
(Figure 3.7), suggesting that these cells were indeed endothelial. However, flow cytometry 
staining for VEGFR2 was heterogenous, with some cells showing strong staining, whilst others 
did not. As VEGFR2 is not solely expressed in ECs, and ECs will express other VEGFRs (e.g. 
VEGFR1) this could be explained by differences in expression levels, or cross reactivity of the 
antibody with different proteins. Evidence for an endothelial origin for these cells is provided 
by the strong expression of the other EC markers. CD45 is expressed on haematopoietic 
progenitor cells, as well as lymphocytes and leukocytes, and is used to differentiate mature 
ECs from immature EC progenitor cells. ECs did not express CD45, suggesting that ECs are 
mature and differentiated[36]. 
The VWF staining in Figure 3.8 is heterogenous with some cells showing clear, bright 
VWF positive WPBs as green rod-shaped granules in the cytoplasm, whereas other cells show 
less bright VWF staining. This could be due to differences in sensitivity between the two 
methods: the flow cytometer might be a more sensitive instrument and so could pick up lower 
levels of VWF that may not be captured by immunofluorescence. These ECs are pooled from 4 
donors and this heterogeneity may be reflected here in different intensities of fluorescence. 
3.7 Activation of HUVECs with Inflammatory Agents 
 HUVECs exist in resting or activated, proinflammatory states and respond to 
inflammatory signals in their microenvironment[96]. To test whether HUVECs were 
physiologically functional, HUVECs were treated with TNFα, IL-1α and lipopolysaccharides (LPS) 
and then tested for inflammatory response. HUVECs will upregulate surface expression of 
VCAM, ICAM and E-Selectin when they are activated and will release soluble portions of these 
receptors into the blood stream in vivo or cell culture media in vitro. Duoset ELISA kits (R&D) 
were used to detect soluble VCAM, ICAM and E-Selectin released into the media and in cell 
lysates after overnight incubation with inflammatory cytokines. 
HUVECs were seeded on collagen I coated surfaces and  TNFα, IL-1α and LPS were then 
added overnight (16h) in EGM2. The media from the wells was then collected, centrifuged at 
1000 xG for 5 mintues to remove cell debris and stored at -80°C. Cells were lysed with ice-cold 
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lysis buffer containing TritonX100 and cOmplete mini protease inhibitors and left on ice, 
shaking, for 30 minutes. Lysates were centrifuged at 13,000 xG for 20 minutes, supernatant 
was collected and stored at -80°C until the ELISA assay was carried out as per manufacturers 
instructions. Cell lysates were diluted 1:10 in the assay.   
A two-way ANOVA with Dunnett’s multiple comparisons test was used to compare the 
expression of inflammatory markers in cell lysates or secreted into the media. The results are 
summarised above in Table 3.11. Both IL-1α and TNFα significantly (****P<0.0001) 
upregulated secretion of VCAM-1 into the media after overnight incubation but LPS had no 
effect on secretion of any of these proteins into the media compared to the control. There was 
no significant increase of ICAM or E-Selectin secretion with any cytokine tested. IL-1α and 
TNFα, but not LPS, incubation resulted in a significant increase of VCAM, ICAM and E-Selectin 
detected in cell lysates (Table 3.11). This suggests that ECs are responding to inflammatory 
cytokines as expected. The effect of LPS on HUVECs, expected to illicit a response at 1μg/ml, 
may require a longer time point than IL-1α and TNFα to trigger the release of inflammatory 
markers. 
 
Detection of VCAM, ICAM and E-selectin released in the media (A) or upregulated in cell lysates (B) 
after overnight activation with 20ng/ml TNFα, 10ng/ml IL-1α or 1μg/ml LPS. TNFα and IL-1α both 
stimulate expression and release of inflammatory markers. DuoSet ELISAs were used, 
concentrations of VCAM, ICAM and E-Selectin were calculated from standard curves. 
Figure 3.9: Detection of VCAM, ICAM and E-selectin in activated HUVECs.  
A B 
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SD N P  VCAM Mean 
concentration 
(ng/ml) 
SD N P  
Control 0.447 0.215 2  Control 2.084 2.659 3  
TNFα 20.084 7.987 2 <0.0001 IL-1α 45.568 6.375 2 0.0260 
IL-1α 23.299 2.218 2 <0.0001 TNFα 47.347 8.283 3 0.0101 
LPS 0.918 0.685 2 0.9952 LPS 2.083 0.717 2 >0.9999 
ICAM     ICAM     
Control 0.046 0.0164 2  Control 8.230 8.998 2  
TNFα 3.144 1.294 2 0.4943 IL-1α 67.189 2.927 2 0.0064 
IL-1α 4.199 2.157 2 0.2802 TNFα 71.892 10.438 2 0.0036 
LPS 0.086 0.0160 2 >0.9999 LPS 22.297 21.456 2 0.7130 
E-
Selectin 
    E-
Selectin 
    
Control 0.068 0.0261 2  Control 0.941 0.424 2  
TNFα 3.192 0.585 2 0.4880 IL-1α 134.301 29.372 2 <0.0001 
IL-1α 3.523 0.764 2 0.4130 TNFα 125.882 42.556 2 <0.0001 
LPS 0.069 0.022 2 >0.9999 LPS 4.955 5.425 2 0.9886 
Mean concentrations are compared to the control mean concentration of each inflammaotry marker 
using two-way AONVA and Dunnett’s multiple comparisons test 
  
In conclusion, HUVECs behaved as expected and increased expression of EC markers of 
activation in the presence of known EC activators, suggesting the cells are indeed endothelial 
and can be used in downstream experiments to study the roles of the collagen-binding 
integrins in the regulation of endothelial cell behaviour. 
3.8 Adhesion of HUVECs to Short Peptides 
 The same adhesion assays described before, Chapter 3.4, for C2C12 cells were then 
carried out with HUVECs. Plates were coated with SPs, blocked with BSA, HUVECs were added 
at 15,000 cells/well and cells were left to adhere for one hour at room temperature. Plates 
were washed and remaining cells were lysed and quantified with the LDH cytotoxicity kit from 
Roche, as described above. Figure 3.10 shows the adhesion profile of HUVECs on SPs. Table 
3.12 shows the statistical analysis of the adhesion data using two-way ANOVA and Dunnett’s 
multiple comparisons test compared to the GPP10 negative control. The mean indicates the 
mean absorbance for each condition. Compared to GPP10, there was no significant binding to 
GHDGEK, GHDGDK, GPKHGER, GQKGEI, GVOGEA, GFOGDR and BSA. HUVECs appear to show 
a more active binding profile to collagen SPs than any of the C2C12 cells. Essentially, the 
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binding profile is the same as C2C12s transfected with ITGA2 but with enhanced binding to 
weaker motifs such as GMOGER and GAOGER. Binding to GSQGEK and GASGER was not 
observed in any transfected C2C12 cells but very weak binding is observed here for HUVECs. 
The rest of the motifs showed strong binding compared to GPP10 (****P<0.0001) or moderate 
in the case of GSOGEK (***P=0.0005). Differences in binding to SPs seen between transfected 
Figure 3.10. HUVEC adhesion to collagen toolkits and short peptides. 
  
A) Adhesion of HUVECs to Toolkit II. B) adhesion of HUVECs to collagen Toolkit III. C) Adhesion of 
HUVECs to SPs. Each graph shows adhesion in the presence of Mg2+ or EDTA. Collagen-binding 
integrins are Mg2+ dependent, any adhesion seen in the presence of the metal ion chelator EDTA 
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C2C12 cells and HUVECs could be partially due to regulatory differences between the human 
and mouse β1-subunits. Perhaps the mouse β1-subunit supports a less active α-subunit 
conformation than the human β1. Alternatively, the integrins could be in a more active state 
in HUVECs as a result of association with a number of other focal adhesion proteins such as 
paxillin, talin or vinculin[251-254]. Integrins cluster together with these proteins to regulate cell 
spreading, adhesion and migration. Many proteins present in HUVECs but not in C2C12 cells 
and vice versa may influence integrin activity, explaining differences between HUVEC and 
C2C12 binding profiles.  
Table 3.12 – Statistical analysis of HUVEC adhesion to SPs compared to GPP10 
Peptide Mean 
absorbance 
SD n P Peptide Mean 
absorbance 
SD n P 
GAOGER 0.839 0.548 3 0.0104 GLOGER 1.781 0.467 3 <0.0001 
GASGER 0.766 0.296 3 0.0307 GLSGER 1.605 0.260 3 <0.0001 
GFOGDR 0.109 0.022 3 >0.9999 GMOGER 0.887 0.564 3 0.0047 
GFOGEK 1.763 0.376 3 <0.0001 GNOGER 1.557 0.376 3 <0.0001 
GFOGER 1.719 0.225 3 <0.0001 GNRGER 1.500 0.467 3 <0.0001 
GFQGEK 1.922 0.467 3 <0.0001 GPKGER 0.459 0.338 3 0.6858 
GFSGER 1.695 0.456 3 <0.0001 GQKGEI 0.678 0.202 3 0.0959 
GHDGDK 1.782 0.374 3 0.9998 GQRGER 0.285 0.220 3 0.9950 
GHDGEK 0.137 0.062 3 >0.9999 GROGER 1.784 0.482 3 <0.0001 
GKOGER 0.123 0.055 3 <0.0001 GRSGET 1.462 0.332 3 <0.0001 
GLKGEN 1.536 0.257 3 <0.0001 GSOGEK 1.020 0.311 3 0.0005 
GLKGER 1.378 0.259 3 0.0013 GSQGEK 0.786 0.489 3 0.0230 
GLOGEA 0.963 0.300 3 <0.0001 GVOGEA 0.486 0.365 3 0.5806 
GLOGEN 1.667 0.432 3 <0.0001 BSA 0.105 0.043 3 0.9999 
One-way ANOVA and Dunnett’s multiple comparison test was used to analyse the mean absorbances 
for each peptide compared to the mean absorbance for GPP10. 
 
In conclusion, the adhesion profile of HUVECs on SPs looks very similar to the α2β1 
adhesion profile in transfected C2C12 cells, but with higher binding affinity seen for HUVECs, 
possibly due to other proteins present in focal adhesions or other adhesion complexes. 
3.9 Adhesion of HUVECs to Collagen II and III Toolkits 
 Collagen Toolkits corresponding to collagens II and III have been designed and 
synthesised in Prof Farndale’s group[233, 234, 243]. HUVEC adhesion to these toolkit libraries was 
tested here to probe integrin binding sites in these two collagen types. Immulon 2HB plates 
were coated with these Toolkit peptides and, after blocking with BSA, HUVECs were added at 
15,000 cells per well, in the presence of Mg2+ to facilitate integrin binding, or EDTA to block 
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integrin binding by chelating metal ions. After one hour, plates were gently washed to remove 
unbound cells and the remaining cells were lysed and quantified using the colorimetric LDH 
cytotoxicity assay.  
The Toolkit II and III sequences, in chapter 2.23, contain many integrin adhesion sites and 
some are expected to bind HUVECs. The adhesion data is shown in Figure 3.10 as the means 
for each condition with error bars depicting SD. Table 3.12 summarises the statistical analysis 
of the HUVEC adhesion to SPs using two-way ANOVA and Dunnett’s multiple comparisons test 
to compare each mean absorbance value to the mean absorbance value for GPP10. The 
similarities and differences seen here between the adhesion of HUVEC and the integrin 
expressing C2C12 cells are summarised below: 
• HUVECs adhered to GMOGER in II-31, III-31 and III-32 whereas GMOGER only bound very 
weakly to C2C12-ITGA2 cells  
• Strong binding was seen for GLOGER in II-7 and II-8 which bound all transfected C2C12 cells 
except C2C12-ITGA1 
• HUVECs bound strongly to GRSGET in II-55 and II-56, which binds C2C12-ITGA1 and C2C12-
ITGA2 cells 
• GLOGEN (or GLKGEN) in III-7 binds strongly to HUVECs, binds all integrins in C2C12 cells 
• As expected, GFOGER in II-28 binds HUVECs strongly. This is well-characterised a motif for 
all collagen-binding integrins 
• II-44 binds HUVECs strongly but does not contain an integrin binding motif. It contains 
GQRGER which is negative for integrin binding in C2C12 cells. However, this peptide is 
promiscuous, and binding has been reported for many other receptors 
• III-35 contains GSOGER which could bind integrins, an analogue GSOGEK was a weak binder 
for α2β1 but the GER pattern could increase binding in this case 
• GROGER in III-4 binds HUVECS, as well as C2C12-ITGA2 and C2C12-ITGA11 
• RGD motifs could be responsible for binding in II-32, II-41 and II-51. Both avb3 and avb5 
bind RGD and are present in ECs 
• GNRGER in III-56 is an α2β1 specific peptide in C2C12 cells and is a strong binder for 
HUVECs as expected 
• GLSGER binds strongly to HUVECs. In C2C12 cells, it binds all but α11β1, which is not 
expressed in HUVECs 




In theory, the RGD motif is only active in its linear form, and so should not be active 
when part of the sequences of peptides adopting a triple helix conformation. Yet, although 
THPs predominantly adopt a triple helical structure, a small portion of peptide remains in an 
unfolded, monomeric conformation. This could explain the adhesion of HUVECs to RGD 
containing peptides. Interestingly, HUVECs bound strongly to II-23 which does not contain any 
immediately obvious integrin binding sequences (the II-23 amino acid sequence is 
GQOGVMGFOGPKGANGEOGKAGEKGLO). DDR1 and DDR2 are all reported to bind to GVMGFO, 
which is present in both II-22, II-23 and III-23. Yet, HUVECs only bound to II-23, so the presence 
of these receptors on the cell surface do not explain alone the binding to II-23. Additionally, 
some binding is also seen in II-24, suggesting that the last three triplets of the II-23 host 
sequence that are also present in II-24 (GKAGEKGLO) could be responsible for this binding. 
Alternatively, the motif that HUVECs recognise could be GVMGFOGPK in II-23. A different, 
lower affinity motif could then be responsible for binding in II-24 through a non-integrin 
receptor. To isolate the active binding sequence in each peptide, an alanine scan on II-23 and 
II-24 could be carried out. However, this is outside the scope of this project. 
There are differences between the binding of SPs and Toolkit II and III peptides 
containing the same integrin motif. For example, GMOGER in the longer toolkit peptides is a 
strong binder for HUVECs and C2C12-ITGA2, whereas the GMOGER short motif alone is a weak 
binder. This could be due to conformational changes imposed by the longer peptide sequence 
or flanking sequences in the Toolkit peptides. The SPs are shorter and contain less amino acid 
residues likely to affect the triple helix stability and folding. This could influence the shape of 
the helix by making it tighter or looser compared to the longer Toolkit peptides, modifying the 
spatial arrangement of amino acid side chains and affecting integrin binding. Additionally, 
there are other motifs in the longer toolkit peptides that could bind other receptors on the 
surface of ECs. However, it is not in the scope of the project to investigate other collagen 
receptors in detail.  
3.10 Conclusions 
The adhesion profiles of purified, recombinant αI-domains and C2C12 cells differ 
substantially, possibly due to the regulatory effect of the β1 subunit, other co-receptors or 
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regulatory proteins present in the C2C12 cells. The results presented here highlight the 
importance of testing full-length receptors where possible as they behave differently to the αI-
domains alone. For the ITGA1 αI-domain, the adhesion to THPs was more active in the isolated 
αI-domain than the C2C12 cells expressing the full-length α1β1. The opposite was observed 
for less active ITGA2 αI-domain compared to the C2C12s expressing the full-length α2β1. 
The transfected C2C12 cells showed very similar adhesion profiles for the four integrins, 
making it impossible to use THPs alone to specifically target one type of integrin. Only α2β1 
exhibited adhesion to specific THPs. The integrin adhesion  motifs were varied and will tolerate 
deviations from the canonical GFOGER quite well.   
 HUVECs express the expected EC markers and exhibit the correct inflammatory 
response suggesting the HUVECs possess an endothelial phenotype. The ITGA2 subunit is the 
most abundant mRNA transcript, followed by ITGA10 and ITGA1, while ITGA11 is not 
detectable. DDR2 is expressed in similar levels to ITGA2 at the mRNA level and SPARC is 
abundant. Due to problems with antibody specificity it was not possible to study the relative 
amounts of each integrin present on the cell surface, at the protein level. This severely limits 
the conclusions that can be drawn about receptor expression levels. Differences in mRNA 
stability, translation efficiency, post-translational modifications and protein turnover will all 
affect the final amount of each receptor present on the cell surface. As a result, the relative 
expression of the mRNA transcript does not infer the true surface expression of each receptor. 
 Lastly, HUVECs show active adhesion profiles on SPs, Toolkit II and Toolkit III. HUVECs 
show a similar adhesion profile to C2C12-ITGA2 but with additional adhesion to GASGER, 
GHDGEK and GSQGEK. HUVECs also exhibited adhesion to all the integrin motifs in Toolkits II 
and III, as well as to other peptides where no evident binding motif has been characterised. 
The toolkit data shows there are varied and numerous adhesion sites for HUVECs in collagen II 
and III and active integrin binding profiles are present in HUVECs.  
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4.1 Chapter Summary 
 This chapter focusses on characterising two integrin inhibitors, TC-I-15 and Obtustatin. 
TC-I-15 is a small-molecule commercially sold as a α2β1 inhibitor, and Obtustatin is a 
disintegrin that inhibits α1β1. These inhibitors are tested using recombinant αI-domains, 
integrin-expressing C2C12 cells and HUVECs on peptides, collagen and other extracellular 
matrix proteins to fully characterise their specificity and potency. All experiments are repeated 
a minimum of three times. 
4.2 Introduction 
In Chapter 3, Figure 3.4, the binding profiles of the four collagen-binding integrins to 
THPs proved to be too similar to use these peptides as a method for ligating or blocking specific 
integrins. Consequently, another method of modulating integrin expression or function 
needed to be established. Commercially available inhibitors were sought out and tested for 
their suitability in HUVECs. Obtustatin, depicted in figure 4.1, is a commercially available α1β1 
inhibitor, also called a disintegrin, originating in the venom of Vipera lebetina obtusa [4, 165, 255-
257]. Disintegrins are a family of integrin inhibitors first discovered as platelet aggregation 
antagonists in snake venoms. They are small cysteine-rich peptides containing an integrin-
binding loop that interferes with integrin adhesion[258]. The integrin binding loop infers 
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selectivity; RGD binding integrins will be inhibited by a disintegrin containing an RGD motif in 
the integrin binding loop in a competitive manner. Other motifs found in disintegrins include 
KGD, WGD, VGD, RTS and KTS, using single amino acid code. Disintegrins show higher potency 
than their synthetic peptide counterparts, suggesting that the tertiary structure is important 
for inhibition. Amino acids adjacent to the RGD motif affect the potency of inhibition, since 
RGDNP is 10 times more potent than RGDW for α5β1[259] and viperistatin (WKTSRTSHYC) is 25 
times more potent that Obtustatin (WKTSLTSHYC) for α1β1[258]. There are a huge number of 
disintegrins, and they can be split into four groups based on their size: 
• Short disintegrins 41-51 residues and 4 S-S bonds (e.g. echistatin and Obtustatin) 
• Medium length disintegrins approximately 70 residues and 6 S-S bonds (e.g. barbourin, 
flavoviridin, atrolysin) 
• Long disintegrins 84 residues and 7 S-S bonds (e.g. bitistatin) 
• Dimeric disintegrins, each subunit 67ish resides 
A) A structural diagram of obtustatin (PDB 1MPZ), adapted from ‘Concerted motions of the integrin-
binding loop and the c-terminal tail of the non-RGD integrin obtustatin’ Monleon et al[4]. S-S bonds 
are shown in yellow. B) A simplified diagram showing the individual residues, taken from the Tocris 
Biosciences website. 
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Obtustatin is a tiny disintegrin of just 41 residues and contains a WKTSLTSHY motif in 
the integrin binding loop, shown in Figure 4.1. This is interesting because the collagen 
recognition sequences for α1β1 described in Chapter 3 (Figure 3.4) do not contain any KTS 
motifs, and the KTS-loop is proposed to bind to the αI-domain to inhibit integrin binding. While 
the RGD-binding integrins are inhibited by RGD containing disintegrins, this is not the case for 
obtustatin and α1β1. Obtustatin inhibits cell-based α1β1 and the isolated full length α1β1 
receptor but has no effect on isolated αI-domains[165]. This suggests that the method of 
inhibition could also employ the β1-subunit or the rest of the α1-subunit in addition to the αI-
domain, differing from the RGD-disintegrins. Alternatively, the isolated αI-domain may just 
behave very differently to the full-length receptor, as seen in Chapter 3, Figures 3.3 and 3.4.  
Obtustatin has been used to inhibit angiogenesis in vitro and in vivo in chick 
chorioallantoic membrane assays. It also reduced tumour development by 50% in the mouse 
Lewis lung carcinoma mouse model and blocked melanoma growth in mice[165, 204]. Another 
α1β1 specific KTS-containing disintegrin, jerdostatin, has been used to inhibit adhesion of α1β1 
to collagen IV[260]. The same study also found that jerdostatin also inhibits migration and 
proliferation of rat aortic VSMCs and α1β1-dependent angiogenesis in HUVEC tube formation 
assays[260]. However, they also stated that VEGF-driven angiogenesis in HUVECs was only 
completely abolished when α2β1 was also inhibited by rhodocetin (another platelet 
aggregation inhibitor from snake venom), suggesting that there is some redundancy between 
the integrins in this role. Obtustatin has been found to reduce proliferation and stimulate 
apoptosis in human microvascular ECs (HMVECs)[204] but has not yet been well characterised 
in HUVECs. 
 
Adapted from the 
Tocris bioscience 
website 
Figure 4.2: Diagram of the Structure of TC-I-15. 




Adapted from ‘Small-molecule inhibitors of integrin α2β1 that prevent pathological thrombus 
formation via an allosteric mechanism’ Miller et al 2009[2]. A) Structural representation of integrin 
α2β1 binding to collagen. B) and C) TC-I-15 binding to the βI-domain to stabilise the inactive 
conformation of α2β1. The β-propeller of ITGA2 is shown in grey with the αI-domain shown with 
solid blocks, and the β1 I-domain is shown in yellow. The C-helix is shown in red and collagen is 
shown in blue, TC-I-15 is shown in orange. When TC-I-15 is bound, the C-Helix moves to the closed 
conformation. C) Structural representation of TC-I-15 binding to the β1-Idomain via an interaction 
with an Mg2+, Y122 and N215 in the βI-domain, locking the inhibitor in place and stabilising the 
closed confirmation of the αI-domain. 
Figure 4.3: Proposed Method of Inhibition by TC-I-15. 
C 
B A 
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Disintegrins for α2β1 were not commercially available at the time of this project and so 
were too difficult to obtain. Instead, the small molecule α2β1 specific inhibitor, TC-I-15, was 
characterised and tested in detail here (Figure 4.2). TC-I-15 (compound 15 in[2]) inhibits α2β1 
via an allosteric mechanism whereby it interacts with the βI-domain to stabilise the inactive 
conformation of the αI-domain (Figure 4.3). In platelets this results in potent inhibition of 
platelet adhesion to collagen and subsequent thrombosis in animal models[2]. In activated 
α2β1, the C-helix moves to coordinate an Mg2+ ion in the βI-domain to stabilise the active 
confirmation of the αI-domain (Figure 4.3). TC-I-15 interacts with this Mg2+ ion alongside Y122 
and N215 in the βI-domain to stabilise the closed confirmation as the C-helix can no longer 
more to coordinate the Mg2+ ion. TC-I-15 reportedly has no effect on the constitutively active 
E318A mutation of α2β1[2], presumably because this integrin is already locked into the active 
state and so cannot be stabilised in the inactive confirmation by TC-I-15. TC-I-15 has reportedly 
been tested for cross-reactivity and no inhibition of αvβ3, α5β1, α6β1 and αIIbβ3 was observed 
according to the manufacturers’ website. 
An inhibitory antibody for α2β1, 6F1, was also used in this study as it has been validated 
and routinely used to target α2β1[261]. Obtustatin and 6F1 are soluble in PBS and so no vehicle 
controls were necessary, whereas TC-I-15 had to be warmed to 50°C in a 1.1M equal 
concentration of NaOH to solubilise. For this reason, the TC-I-15 vehicle control is a 1.1M equal 
concentration of NaOH where 200μM of TC-I-15 is used, 220μM NaOH is added for the vehicle 
control, called “TC-I-15 control” from this point forward. 
4.3 Effects of Inhibitors on Recombinant αI-domain Adhesion to Peptides 
TC-I-15 and Obtustatin were tested using the recombinant GST-tagged αI-domains 
expressed by Dr Samir Hamaia. Additionally, GST-tagged I-domains containing mutations (also 
expressed by Dr Samir Hamaia) were used, specifically ITGA1R-G and ITGA2Y-G. The ITGA1R-G 
involves a mutation of R288 to G, which increases the affinity of α1β1 for collagen as this 
stabilises the active conformation of the αI-domain. The ITGA2Y-G involves a mutation from 
Y285 to a G, again stabilising the active conformation of the αI-domain. Adhesion to collagen 
peptides was tested in static adhesion assays, as described above, in the presence or absence 
of inhibitors or vehicle controls (Figure 4.4). GLOGEN-coated wells were used to test the 
binding of the ITGA1 and ITGA1R-G αI-domains, and GFOGER-coated wells were used for ITGA2 
and ITGA2Y-G αI-domain, as these were the highest binders in previous assays. Wells coated 
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with BSA were included as negative controls.  All αI-domains were added at 10μg/ml and left 
to adhere for one hour. One-way ANOVA and Sidak’s multiple comparisons test were used to 
analyse the effects of the inhibitors on αI-domain binding. The statistical analysis is summarised 
in table 4.1 below. 
No inhibition was observed for ITGA1 I-domain for any compound tested for the 
wildtype or the ITGA1R-G mutant. In all conditions, both ITGA1 αI-domains bound strongly to 
GLOGEN compared to BSA. This suggests that either the rest of the α-subunit or the β1-subunit 
are necessary for the inhibition by Obtustatin. The KTS integrin-binding loop in Obtustatin may 
not interact with the I-domain of ITGA1 at all, and there could be secondary site on ITGA1 αI-
domain that binds Obtustatin and facilitates inhibition. 
 There was no inhibition of either ITGA2 αI-domain by Obtustatin or TC-I-15, and both 
αI-domains bound strongly to GFOGER compared to BSA. 6F1 significantly inhibited adhesion 
of both ITGA2 αI-domains to GFOGER. This suggests that 6F1 inhibits the ITGA2 αI-domain 
directly and does not require  the β1 subunit for inhibition, whereas TC-I-15 appears to work 
Static adhesion assay showing the binding of I-domain mutants to collagen peptides. Adhesion is 
shown as a function of absorbance. After strenuous washing, remaining I-domains were detected 
using anti-GST-HRP conjugated antibody and TMB substrate with H2SO4 to stop the reaction. 
GLOGEN was used for ITGA1 and ITGA1R-G, and GFOGER was used for ITGA2 and ITGA2Y-G. 200μM 
TC-I-15 and 20μM Obtustatin and 10μg/ml 6F1 were used in the presence of Mg2+. 
Figure 4.4. Inhibition of αI-domains. 
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by encouraging the β1 subunit to stabilise the inactive conformation of the αI-domain (Figure 
4.3)[2]. The ITGA2Y-G mutant showed significantly lower adhesion than ITGA2 wildtype. This 
mutation seems to make the αI-domain less active overall which is the opposite of what the 
mutation should do. This could be an artefact of the experiment whereby the starting 
concentration of ITGA2Y-G is not as accurate, as these are purified from bacterial lysates via a 
GST affinity column but could also contain other proteins which would affect the concentration 
determination. To correct this, High-performance liquid chromatography (HPLC) could have 
been used to purify these αI-domains further. 
 The data here agrees with the literature described earlier in that neither TC-I-15 nor 
Obtustatin will inhibit αI-domain adhesion to collagen, although the mode of inhibition by 
Obtustatin remains unclear.  
Table 4.1 – Statistical Analysis of αI-domain inhibition  
ITGA1 αI-domain ITGA1R-G αI-domain 
 Mean SD n P  Mean SD n P 
Control 2.486 0.1293 2  Control 2.205 0.1640 2  
Obtustatin 2.509 0.1880 2 0.9999 Obtustatin 2.168 0.1817 2 0.9994 
6F1 2.479 0.2352 2 >0.9999 6F1 2.127 0.2556 2 0.9894 
BSA 0.1376 0.0093 2 <0.0001 BSA 0.5469 0.08307 2 0.0004 
TC-I-15 Control 2.624 0.1980 2  TC-I-15 Control 2.255 0.1881 2  
TC-I-15 2.545 0.1842 2 0.9873 TC-I-15 2.181 0.1652 2 0.9911 
ITGA2 αI-domain ITGA2Y-G αI-domain 
 Mean SD n P  Mean SD n  
Control 2.355 0.2227 2  Control 1.475 0.1991 2  
Obtustatin 2.295 0.2104 2 0.9952 Obtustatin 1.417 0.2339 2 0.9963 
6F1 0.2621 0.0393 2 <0.0001 6F1 0.1961 0.0331 2 0.0014 
BSA 0.2223 0.0448 2 <0.0001 BSA 0.1582 0.0265 2 0.0012 
TC-I-15 Control 2.373 0.1968 2  TC-I-15 Control 1.430 0.1873 2  
TC-I-15 2.354 0.1949 2 >0.9999 TC-I-15 1.461 0.2333 2 0.9997 
Mean indicates mean absorbance at 450nm. One-way ANOVA and Sidak’s multiple comparisons test 
were used to compare the mean absorbances to the control mean absorbance 
 
4.4 Inhibition of Integrin Expressing C2C12 Cells 
 To test these inhibitors in full length integrin heterodimers, C2C12 cells that have been 
stably transfected to express one of the four integrins were used, as described in Chapter 3, in 
static adhesion assays in the presence or absence of inhibitors or controls at varying 
concentrations. Plates were coated with GFOGER or GLOGEN, using GPP10 as the negative 
control. Cells were detached and inhibitors were added to the cells in a serial dilution for five 
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minutes before adding 15,000 cells/well on 96-well plates. After one hour, plates were gently 
washed, and cells were lysed with 2% TritonX100. The relative number of cells still adhered to 
the peptides was quantified using the Roche LDH cytotoxicity kit as described above. Cell 
adhesion is reported as a function of absorbance at 490nm in Figure 4.5. Non-linear curve fits 
were used to determine the IC50s, summarised in Table 4.2 
 Obtustatin proved to be a potent, specific, inhibitor of α1β1 adhesion to both GFOGER 
and GLOGEN at concentrations of 10-20μM. No other integrin was affected by Obtustatin, 
suggesting that it can be used to inhibit α1β1 selectively (Figure 4.5). Here, TC-I-15 inhibited 
α2β1 as expected, albeit at rather high concentrations of approximately 200μM for GFOGER 
and much lower concentrations of <10μM for GLOGEN. GFOGER is a higher affinity ligand for 
α2β1 than GLOGEN. The difference in potency of TC-I-15 inhibition of adhesion to these two 
ligands suggests a competitive-like mode of inhibition whereby the higher affinity GFOGER 
requires a higher concentration of TC-I-15 to bind to the β-subunit for inhibition to take place. 
It is possible that, for GFOGER, the affinity of the αI-domain for the ligand overcomes some of 
the affinity of TC-I-15 for the inhibitory site on the βI-domain. In contrast, the lower affinity 
GLOGEN does not require such a high concentration of TC-I-15. Additionally, TC-I-15 inhibited 
α1β1 at concentrations of approximately 220μM, meaning that TC-I-15 is not specific for α2β1 
and cannot be used to selectively inhibit α2β1. TC-I-15 inhibited α1β1 binding to both GFOGER 
and GLOGEN equally so there is no peptide-affinity effect seen here. TC-I-15 also shows weaker 
inhibition of α11β1 integrin at higher concentrations, in an affinity-dependent manner similar 
to α2β1. However, since HUVECs express tiny amounts of α11β1 (Figure 3.6) this is not of 
concern as the effects are assumed to be negligible. TC-I-15 had no effect on α10β1 adhesion 
to either peptide. Although TC-I-15 is proposed to bind to the β1 subunit, the α-subunit clearly 
plays a role in determining the specificity of TC-I-15 here. NaOH (the TC-I-15 vehicle control) 
had no effect on integrin binding, even at high concentrations. Therefore, all observed 
inhibition of integrin binding is due to the TC-I-15 and not the NaOH it is dissolved in. 
 In conclusion, Obtustatin can be used to selectively inhibit α1β1 on the surface of 
HUVECs, but TC-I-15 cannot be used as a selective inhibitor for α2β1. However, TC-I-15 can be 
used as a dual inhibitor for α1β1 and α2β1 together, and 6F1 can be used as a selective α2β1 
inhibitor. In subsequent experiments, Obtustatin will be used at 20μM, while TC-I-15 will be 
used at 200μM as this was the concentration required to inhibit integrin binding in C2C12 cells. 
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  Figure 4.5. Inhibition of C2C12 Cells Expressing integrins. 
Dose curves showing the TC-I-15 and Obtustatin mediated inhibition of C2C12 cells expressing α1β1 
(A and B), α2β1 (C and D), α10β1 (E and F) and α11β1 (G and H) adhesion to GFOGER, GLOGEN and 
GPP10. NaOH is used as the TC-I-15 vehicle control.  
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 Table 4.2 – Comparison of IC50s for C2C12 inhibition 
 
4.5 Inhibition of HT1080 Cell Adhesion to Collagen Peptides 
 To further investigate TC-I-15 inhibition of integrins, HT1080 cells were used in static 
adhesion binding assays with the addition of different concentrations of TC-I-15. HT1080 cells 
 TC-I-15 Obtustatin 
ITGA1 IC 50 R2 95% CI IC50 R2 95% CI 
GFOGER 23.55 0.9814 18.75 to 29.62 0.4457 0.8920 -infinity to 1.164 
GLOGEN 24.43 0.9435 15.70 to 38.34 0.9634 0.2521 0.1940 to 2.191 
ITGA2       
GFOGER 26.77 0.9066 15.32 to 47.67 N/A   
GLOGEN 0.3900 0.9943 -infinity to 1.089 N/A   
ITGA11       
GFOGER 3177 0.8025 151.1 to +infinity N/A   
GLOGEN 177.2 0.7012 31.05 to +infinity N/A   
Statistical test – non-linear regression curve fit –  IC50 
A) Obtustatin has no effect 
on HT1080 binding to 
GFOGER as HT1080s do 
not express α1β1. B) TC-I-
15 abolishes binding to 
GFOGER at much lower 
concentrations than 
C2C12 cells, 20μM vs 
200M respectively  
Figure 4.6: Inhibition of HT1080 Adhesion to GFOGER.  
A 
B 
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are human fibrosarcoma tumorigenic cells commonly used to model tumour cell migration, 
that express α2β1 but none of the other collagen-binding integrins. Plates were coated with 
GFOGER and blocked with BSA before adding serial dilutions of inhibitors in HT1080s at 15,000 
cells/well. GPP10, the negative control peptide, was taken as the baseline. 
 As expected, Obtustatin has no effect on HT1080 binding to collagen peptides as these 
cells do not express α1β1 and Obtustatin has been shown not to inhibit any other receptors 
tested here. TC-I-15 inhibits HT1080 binding to GFOGER at much lower concentrations than 
transfected C2C12-ITGA2 cells, around 15μM (Figure 4.6). The IC50 for TC-I-15 inhibition of 
HT1080 adhesion to GFOGER was 3.694μM (95% CI = 1.394μM to 8.961μM, R2 = 0.8959), 
compared to 26.77μM (95% CI = 15.32μM to 47.67μM) for C2C12 cells expressing α2β1. This 
could be due to the C2C12 and HT1080 cells expressing different levels of α2β1. The C2C12s 
could express much higher levels of α2β1 and so will need more TC-I-15 molecules to bind to 
each βI-domain to stabilise the receptor in an inactive confirmation, whereas lower expression 
of α2β1 in HT1080s would require fewer TC-I-15 molecules to achieve the same inhibitory 
effect. Alternatively, the human β1 subunit in the HT1080s could behave differently to the 
C2C12 mouse β1 subunit, changing the affinity of TC-I-15 to the receptor and ultimately 
changing its efficacy. Lastly, the HT1080s may express other regulatory receptors or signalling 
molecules that affect integrin binding or integrin expression. 
 In conclusion, TC-I-15 inhibits α2β1 adhesion in both C2C12 cells, which express the 
mouse β1-subunit, and HT1080 cells which express the human β1-subunit.  
4.6 Inhibition of HUVEC Adhesion to Collagen Peptides 
 Obtustatin and TC-I-15 have been characterised in C2C12 and HT1080 cells. Obtustatin 
is a potent inhibitor of α1β1 mediated adhesion at 20μM, and TC-I-15 inhibits α2β1 mediated 
adhesion at 200μM in C2C12s or 15μM in HT1080s. Next, these inhibitors were tested in 
HUVECs in the same static adhesion binding assays used above. 96-well Immulon 2HB plates 
were coated with peptides GFOGER, GLOGEN and GNRGER, an α2β1-specific peptide. A serial 
dilution of inhibitors was made in suspended HUVECs and added to the coated peptides at 
15,000 cells/well. After one hour, plates were gently washed and remaining adherent cells 
were lysed in 2% TritonX100 before quantification using the LDH cytotoxicity colorimetric 
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assay. Figure 4.7 shows the quantification of TC-I-15 and obtustatin inhibition of HUVECs 
binding to GFOGER, GLOGEN and GNRGER.  
 Obtustatin had no effect on HUVEC adhesion to GFOGER, GLOGEN or GNRGER at any 
concentration tested. This is not surprising as HUVECs express α2β1 that will compensate for 
any loss of α1β1 binding to collagen peptides.  
 Secondly, TC-I-15 had varying effects depending on which peptide was used. HUVEC 
adhesion to the α2β1 specific peptide GNRGER was completely attenuated at 200μM. This can 
be explained by the fact that no integrin other than α2β1 will bind to GNRGER and all the α2β1 
receptors are presumably locked into the closed conformation by TC-I-15 at this concentration. 
Figure 4.7: Inhibition of HUVEC Adhesion to Peptides. 
Inhibition of HUVEC adhesion to collagen peptides GFOGER, GLOGEN and GNRGER using TC-I-15 (A) 
and Obtustatin (B). Adhesion is shown as absorbance at 490nm which relates to the number of cells 
still bound after washing, using a colorimetric LDH assay. 
A 
B 
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HUVEC adhesion to GLOGEN and GFOGER was partially inhibited, but not fully. This could be 
due to compensatory adhesion of the α10β1 integrin, also binding to GFOGER and GLOGEN, 
which is present in HUVECs but, unlike α1β1, is not affected by TC-I-15. Additionally, the affinity 
of the GLOGEN and GFOGER peptides for α2β1 and α1β1 could be stronger than the affinity of 
TC-I-15 to the β1-subunit, compared to GNRGER, making the inhibitor less effective. GFOGER 
was inhibited to a lesser extent than GLOGEN, possibly because it is a higher affinity ligand for 
the more abundant α2β1 and so requires an excess of TC-I-15 to achieve further inhibition, as 
seen with C2C12 cells. Additionally, inhibition of C2C12-ITGA1 binding to both GFOGER and 
GLOGEN by TC-I-15 was very similar whereas the HUVEC inhibition profile seen here looks 
similar to that of C2C12-ITGA2. This is likely because α2β1 is expressed at higher levels in 
HUVECs. NaOH, the TC-I-15 vehicle control, has no effect on HUVEC binding and all integrin-
binding inhibition can be assumed to be due to TC-I-15.   
 In conclusion, inhibiting α1β1 with Obtustatin has no effect on the adhesion of HUVECs 
to collagen peptides most likely because cell attachment through α2β1 will compensate for 
the loss of α1β1 functionality. Inhibition of α2β1 and α1β1 by TC-I-15 results in an inhibition 
profile very similar to that seen with C2C12-ITGA2, as this receptor is expressed in much higher 
levels. 
4.7 Inhibition of HUVEC Adhesion to Extracellular Matrix Proteins 
 Obtustatin proved to be a very specific inhibitor for α1β1. However, TC-I-15 is more 
promiscuous and shows inhibition of α1β1, α2β1 and slightly to α11β1. Therefore, due to the 
observed promiscuity, TC-I-15 could also be affecting non-collagen-binding integrins as well. 
TC-I-15 associates in the interface between the α and β1 subunits (Figure 4.3), The β1 subunit 
can also form a heterodimer with α9, α4, α7, α6, α3 α8 α5 or αv, some of which may be present 
in HUVECs. According to the manufacturers’ website, no cross reactivity with αvβ3, α5β1, α6β1 
and αIIbβ3 is observed, but TC-I-15 could still interfere with α9, α4, α7, α3 α8 or αvβ1. 
• α9β1 has been reported to bind Thrombospondin in Human Dermal Microvascular 
Endothelial Cells (HDMVECs) to regulate angiogenesis and proliferation[262] and it also binds 
VEGF-C and VEGF-D[263] 
• α4β1 has been reported in proliferating ECs[264]. It binds fibronectin and VCAM 
• α7β1 is a laminin receptor found in VSMCs but not ECs[265] 
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• α3β1 is a laminin receptor present in ECs that regulates angiogenesis in mice[266] 
HUVEC adhesion to other matrix proteins was tested in real time adhesion studies using 
the xCELLigence electrical impedance system. In this system, matrix proteins or peptides are 
coated at 10μg/ml to xCELLigence E-plates, which contain electrodes capable of measuring tiny 
differences in electrical current imposed by cells binding to the bottom of the wells (Figure 
4.8). This technique is very sensitive, and measurements are influenced by a range of 
environmental parameters such as temperature, media composition, well coatings, 
xCELLigence-plate batch and cell handling. As a result, the absolute values vary from one 
experiment to the next. Nevertheless, the overall trend is the same and the curves of the 
resulting graphs are identical and so only one out of three representative experimental repeats 
is shown here. Each experiment was performed in triplicate and the experimental repeat with 
the intermediate values was chosen here.   
Figure 4.9 shows the effect of TC-I-15 on the adhesion of HUVECs to various matrix 
proteins and peptides. Both TC-I-15 and 6F1 inhibited HUVEC adhesion to collagen I and 
collagen IV, as expected, although there is some residual binding due to α10β1 or possibly 
Adapted from the xCELLigence website: https://www.aceabio.com/products/rtca-sp/. Electrodes 
on the bottom of the wells pick up changes in current induced by the adhesion of cells to the bottom 
of the well. Adhesion and cell spreading can be quantified as a function of electrical impedance 
called Cell Index (CI). The gold electrodes cover 70-80% of the bottom surface of the well. 
Figure 4.8: Diagram Depicting xCELLigence technology. 
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other collagen receptors present in HUVECs. HUVEC adhesion to fibronectin is unaffected, 
suggesting that α4β1, α5β1 and αvβ1 are not affected by TC-I-15.   
HUVEC adhesion to laminin was completely attenuated by TC-I-15 and severely 
impeded by 6F1. Integrins α1β1 and α2β1 have been reported to bind to laminin, but HUVECs 
should also express other laminin receptors like α3β1, α6β4 and αvβ3 which should 
compensate for some of the loss of binding. TC-I-15 reportedly does not inhibit αvβ3 but has 
Real time adhesion studies showing the effects of TC-I-15 and 6F1 on the adhesion of HUVECs to 
collagen I (A), collagen IV (B), laminin (C) and fibronectin (D). xCELLigence E-plates were coated with 
matrix proteins or peptides and blocked before adding cells at 15,000 per well. Adhesion is 
quantified as Cell Index, which is measured as the electrical impedance induced by cell adhesion to 
the electrodes on the bottom of the wells. Three technical replicates were carried out for each 
experiment and three separate experiments were performed but only one experiment is shown 
here, as described above. 
Figure 4.9: Inhibition of HUVEC Adhesion to ECM Proteins 
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not been tested on α3β1 or α6β4. TC-I-15 may be inhibiting these other laminin receptors as 
well as resulting in a severe loss of adhesion. If so, α3β1 is most likely to be affected as it also 
contains the β1 subunit known to be targeted by TC-I-15. 6F1 is a specific α2β1 inhibitor and 
was sufficient to provoke severe inhibition of HUVEC adhesion to purified laminin. It is possible 
that in these conditions HUVECs mainly bind to laminin via α2β1 and α1β1, leading to a 
complete loss of binding on addition of TC-I-15. However, a detailed study of laminin binding 
by HUVECs or α3β1 falls outside of the scope of this project.  
In conclusion, TC-I-15 is a more potent inhibitor when the ligand is of lower affinity for 
integrins. Also, TC-I-15 could possibly be affecting other laminin receptors in addition to α1β1 
and α2β1, as the adhesion to laminin is completely abolished in the presence of TC-I-15 when 
HUVECs should express several laminin receptors.  
4.8 Inhibition of α3β1 Adhesion to Laminin 
In order to rule out TC-I-15 inhibition of α3β1 to laminin, a commercially available 
recombinant full-length α3β1 was purchased and used in static adhesion assays with collagen 
I, fibronectin and laminin in the presence of TC-I-15 or the vehicle control, NaOH. As before, 
Immulon 2HB plates were coated for one hour with extracellular matrix proteins in PBS for 
Initial static binding 
adhesion assay testing the 
effects of TC-I-15 inhibition 
on α3β1 adhesion to ECM 
proteins. TC-I-15 does not 
affect the adhesion of 
commercially purchase 
α3β1 to laminin. No 
adhesion is seen for 
fibronectin or collagen I. 
Figure 4.10: Inhibition of α3β1 Adhesion to ECM Proteins. 
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laminin and fibronectin or in 0.01M AcOH for collagen I. Plates were blocked with 3% BSA in 
PBS before adding α3β1 at 10μg/ml for one hour, with or without TC-I-15. After washing with 
PBS, an anti-β1 antibody was used to detect the receptor and an anti-mouse HRP conjugate 
was used to detect the amount of α3β1 still bound to the plate with the TMB substrate as 
before (Figure 4.10). Two-way ANOVA with Sidak’s multiple comparisons test was used to 
analyse the effects of TC-I-15 inhibition on the binding of α3β1 to matrix proteins. The 
statistical analysis is summarised in Table 4.2 below. 




SD n Mean 
absorbance 
SD N P 
Collagen 0.198 0.016 3 0.204 0.009 3 0.9992 
Fibronectin 0.387 0.017 3 0.442 0.016 3 0.2213 
Laminin 1.077 0.039 3 1.150 0.063 3 0.0701 
BSA 0.218 0.014 3 0.308 0.051 3 0.0193 
Two-way ANOVA with Sidak’s multiple comparisons test was used to compare mean absorbances 
between TC-I-15 and the control for each condition 
 
TC-I-15 had no effect on the adhesion of α3β1 to laminin, and no real adhesion was 
seen for α3β1 to collagen or fibronectin (Figure 4.9). This suggests that the TC-I-15 inhibitor is 
not affecting α3β1 on HUVECs, although the expression patterns of α3β1 in ECs should be 
tested in the future. Due to time constraints no further analysis of α3β1 was carried out to 
characterise this commercial recombinant protein. Further analysis should have been carried 
out to confirm the recombinant protein is the fully functional α3β1 heterodimer. 
4.9 The effect of HUVEC activation or inhibition on integrin expression 
 HUVECs were cultured in EGM2 and stimulated overnight with cytokines alongside the 
inhibitors characterised here. Obtustatin, 6F1, TNFα, IL-1α, LPS, VEGF and TC-I-15 were added 
to HUVECs overnight and the effects of these compounds on the expression of collagen binding 
integrins was tested using qPCR. The results are shown in Figure 4.11 and the statistical analysis 
of the data is shown in table 4.4. The mean fold change, relative to HPRT1, values are plotted 
with error bars indicated SD. Addition of IL-1α increased expression of ITGA1 compared to the 
control (1.378-fold change relative to HPRT1 compared to 0.3337-fold change relative to 
HPRT1, *P=0.0218). None of the other conditions tested here increased mRNA expression of 
ITGA1. Additionally, no significant upregulation of either ITGA2 or ITGA10 was observed for 
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any condition tested. However, only one 24-hour time point was tested. It is possible that 
longer time points would reveal changes in integrin expression. Due to time constraints this 
was not repeated at other time points. VEGF has been shown to upregulate α2β1 and α1β1 
expression, so it was surprising not to see this effect here. In future, different concentrations 
and time points should be tested and analysed to investigate the effects of inflammatory 
cytokines and integrin inhibition on integrin expression in ECs. 
Figure 4.11: Effects of HUVEC Activation and Integrin Inhibition on Integrin Expression 
Graphs showing the differences in mean fold change, compared to HPRT1, for each integrin 
transcript after 24 hours activation or inhibition of integrins. A) shows the change in α1β1 
expression, B) shows the change in α2β1 expression and C) shows the change in α10β1 
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Table 4.4 Statistical analysis of integrin expression after activation 
 Mean fold 
change 
SD n P Mean fold 
change 
SD N P 
 ITGA1 ITGA2 
Control 0.3337 0.08527 5  3.59 0.6798 5  
Obtustatin 0.3406 0.1077 3 >0.9999 4.025 0.7633 3 0.9993 
6F1 0.3347 0.1219 3 >0.9999 3.924 1.105 3 0.9999 
TNFα 0.5642 0.2968 5 0.9897 5.56 0.7507 5 0.1389 
IL-1α 1.378 1.265 5 0.0218 5.097 0.8539 5 0.4067 
LPS 0.3258 0.07961 5 >0.9999 4.242 0.7582 5 0.9792 
VEGF 0.4998 0.196 4 0.9991 5.581 3.135 4 0.1762 
TC-I-15 0.3587 0.04712 3 >0.9999 3.742 0.3477 3 0.9997 
TC-I-15 
control 
0.336 0.1009 3 >0.9999 4.175 0.7275 3 0.9993 
One-way ANOVA with Sidak’s multiple comparisons test was used to compare the mean fold change 
values of each condition with the appropriate control mean fold change. 
  
ITGA10 Mean fold 
change 
SD n P     
Control 1.578 0.5632 5      
Obtustatin 1.966 0.9098 3 0.9773     
6F1 1.999 0.7199 3 0.9644     
TNFα 1.157 0.6745 5 0.9262     
IL-1α 1.027 0.4735 5 0.7670     
LPS 1.257 0.7454 5 0.9821     
VEGF 2.099 0.4311 4 0.8524     
TC-I-15 2.036 0.3196 3 >0.9999     
TC-I-15 
control 
1.937 0.8858 3 0.9773 
   
 
One-way ANOVA with Sidak’s multiple comparisons test 
was used to compare the mean fold change values of each 




 In conclusion, Obtustatin can be used to selectively inhibit α1β1 at 20μM. TC-I-15 can 
be used to inhibit both α1β1 and α2β1 simultaneously at 200μM. 6F1 can be used to selectively 
inhibit α2β1. However, no inhibitors exist for α10β1 so another method must be found to 
modulate the function of this integrin. CRISPR and siRNA are candidates for the modulation of 
integrin expression in the next chapter. 
 TC-I-15 is promiscuous and may also interact with other integrins on the surface of 
HUVECs. No inhibition was seen with TC-I-15 for recombinant α3β1 adhesion to laminin but no 
other integrins were tested due to time constraints. Additionally, TC-I-15 and 6F1 both severely 
Chapter 4 – Characterisation of Integrin Inhibitors TC-I-15 and Obtustatin 
114 
 
impede adhesion of HUVECs to laminin suggesting that α2β1 is the main laminin receptor in 
HUVECs in these conditions. This is in agreement with previous literature that states HUVECs 
use α2β1 to adhere to laminin[267]. 
 Finally, integrin expression is not affected by overnight stimulation with inflammatory 
cytokines or overnight integrin inhibition.   
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5.1 Chapter Summary 
 This chapter focusses on using CRISPR to KO integrins first in BE cells to test the 
efficiency of the system and then in HUVECs using both lentiviral and liposomal methods of 
transfection. siRNA is also used to KD integrin in HUVECs and these KDs are characterised and 
validated using qPCR, western blots and adhesion assays.  
5.2 Introduction 
In this project, obtustatin has been further validated as a specific α1β1 inhibitor, but 
TC-I-15 has proved to be promiscuous and inhibits both α1β1 and α2β1. Consequently, TC-I-
15 proved unsuitable for modulating the function of a single integrin but can be used to 
determine the effects of inhibition of α1β1 and α2β1 simultaneously. To assess the 
contribution of each single collagen-binding integrin on the regulation of EC function, 
CRISPR/Cas systems will be used to KO each receptor in turn.  
CRISPR/Cas systems were discovered as a defence mechanism against viral phages in 
prokaryotes. 50% of bacterial and 85% of archaeal genes contain CRISPR/Cas systems[268-270]. 
CRISPRs are Clustered Regularly Interspaced Short Palindromic Repeats found in prokaryotic 
genomes, and Cas proteins are CRISPR-associated endonucleases. The CRISPR sequences were 
initially described by Dr Nakata’s group years before their function was known[271]. CRISPR 
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repeats are separated by non-repeating DNA spacers which, when sequenced, were noticed 
to have homology to viral genomes and plasmids[272-274], the repeats were also always 
positioned near conserved genes, the Cas enzymes[275]. After a study discovered that the 
bacteria Streptococcus thermophilus integrated phage genomic sequences to these spacer 
sites following a viral challenge, it was clear the CRISPR repeats were involved in conferring a 
sort of bacterial immunity using the viral DNA[270, 276]. CRISPR systems are also transferable 
between different bacterial strains and so can be acquired[277]. Following phage or plasmid 
infection in bacteria, foreign double stranded viral DNA is cleaved by endonucleases and short 
stretches of the viral DNA are incorporated into the prokaryotic genome, between the CRISPR 
sites. These CRISPR sites plus the incorporated viral DNA are transcribed and processed into 
crRNA which associates with, and guides, Cas endonucleases to cleave incoming 
complementary viral DNA: the viral DNA is used against the virus[278]. The crRNA can be 
modified to target a gene of interest instead of viral DNA, guiding the Cas endonuclease to the 
target gene in the host genome. Complementary, specific sequences from a target gene can 
be inserted into the crRNA in the place of the viral genome fragments so that the Cas protein 
then cleaves the target gene, rendering it permanently inactive. Incorrect design of guide RNAs 
can introduce off-target effects and care must be taken to avoid this. Additionally, the target 
DNA must have a recognition sequence next to the crRNA binding site, called the protospacer-
adjacent motif (PAM), for the CRISPR/Cas system to be functional[279-282]. The PAM sequence 
ensures that the CRISPR/Cas complex does not cleave its own genes as this is not present in 
the CRISPR array. In endogenous CRISPR/Cas systems, two short RNAs are required to form the 
active endonuclease Cas-RNA complex: the crRNA and the trans-activating crRNA (tacrRNA). 
By creating a single chimeric crRNA that contains crRNA and tacrRNA, called a single guide RNA 
(sgRNA), CRISPR/Cas9 systems can be reprogrammed to target any gene[279-282]. However, 
mismatches are tolerated in some CRISPR/Cas9 systems, more so at the end furthest from the 
PAM and off-target effects must be monitored closely[283, 284]. Figure 5.1 shows a 
representation of the CRISPR/Cas system and associated guide RNA targeting the host genome. 
There are a number of different Cas proteins and Cas9 from Streptococcus pyogenes 
(spCas9) is most commonly used. The PAM sequence requirements for this spCas9 are simple 
(NGG) and spCas9 is a functional endonuclease. spCas9 creates blunt ends approximately 3 
base pairs to the 5’ of the PAM sequence. Other Cas proteins include Cpf1 which creates a 5 
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base pairs overhang[285]. Cas proteins have a range of other functions: wildtype spCas9 causes 
blunt end double strand breaks (DSBs) which often results in insertion/deletions at the target 
site when the DNA is repaired via non-homologous end re-joining (NHEJ), but other Cas 
proteins are capable of converting specific bases at the target site, for example from C to T or 
A to G without introducing DSBs[286]. Additionally, an adenosine deaminase enzyme can be 
fused to a catalytically inactive Cas protein resulting in a C to G conversion at the target site 
[286]. It is possible to use CRISPR/Cas systems to introduce an early stop codon by fusing Cas9 
to cytidine deaminases such as Apolipoprotein B mRNA editing enzyme, catalytic polypeptide 
1 (APOBEC1), resulting in a site directed mutagenesis from C to a T in CGA, CAG and CCA 
codons, rendering the gene dysfunctional[287]. Similarly, a catalytically dead Cas9 that binds and 
remains attached to the target DNA has been engineered, disturbing transcription and 
transiently downregulating the target gene[288]. Fusing histone modifying enzymes like 
acetyltransferases to catalytically dead Cas9 leads to the modification of histones at target 
sites, resulting in gene activation or inactivation[289]. Finally, another CRISPR/Cas system fused 
the Cas protein with a tag displaying several binding sites for the synthetic transcription 
activator VP64 (4 copies of Herpes virus VP16), resulting in the recruitment of multiple 
A graphical representation of the Cas9 endonuclease associated with the sgRNA targeting a 
complementary sequence in the host-DNA. The PAM sequence is shown on the left, and the scissors 
represent the DNA cleavage sites. The yellow represents the inserted sgRNA sequence while the 
orange represents the rest of the sgRNA structure. Figure taken from ‘What is CRISPR/Ca9’ Redman 
et al, 2016[5]. 
Figure 5.1: Diagram of CRISPR/Cas9 Targeting DNA. 
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transcription activators to the Cas9 protein. The sgRNA then guides the catalytically dead Cas9 
and multiple transcription activators to a target gene, resulting in as much as 50-fold increase 
in expression[282, 290]. 
Commercially available plasmid vectors containing the CRISPR sequences and 
associated Cas proteins are readily available for a variety of set-ups, with fluorescence reporter 
genes, antibiotic resistance genes, inducible expression systems and a range of endonuclease 
cloning sites. Addgene #57819 plasmid (pL-CRISPR.EFS.tRFP) was a kind gift from Dr Frank 
McCaughan (Biochemistry Department, Cambridge) and was used here to KO the gene coding 
for ITGA1. ITGA1 was selected as the first target as the aim was to knock each receptor out 
systematically.  
Introducing DNA or RNA into primary cells like HUVECs can be troublesome, as they do 
not readily absorb DNA and they are particularly sensitive to toxicity. There are three main 
approaches when delivering the CRISPR/Cas system into mammalian cells, 1) introduction of a 
single plasmid containing both the Cas9 gene and the guide RNA, 2) delivery of mRNA encoding 
Cas9 alongside a separate guide RNA and 3) delivery of the Cas9/sgRNA ribonuclease protein 
complex. These can be delivered physically, by microinjection, or using vectors, either viral or 
non-viral[291]. Microinjection is the most efficient method, with efficiencies at almost 100% as 
vectors are injected directly into cells. There is no limit to the size of the vector for this method 
and concentrations of vectors or proteins can be carefully controlled. However, this method is 
not suitable for transfecting high numbers of cells and so would not be suitable for this 
application (it is more suited to injecting zygotes with CRISPR/Cas systems to create animal 
models[291]). Microinjection also requires specialised equipment such as 0.5-5μm needles and 
a microscope in a sterile environment that were not available for this project. Electroporation 
is another commonly used method of delivering CRISPR/Cas9 systems into cells: a high voltage 
pulse in the presence of DNA will transiently permeabilise the membrane allowing DNA to 
enter the cell. However, electroporation is somewhat toxic to sensitive primary cells and 
requires specialised equipment not available in this project. Additionally the transfection 
efficiencies are variable between cell types[291].  
Liposome mediated transfection is a non-viral vector system. It works by encasing the 
negatively charged DNA into positively charged lipid nanoparticles that mimic the cell 
membrane phospholipid bilayer. The liposomes fuse with the membrane and the DNA or RNA 
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is released into the cell. Inside the cell, the vector is still encased within an endosome and so 
could be targeted for degradation before entering the nucleus, which in itself is another 
challenge[291]. This method is also potentially toxic, especially to primary cells, as the 
membrane structure is altered[291].  
Viral methods include adeno-associated viruses (AAVs) and lentiviruses. AAV is a single 
stranded DNA virus that does not cause disease in humans and is capable of entering cells with 
little immune reaction[291, 292]. Lentiviruses are a subset of retroviruses and lentiviral systems 
have been exploited to find more efficient ways of transfecting CRISPR/Cas systems into 
primary mammalian cells. AAVs and lentiviral CRISPR/Cas systems use viral packaging proteins 
to form complexes that interact with host-cell endocytosis proteins, transporting the plasmid 
DNA into the cell, much like natural virus infection. AAVs have a limited capacity for large 
plasmids and only allow for 5kb of genomic material to be inserted, limiting the CRISPR/Cas 
system severely[291, 292]. In lentiviral systems, used here, the viral packaging protein gene 
sequences are contained on two plasmids. These are transfected into an easy-to-transfect cell 
line along with the CRISPR/Cas9 plasmid, where viral particles containing the CRISPR and 
associated Cas9 endonuclease are created. Lentiviral systems can accommodate much larger 
plasmid insertions. However, Cas9 from Streptococcus pyogenes is a large protein of 1366 
amino acids, which poses problems when trying to package the CRISPR/Cas9 plasmid. Smaller 
Cas9 proteins were discovered in other strains, like Staphylococcus aureus which contains 1053 
amino acids instead[293]. Since lentiviruses are retroviral, they can integrate into the host cell 
DNA and this could potentially increase off-target effects[291]. To make sure the viral system is 
safe, the gene components essential to creating viral particles are split between multiple 
plasmids; for 2nd generation lentiviral systems, three plasmids are used to ensure safety. One 
plasmid contains the packaging genes that are essential for making the viral capsid. A second 
plasmid contains the envelope protein genes, such as vesicular stomatitis virus G (VSV-G), and 
a third plasmid contains the viral genome, the CRISPR array and Cas9. Packaging plasmid 
psPAX2 and envelope plasmid pMD2.G were gifts from Dr Frank McCaughan and were used to 
create lentiviral particles to transport sgRNA/Cas9 complexes. psPAX2 contains genes 
sequences for Gag, Pol, Rev and Tat, and pMD2.G contains the VSV-G gene which is essential 
for the fusion of the viral and host-cell membranes; both have been used for successful viral 
transduction of mammalian cells[294]. 
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Green Merge Red 
Left (green), middle (red) and right (merge) images are shown. Sg1, sg2 and sg3 are the three ITGA1 
targeting sgRNA containing CRISPR plasmids, whereas sgNT denotes non-targeting sgRNA and 
sgFRA denotes a random targeting plasmid from Dr Frank McCaughan. BE cells express GFP and are 
green, the successfully transduced BE cells are red and green, merged. The scale bar represents 
75µm. 
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5.3 Annealing of sgRNAs 
First, three sets of complementary primers that anneal to form sgRNA sequences 
specific to one integrin (ITGA1 was chosen first to be systematic) were designed using the 
CRISPR design tools on the website http://crispr.mit.edu. Primers were annealed and cloned 
into CRISPR plasmid #57819. The resulting plasmids were electroporated into DH5α cells grown 
on ampicillin plates. After 24h, colonies were selected, plasmids were extracted and sequenced 
using PLKO U6 forward primer until 3 separate sgRNA CRISPR/Cas9 plasmids were obtained, 
called sg1, sg2 and sg3, as well as a non-targeting control (sgNT).  
Cloning the sgRNAs into the CRISPR plasmid was surprisingly inefficient and the process 
had to be repeated a lot of times to obtain colonies expressing the CRISPR plasmid containing 
the sgRNA insert. For reasons unknown, the plasmid was prone to re-ligating without the 
sgRNA insert, even when the primers were treated with T4 polynucleotide Kinase (PNK), 
inferring ampicillin resistance to the DH5α without the insert. When the three sgRNAs were 
finally all cloned into the vector, these were transfected into HEK283T cells alongside psPAX2 
and pMD2.G, using Lipofectamine 2000 reagent in 10cm tissue culture dishes to create viral 
particles. After 5 days the media was collected and filtered through a 0.45μm filter to obtain 3 
sets of viral particles containing CRISPR/Cas9 plasmids with the sgRNA sequences. These viral 
particles were then transduced into BE cells (also from Dr Frank McCaughan). These plasmids 
included a red fluorescent protein (RFP) reporter gene, enabling the monitoring of successfully 
transfected cells after 3-5 days by detecting red fluorescence reporter on a Leica DM6000 
microscope. 
5.4 Transduction of lentiviral CRISPR/Cas9 into Immortalised Bronchial Epithelial Cells 
 Before testing the ITGA1 gene targeting lentiviral CRISPR KO system in primary HUVECs, 
BE cells were tested, as they are immortalised, human and express α1β1. These BE cells express 
green fluorescent protein (GFP) and so can be easily monitored in-situ using green 
fluorescence. BE cells were cultured in tissue culture treated 6-well plates until 70% confluent, 
100μl filtered viral particles were added to the wells along with 8µg/ml polybrene in serum-
free, antibiotic free media. After 6 hours the media was changed to complete media and viral 
particles in cells were monitored every day for 5 days for red fluorescence. Figure 5.2 shows 
immunofluorescence images of live BE cells 5 days after transduction of viral particles. All BE 
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cells appear green and successfully transduced cells exhibit red fluorescence as well. The 
transduction efficiencies of these lentiviral CRISPR plasmids were very low, with very few RFP-
positive cells. It was difficult to find any red cells at all: the images shown in Figure 5.2 capture 
non-representative fields of view where red cells were present to give an idea of what 
transfected cells would look like under the microscope and so this is an overrepresentation of 
successfully transfected cells. Higher transduction rates were expected for this lentiviral 
system. It is possible there were problems with the CRISPR/Cas plasmid as it was very difficult 
to clone the sgRNAs into the backbone when it should have been straightforward. Fresh 
bacteria, maxiprep kits, agar plates and antibiotics were purchased and tested, to no avail. On 
the other hand, the microscope may just not be sensitive enough to pick up other cells that 
may be RFP-positive but not bright enough. Next, a MoFlo® Astrios™ cell sorter was used to 
sort RFP-positive from RFP-negative cells, and HUVECs were used instead of BE cells. 
5.5 Cell Sorting Analysis Confirms Transfection Efficiency is Low 
 Lentiviral transductions were repeated as described above with HUVECs and viral 
particles were added in serum-free EBM with polybrene, when cells were 70% confluent. After 
the 6-hour transduction, as before, cells were left for 3-5 days before detaching and running 
on the MoFlo Astrios cell sorter. Untreated cells were used as a baseline for red fluorescence 
to set up a sorting gate that only collects RFP-positive cells. However, there was some overlap 
between the RFP-positive and untreated populations and since it was necessary to collect only 
RFP-positive cells, the gating had to be very stringent (less than 0.1% untreated cells in the 
RFP-positive gate). Consequently, some of the RFP-positive cells were lost to ensure RFP-
negative cells were not included. Figure 5.3 shows the cell sorting data from one experiment, 
with the top right graph showing the percentage of cells sorted as RFP-positive over three 
experiments. The transduction efficiencies were very variable between viral batches, from 0.1 
to 15%. 
After cell sorting, it was clear that the transfection efficiency is too low for this approach 
to be viable in HUVECs. HUVECs can only be passaged up to passage 5, as they begin to lose 
their endothelial phenotype and proliferative potential past this point. For immortalised cells 
and cell lines the RFP-positive cells can be separated and expanded many times to create a KO 
population, but this cannot be done when using primary cells. There are simply not enough 
RFP-positive cells to complete downstream experiments on cell function. The reason for the 
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very low transfection rate is unclear: the plasmids may have been damaged or degraded; there 
were difficulties extracting sterile, endotoxin-free plasmids using Qiagen Maxi-prep kits and 
the yields were often low. There were many points at which the transfection/transduction 
process could be losing efficacy. In the end liposomal transfection methods were tested 
instead of troubleshooting the lentiviral system due to time constraints. 
    Several transfection reagents were tested (Lipofectamine LTX with plus reagent, 
Promofectin and Transfex) in forward and reverse transfection set-ups but none yielded 
promising results (data not shown). It is also worth noting that RFP-positive cells are not 
necessarily KO cells: the CRISPR/Cas9 system could have silenced one copy of the targeted 
gene and not the others, or the transduction may have been successful, but the gene editing 
could have gone wrong. RFP-positive cells must then be analysed for ITGA1 gene expression 
Figure 5.3: Flow Cytometry Analysis of HUVEC Transduction. 
A) A series of graphs showing flow cytometry data from the gating used to sort RFP positive from 
RFP negative cells. The baseline was chosen so that the untreated cells displayed less than 0.1% 
positive cells, and this was copied to other populations. B) Graph showing collated data from 3 
transductions in HUVECs. sgNT is the non-targeting CRISPR-Cas9 plasmid that contains a random 
guide RNA sequence.  
A B 
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by qPCR to confirm gene silencing. Since the transfection efficiency was too low to use in future 
experiments no further analysis was carried out for the RFP-positive cells. 
 In conclusion, neither lentiviral transduction systems nor conventional transfection 
reagents are suitable for use with CRISPR/Cas9 KO plasmids in HUVECs due to low transduction 
efficiency. Transient KD with siRNA may prove to be a more efficient and convenient tool for 
modulating integrin expression. 
5.6 Optimisation of siRNA Knockdown using siGLO and GAPDH 
 Transient KD can be achieved with RNA interference (RNAi) using short interfering 
(si)RNA, which are short double stranded (ds)RNA molecules that induce gene silencing by 
targeting complementary mRNA for degradation[295]. Originally discovered as a method of gene 
regulation in C. elegans[296] and plants, RNAi is a gene silencing mechanism present in 
eukaryotes that can be manipulated to target an mRNA of interest. Long dsRNAs (like those in 
viruses) are cleaved and processed into 21 nucleotide siRNAs, with a 2-nucleotide overhang at 
the 3’ end, by Dicer, a RNase-III-like enzyme. The siRNAs then associate with argonaute, a 
catalytic component of the RNA induced silencing complex (RISC), where the RNA strands are 
separated. The most stable strand is incorporated into the RISC. This single stranded RNA 
(ssRNA) guides the RISC complex to complementary mRNA and RISC cleaves the mRNA strand, 
marking it for degradation by RNases in the cell. Mammals and nematodes have a single Dicer 
enzyme that processes miRNAs and siRNAs, whereas Drosophila melanogaster expresses two 
and Arabidopsis thaliana has four[297]. Dicer proteins have two RNase III domains and each one 
cleaves one strand of the dsRNA to create the 2-nucleotide overhang. The length of the 
catalytic domains of Dicer effectively determine the length of the siRNA[298]. Endogenous 
siRNAs are degraded quickly by RNases and as a consequence commercial siRNAs are 
chemically modified to increase stability[299, 300].  
As with CRISPR, it is tricky to transfect siRNAs into primary cells and liposomal mediated 
transfection is the most commonly used method. First, several transfection reagents were 
tested for suitability in HUVECs using commercially available fluorescent siRNA (siGLO) (Figure 
5.4). Cells were reverse transfected with 50nM of siGLO and 1:50 dilution of transfection 
reagent (equal to 0.2μl in a 10μl transfection mix in a 96-well plate, described in materials and 
methods) for 8 hours in EGM2 without heparin, before changing the media to complete EGM2. 
After 24 hours, cells were detached and propidium iodide (PI) was added for 5 minutes to stain 
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dead cells before analysis on a C6 flow cytometer. Non-transfected cells that were incubated 
with siGLO in the absence of the transfection reagent were used as a negative control for 
transfected versus non transfected cells. Untreated cells without the addition of PI were used 
as a negative control for PI positive (dead) cells. Figure 5.4 (left) shows the comparison of 
transfection reagents. Table 5.1 summarises the statistical analysis of this data using one-way 
ANOVA and Tukey’s multiple comparison test to compare the means of each condition to all 
the other means. DharmaFECT1 (D1), D2 and D4. D4 showed higher transfection efficiency 
than D1 (84.47% vs 44.38% and **P=0.0013) or D2 (57.83% and *P=0.0154) with no significant 
increase in cell death compared to D1 or D2 or the control. D4 was used as the transfection 
reagent in all further siRNA experiments. Control cells with siGLO in the absence of the 
transfection reagent were not positive for siGLO, confirming there is no passive up-take of 
siRNA.  
Figure 5.4 (right) shows the optimisation of D4 concentration as subsequent 
percentage expression of both ITGA2 and GAPDH mRNA after siRNA KD. Table 5.2 summarises 
Figure 5.4: Comparing siRNA Transfection Reagents. 
 
A) A comparison of 3 transfection reagents from DharmaFECT using flow cytometry and fluorescent 
siRNA, DharmaFECT4 (D4) shows the highest transfection efficiency for siGLO, without increasing 
the number of PI positive (dead) cells. The control bar shows the fluorescence of cells where siGLO 
was added but in the absence of transfection reagent, i.e. passive absorption of siGLO or 
background fluorescence. B) shows qPCR data after siRNA KD of ITGA2 and GAPDH using different 
concentrations of D4 (μl/well) 
A B 
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the statistical analysis of this data using two-way ANOVA and Tukey’s multiple comparisons 
test to compare the mean percentage expression. For GAPDH siRNA there were no significant 
differences between the different concentrations used here. For ITGA2 KD, 0.15μl per well 
(60.23% expression) was significantly higher than 0.2μl per well (43.75% expression, **P=0.0065), 
0.25μl per well (40.04% expression, ***P=0.0008) and 0.3μl per well (39.34% expression, 
***P=0.0005). However, there were no significant differences between 0.2μl per well, 0.25μl 
per well and 0.3μl per well, suggesting that the optimal concentration would be 0.2μl per well 
for efficient KD while eliminating unnecessary costs and toxicity. From here on in, this dilution 
of D4 is used (1:50 or 0.2μl per well in a 96-well plate). 
Table 5.1 Comparison of transfection reagent efficiency 
 Percentage % of siGLO positive cells 
 Mean % SD n P value vs D2 P value vs D4 P value vs control 
D1 44.38 14.29 3 0.2481 0.0013 0.0008 
D2 57.83 3.107 3  0.0154 0.0001 
D4 84.47 6.691 3   <0.0001 
Control 1.168 0.4417 3    
 Percentage of PI positive (dead) cells 
 Mean % SD n P value vs D2 P value vs D4 P value vs control 
D1 19.15 7.569 3 >0.9999 >0.9999 0.1188 
D2 18.84 9.738 3  0.9995 0.1271 
D4 19.54 9.493 3   0.1090 
Control 2.474 2.602 3    
Two-way ANOVA and Tukey’s multiple comparisons test to compare the mean percentage 
expression of each condition with all other conditions 
 
Table 5.2 – Optimisation of D4 concentration 
 Percentage expression of ITGA2 after siRNA Knockdown 
ITGA2 Mean % SD n P value vs 0.02 P value vs 0.25 P value vs 0.3 
0.15 60.23 6.711 5 0.0065 0.0008 0.0005 
0.2 43.75 7.383 5  0.8506 0.7731 
0.25 40.04 9.930 5   0.9987 
0.3 39.34 9.372 5    
 Percentage expression of GAPDH after siRNA Knockdown 
GAPDH Mean % SD n P value vs 0.02 P value vs 0.25 P value vs 0.3 
0.15 28.12 6.067 4 0.4255 0.0881 0.2034 
0.2 20.18 4.132 4  0.7948 0.9630 
0.25 15.46 5.098 4   0.9710 
0.3 17.72 5.573 4    
Two-way ANOVA and Tukey’s multiple comparisons test to compare the mean percentage 
expression of each condition with all other conditions 
 
Chapter 5 – CRISPR and siRNA as Techniques for Modulating Integrin Expression 
128 
 
5.7 – Using siRNA to Modulate Integrin Expression 
Silencer Select™ siRNAs were purchased from Thermo and two siRNAs for each target 
gene were pooled (detailed in materials and methods). The siRNAs were extensively tested and 
optimised for efficiency until a 90% KD was achieved using the D4 transfection reagent. Figure 
5.5 shows the mean mRNA percentage expression 48 hours after siRNA transfection with error 
bars depicting SD. All means are normalised using the HPRT1 control and then shown as a 
percentage of the negative control siRNA condition. Table 5.3 shows the statistical analysis of 
integrin expression after siRNA KD. The mean percentage expression is compared to all other 
means using two-way ANOVA and Tukey’s multiple comparisons test. 
Table 5.3 – Statistical analysis of integrin expression after siRNA KD of each integrin 
 Percentage expression of ITGA1 after siRNA Knockdown 
ITGA1 Mean % SD n 
P value vs 
ITGA2 KD 
P value vs 
ITGA10 KD 
P value vs ALL 
KD 
P value vs 
Control 
ITGA1 KD 9.70 2.88 3 <0.0001 <0.0001 >0.9999 <0.0001 
ITGA2 KD 98.89 6.83 3  0.9998 <0.0001 0.9999 
ITGA10 KD 100.22 7.18 3   <0.0001 >0.9999 
All KD 10.56 6.80 3    <0.0001 
Control 100 0 3     
 Percentage expression of ITGA2 after siRNA Knockdown  
ITGA2 Mean % SD n P value vs 
ITGA2 KD 
P value vs 
ITGA10 KD 
P value vs ALL 
KD 
P value vs 
Control 
ITGA1 KD 104.99 11.99 3 <0.0001 0.3098 <0.0001 0.9657 
ITGA2 KD 12.61 1.44 3  <0.0001 0.9972 <0.0001 
ITGA10 KD 120.08 27.88 3   <0.0001 0.0944 
All KD 15.19 3.66 3    <0.0001 
Control 100 0 3     
 Percentage expression of ITGA10 after siRNA Knockdown 
ITGA10 Mean % SD n P value vs 
ITGA2 KD 
P value vs 
ITGA10 KD 
P value vs ALL 
KD 
P value vs 
Control 
ITGA1 KD 102.59 7.44 3 0.141 <0.0001 <0.0001 0.9971 
ITGA2 KD 84.05 4.03 3  <0.0001 <0.0001 0.2587 
ITGA10 KD 13.55 3.51 3   0.9975 <0.0001 
All KD 16.04 12.73 3    <0.0001 
Control 100 0 3     
two-way ANOVA and Sidak’s multiple comparisons test to compare the mean percentage 
expression of each condition with all other conditions 
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Overall this analysis shows that the siRNA KD was very efficient: 9-16% expression is 
seen for all targets compared to the negative control siRNA or compared to the siRNA KD of 
other integrins (for all of these comparisons: ****P<0.0001). The same is true for the triple KD 
condition where all three integrins are targeted with siRNA. There is no significant difference 
between the single integrin knockouts and the expression of the same integrin in the triple KD 
condition. There also does not seem to be any compensation by other integrins (Figure 5.5). 
For example, in the siRNA ITGA2-KD condition there is no upregulation of the ITGA1 or ITGA10 
mRNA to compensate for the loss of ITGA2 after 48h. This is surprising as many studies have 
speculated that there is a functional redundancy between these integrins suggesting a 
compensatory mechanism may be present[168].   
 To ensure the KD was effective, quantitative protein expression western blots were 
carried out using HUVECs lysed directly in Laemmli’s buffer 48h post siRNA. Cell lysates were 
boiled in Laemmli’s buffer and run on SDS-PAGE gels before blotting onto PVDF membranes. 
The Licor Odyssey blocking buffer was used for blocking and antibody incubations, and Licor 
IR-dye secondary antibodies were used for detection of integrin bands. Various primary 
antibodies for ITGA1, ITGA2 and ITGA10 were all tested using cell lysates from the integrin-
transfected C2C12 cells, but nearly all of them showed cross-reactivity to the other integrins 
and could not be used to target specifically one type of integrin. Only one antibody, targeting 
ITGA2, did not demonstrate any cross reactivity to the other integrins, so only western blots 
for ITGA2 KDs are shown here (Figure 5.5). All bands were normalised to a loading control (α-
tubulin) and compared to the negative control siRNA to get a percentage value for protein 
expression. Data is shown as a percentage of fluorescence intensity, normalised to α-tubulin. 
Western blots showed a huge decrease in protein expression of ITGA2 in both the ITGA2 KD 
and KD of all three integrins, as expected. Timepoints from 48h to 120h post transfection were 
analysed and protein expression was found to be lowest at 48-72h post transfection. As a 
result, all downstream experiments were carried out at this time point. Figure 5.5 shows the 
western blot images obtained from the Licor from which fluorescence measurements were 
taken and analysed. 
  




Quantification of siRNA knockdowns. A)  shows the validation of ITGA2 antibody against cell lysates 
from C2C12 cell expressing each of the integrins, red = α-tubulin and green = ITGA2. B) Shows the 
detection of ITGA2 in HUVEC cell lysates 48 hours post siRNA using western blot. C) Shows qPCR 
quantification of integrin expression after each siRNA KD, normalised to the negative control siRNA, 
with a 90% KD for ITGA1 and ITGA2, and 80-85% KD for ITGA10. ITGA11 was included but not 
detected in any condition. KD of each integrin has no effect on the expression of other integrins at 
48h time point. D) The quantification of western blot data from the Licor quantitative Western blot 
analysis, normalised to α-tubulin and then the negative control.  
Figure 5.5. Quantification of siRNA Knockdown. 
A) B) 
C) D) 
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In conclusion, siRNA has proved to be an efficient way to KD integrin expression in 
HUVECs and will be used further to probe the effects of integrin KD on HUVEC cell function. 
Additionally, there does not seem to be any compensatory upregulation of integrin expression 
in each KD condition. This allowed us to selectively pinpoint the effect of individual integrins in 
cellular behaviour. 
5.8 Functional Adhesion Tests Using HUVEC Knockdowns 
 Once the siRNA knockdown was established, functional assays were carried out to 
assess the effects of integrin KD on cell function. Since ECs adhere tightly to the ECM forming 
a barrier between the blood and surrounding tissues, HUVEC adhesion to collagen and 
peptides was first tested in each KD condition. Adhesion was studied in real-time xCELLIigence 
electrical impedance assays as described in Chapter 3. xCELLigence E-plates were coated with 
collagen and peptides before blocking and subsequently adding 15,000 cells/well. Adhesion 
was measured as a function of electrical impedance as cells adhered to the bottom of the wells 
and obstructed electrical currents between the E-plate electrodes.  
Figure 5.6 shows the real-time effects of integrin KD on the binding of HUVECs to 
collagen I and the GFOGER THP. KD of ITGA1 and ITGA10 had no effect on HUVEC adhesion to 
either collagen I or GFOGER. This is dues to ITGA2 still being present on the cell surface to 
adhere to these ligands. In contrast, KD of the ITGA2 in both ITGA2-KD and All-KD severely 
depletes adhesion of HUVECs to collagen I and GFOGER. There is no difference between the 
ITGA2-KD and All-KD conditions, suggesting that the presence of ITGA1 and ITGA10 in the ITGA-
KD condition does not contribute to the overall binding of HUVECs to collagen. ITGA2-KD is 
sufficient to deplete integrin binding to collagen and further KD of ITGA1 and ITGA10 does not 
inhibit HUVEC binding further. The ITGA1 or ITGA10 still present on the surface of HUVECs 
should bind to both collagen I and GFOGER, even in the absence of ITGA2, but there was no 
evidence of this happening here. It is possible that the expression of ITGA10 and ITGA1 are too 
low to begin with, or that they require interaction with ITGA2 to bind. In HUVECs, it appears 
the α2β1 integrin is the main adhesion receptor for collagen and the primary collagen-binding 
integrin, as our qPCR data suggested. 
 
 





In conclusion, CRISPR/Cas9 is not suitable for the KO of integrins in HUVECs as neither 
lentiviral transduction nor liposomal transfection could achieve high enough transfection 
efficiencies for downstream experiments in HUVECs. However, siRNA proved to be a reliable 
and effective method for the KD of integrins in HUVECs and will be used in all future 
experiments alongside inhibitors TC-I-15, obtustatin and 6F1 where possible. Adhesion to 
Real-time adhesion assays after siRNA KD of integrins. A) HUVECs 48 hours post-siRNA KD of each 
integrin adhering to soluble collagen I. B) HUVECs 48 hours post-siRNA KD of each integrin 
adhering to GFOGER. Knockdown of ITGA2 is enough to attenuate HUVEC binding to both collagen 
I and the integrin binding motif GFOGER. 
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collagen is impaired by both inhibition and KD of α2β1, but not α1β1 or α10β1. This is likely 
due to the fact that α2β1 is expressed in much high levels than α1β1 or α10β1. As a result, 
HUVEC attachment through α1β1 or α10β1 lost by KD of ITGA1 or ITGA10 genes may be 
compensated by binding through α2β1, but not vice versa. Very little α2β1-independent 
binding to collagen was detected, suggesting that the α1β1 and α10β1 integrins are not 
involved in HUVEC interaction with collagen in these conditions.  
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6.1 Chapter Summary 
 This chapter focusses on using the characterised integrin inhibitors and integrin siRNA 
KD to study the effects of integrin inhibition or KD on the proliferation of HUVECs. Proliferation 
was measured using cell number quantification assays and EdU incorporation assays on 
collagen coated surfaces. The effects of integrin inhibition and KD on HUVEC cell death were 
also explored. Fluorescently conjugated Annexin V was used to detect early stage apoptosis 
and cytotoxicity kits measuring LDH released into the media were used to measure necrosis. 
6.2 Introduction 
 Cell proliferation describes the process by which cells divide and multiply. This process 
is essential in development to form an adult organism from an embryo. It is a tightly regulated 
process involving many cell cycle checkpoints[11]. The deregulation of cell proliferation has 
consequences in many disorders. For example, cancers occur when cell cycle checkpoints are 
deregulated in some cells. These cells undergo pathologically upregulated proliferation 
alongside pathologically upregulated cell survival and tumours can be formed from these 
incorrectly proliferating cells[11]. Psoriasis, a chronic inflammatory skin condition, is 
characterised by intensely itchy plaques of red or silver scales on the skin. These plaques are 
caused by unchecked, increased keratinocyte and dermal EC proliferation alongside an 
inflammatory response and they can cause severe discomfort in sufferers[301]. Carefully 
regulated proliferation is vital in sprouting angiogenesis as the stalk cells must proliferate to 
allow the tip cell to migrate away from the existing blood vessel. (see Chapter 8 for more details 
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on angiogenesis). This stalk-cell proliferation must then cease when the new vessel is 
formed[179]. 
 Cell cycle progression (reviewed in[11]) involves several stages: first the cell enters a 
growth phase, then the DNA is replicated, the chromosome replicates are separated and the 
cell divides. Cyclins and their associated cyclin-dependent kinases (CDKs) play an important 
role in regulation of cell cycle progression[11]. CDKs are expressed stably throughout the cell 
cycle and their activity is regulated by modulating the expression of their activating cyclins. 
Figure 6.1 shows the general stages of cell cycle progression. G0 denotes the resting cell state 
which applies to all non-proliferating cells, including the majority of ECs[87]. In response to 
growth factors or mitogens cells switch from the G0 to G1 phase, entering the growth phase of 
the cell cycle. This requires growth factor-stimulated upregulation of cyclin D which associate 
with CDK4 and 6. Cyclin E is upregulated to induce progression from G1 into S phase, in which 
the process of DNA replication takes place. For post-replication transition into G2 phase, Cyclin 
A binds to CDK2. Cyclin A and Cyclin B both associate with CDK1 to promote transition from G2 
into the M phase, where mitosis occurs. When CDKs are cyclin-activated, they phosphorylate 
target proteins that promote cell cycle progression. CDK4/6-Cyclin D phosphorylates the 
tumour suppressor pRb which results in the activation of transcription factors, which promote 
cell-cycle progression genes such as cyclin A. Cyclin expression promotes cell cycle progression 
and cyclins are broken down at the end of each phase via ubiquitin mediated degradation. 
Processes that regulate cyclin expression or CDK activation/inhibition will effectively influence 
cell cycle progression. CDK inhibitors (CDKIs) can either block cyclin binding or inactivate the 
cyclin-CDK complex resulting in cell-cycle arrest. Table 6.1 summarises some CDKIs and their 
targets. The CDKI p21 is transcriptionally upregulated by the tumour suppressor p53, while p15 
and p27 are increased or activated in response to TGFβ, resulting in cell cycle arrest[11]. 
Table 6.1 – List of Cyclin Inhibitors 
INK4 CDKI Family Function Cip/Kip CDKI Family Function 
p15, p16, p18, p19 
Form stable 
complexes with CDK4 
and CDK6 preventing 
binding to cyclin D 
p21, p27, p57 
Inhibit CDK4-Cyclin D 
and CDK6-Cyclin D 
complexes and CDK1-
Cyclin B complexes 
 




For a cell to commit to cell cycle progression, many checkpoints must be overcome. For 
example, DNA damage checkpoints must be passed for the cell to progress from G1 into S, and 
failure to pass this checkpoint will result in p53-mediated cell cycle arrest so that DNA repair 
can take place. Cancer cells generally contain mutations in genes that encode proteins that 
would normally contribute to cell cycle arrest or promote apoptosis. In conclusion, the 
regulation of cyclins, CDKs and CDKIs will control cell cycle progression and determine whether 
a cell proliferates, remains quiescent or dies (reviewed in[11]). 
   Adhesion to the ECM is required for proliferation and survival of adherent cells[302, 303]. 
Integrin signalling contributes to VEGF mediated extracellular signal-regulated kinases (ERK) 
activation[303] and ERK signalling is heavily implicated in the upregulation of EC proliferation[304]. 
Integrins also activate the MAPK c-Jun NH2-terminal kinase (JNK) which contributes to the 
regulation of cell cycle progression through G1 phase. JNK phosphorylates c-Jun which binds c-
Fos to create AP-1 transcription factor complex[303]. AP-1 in turn regulates many pathways 
involved in proliferation, including the expression of Cyclin D1. Additionally, integrins stimulate 
Figure 6.1. Cell Cycle 
Diagram. 
A diagram adapted 
from ‘The cell cycle: a 
review of regulation, 
deregulation and 
therapeutic targets in 
cancer’ Vermeulen et 
al 2003[11], showing 
the cell cycle 
progression and the 
CDK-Cyclin complexes 
associated with each 
stage. 
Figure 6.1. Cell Cycle Diagram. 
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p70 S6-kinase which is thought to promote cyclin D1 translation[167]. Generally, cell adhesion 
to the ECM downregulates the CDKIs p21 and p27, resulting in the activation of CDK2-Cyclin 
complexes[177]. Integrin α10β1 has been shown to regulate proliferation in Glioblastoma 
cells[169] and integrin α1β1 regulates collagen-dependent proliferation in vivo in mouse 
fibroblasts[305]. This suggests it is likely that integrin modulation in HUVECs could affect 
proliferation.  
 Apoptosis is a highly regulated process by which cells undergo organised cell death. 
Cells that fail to overcome cell cycle checkpoints will undergo apoptosis. Additionally, loss of 
cell adhesion to the ECM causes apoptosis, termed anoikis[303]. In EC dysfunction, sustained 
chronic inflammation in response to TNFα can result in apoptosis or detachment of ECs into 
the blood stream[88]. There are multiple integrin signalling pathways implicated in the 
regulation of cell survival. For example, integrin ligation to the ECM leads to focal adhesion 
kinase (FAK) activation which in turn activates PI3 Kinase, and protein kinase B. These signals 
promote cell survival by inactivating the pro-apoptotic proteins caspase-9 and Bad[303]. 
Additionally, antagonist blocking of αvβ3 induces apoptosis in proliferating ECs[306]. Clearly, EC 
attachment, proliferation and apoptosis are all linked to adhesion. Cell attachment through 
collagen-binding integrins could regulate these processes in HUVECs. To further study these 
interactions, proliferation and apoptosis studies were carried out in HUVECs after integrin 
inhibition and siRNA knockdown. 
6.3 Effects of Integrin Inhibition or siRNA Knockdown on Proliferation 
 HUVECs were grown on collagen coated surfaces for all proliferation assays. First, 5-
ethynyl-2-deoxyuridine (EdU) incorporation assays were carried out downstream of integrin 
inhibition or KD. EdU assays work in a similar way to (Bromodeoxyuridine) BrdU assays in that 
a Thymidine DNA base analogue, EdU, is added to live cells in culture for a limited duration. 
The cells then passively uptake the EdU and incorporate it into DNA during synthesis that 
occurs during the S phase. Copper-catalysed azide-alkyne (click) chemistry is then utilised to 
specifically label the DNA-incorporated EdU with a fluorescent tag, staining the nuclei of cells 
that have taken incorporated EdU into their DNA. EdU assays give a snapshot of the cells that 
are actively proliferating at the time of the experiment. 
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For assays involving inhibitors, HUVECs were seeded in EGM2 and left to attach 
overnight before adding inhibitors for 24 hours. For assays involving siRNA KD of integrins, the 
cells were seeded 48 hours post-siRNA transfection and incubated overnight in EGM2. After 
24 hours, EdU was added to a final concentration of 10μM and the cells were incubated at 
37°C for two hours to allow EdU incorporation into actively proliferating cells. Initially, this was 
quantified with flow cytometry using the Thermo Click-iT Alexa 488 EdU proliferation assay kit. 
However, the data obtained using this kit was extremely variable over several repeats and 
could not be used. The protocol for the flow cytometry EdU assay involves detaching cells, 
fixing them and then several staining, washing and spinning steps. It is possible that some cells 
were lost during these steps and this loss of cells managed to skew the data. Additionally, a 
nuclear stain was not used for this approach and as such the total number of cells may not 
have been entirely accurate. On top of that, the Accuri C6 Flow Cytometer was problematic 
and broke down many times during the course of this project and as such the data obtained 
may have been affected by faults within the cytometer. Either way, the kits did not return 
reliable data in this set-up. Instead, the cells were fixed directly in the wells of the tissue culture 
plate, stained with Hoechst and the EdU Click-iT Alexa 488 dye and a Leica DM6000 microscope 
was used to take 10 randomly selected fields of view per well. From these images, cell counts 
were performed using ImageJ and the percentage of green EdU-positive cells was calculated 
using the Hoechst staining to calculate the total cell number. Figure 6.2 shows one 
A representation of the EdU staining seen with the Thermo Click-iT EdU Proliferation kit on the Leica 
microscope.. Left panel: Hoechst staining (blue); middle panel: EdU staining (green); right panel: 
merge. A field of view from the negative control siRNA condition is seen here, but all the images 
were very similar. Approximately 200 cells were analysed per field of view, 10 fields of view were 
taken for each well and three wells were analysed per condition. 
Figure 6.2: EdU staining in HUVECs.  
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representative field of view from the Control siRNA condition as an example of the Images 
obtained with this approach. The staining was clear and crisp with virtually zero background 
staining and the cell nuclei were sparse enough for accurate automatic cell counting using 
ImageJ. 
In addition to EdU incorporation analysis, a cell number quantification assay was carried 
out using the Roche LDH cytotoxicity kit to determine cell number over 3 days. HUVECs were 
seeded on collagen I coated surfaces in 96 well plates at a low density, 2,000 cells per well, in 
EGM2. The cells were then left for 6, 24, 48 or 72 hours. At each time point the media was 
carefully aspirated and 50μl of 2% Triton X100 in H2O was added to each well to lyse the cells, 
releasing the LDH. A cell number standard curve was created in the same lysis buffer and 50μl 
of the LDH detection reagent was added to quantify the amount of LDH released by cell lysis. 
The cell number was then quantified using the standard curve. This proliferation assay was only 
carried out downstream of siRNA KD and was not carried out using integrin inhibitors, as the 
stability of the inhibitors over the three-day duration of this experiment is unknown. 
Additionally, re-adding inhibitors each day would involve changing the media continuously 
which would involve replenishing the growth factors bFGF, VEGF, EGF and IGF every 24 hours. 
This could have undesirable effects on the proliferation of HUVECs and so inhibitors were 
avoided entirely for this assay. One-way ANOVA and Sidak’s multiple comparison test was used 
to analyse the effect of integrin inhibition on the percentage of EdU positive cells. One-way 
ANOVA with Dunnett’s multiple comparisons test was used to analyse the effect of siRNA KD 
on the percentage of EdU positive cells. Table 6.2 summarises the statistical analysis from these 
tests. The mean percentage of EdU positive cells is compared to the appropriate control 
condition mean percentage. 
Table 6.2 – Statistical analysis of EdU incorporation assays 
 Mean % SD n P  Mean % SD n P 
Control 29.98 4.176 6  ITGA1 28.04 1.458 6 0.9932 
Obtustatin 30 4.946 6 >0.9999 ITGA2 30.51 3.372 6 0.8766 
6F1 29.84 4.523 6 >0.9999 ITGA10 26.48 4.401 6 0.6545 
TC-I-15 Control 30.17 5.333 6  All 30.07 4.041 6 0.9601 
TC-I-15  29.98 4.176 6 0.6951 Control 28.85 2.559 6  
     Untreated 29.67 4.213 6 0.9944 
One-way ANOVA and Sidak’s multiple comparison test (inhibitors) or Dunnett’s multiple comparison 
Test (siRNA) was used to compare the mean percentages of EdU positive cells for each condition to 
the mean percentage of EdU positive cells for the appropriate control condition 
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 Figure 6.3 (top) shows the effects of integrin inhibition or siRNA knockdown on EdU 
incorporation in HUVECs after 24 hour of integrin inhibition or 48-hours post siRNA integrin 
KD. There was no significant difference between the percentage of EdU positive cells in any 
condition tested, with inhibitors or siRNA. The percentage of EdU positive cells remains 
constant, at around 30%, for all conditions tested. This suggests that inhibition of α2β1 or α1β1 
The quantification of proliferation as the percentage of EdU positive cells in HUVECs after A) integrin 
inhibition for 24 hours or B) KD using siRNA. There is no significant difference between any of the 
conditions tested. C) quantification of cell number over three days, after siRNA KD of each integrin. 
Again, integrin KD had no effect on the cell number after three days. 
Figure 6.3: Quantification of Proliferation in HUVECs. 
A B 
C 
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or siRNA KD of ITGA1, ITGA2 or ITGA10 effectively does not influence the number of actively 
proliferating cells at a given time point. Figure 6.3 (lower) shows the quantification of cell 
number over three days, 24-72 hours post siRNA transfection. Again, siRNA KD of each integrin 
had no effect on the proliferation rates of HUVECs over three days in the conditions tested. 
The EdU analysis essentially gives a snapshot of the percentage of actively proliferating 
cells in a two-hour time window. This experiment is based on the assumption that this 
percentage is constant and will accurately reflect the proliferation rate of all the cells. To test 
this, a comparison was made between the EdU proliferation assay and a simpler cell-count 
assay. Additionally, culturing HUVECs in media without growth factors or FBS considerably 
slows their proliferation rate. To compare the two quantification methods, HUVECs were 
cultured in EGM2 or EBM and the EdU proliferation assay was carried out in these two 
conditions. The percentage of EdU positive cells was calculated as before, alongside the 
average number of cells per field of view and the two were compared (Figure 6.4). The two 
Figure 6.4. Comparison of Proliferation Assay Methods 
A comparison of the EdU proliferation assay quantification vs a simple cell count using the Hoechst 
stained cells from the same experiment. A) EdU quantification of actively proliferating cells. B) 
Differences in cell number in the same conditions. The same images were used for both 
quantifications of cell proliferation. An unpaired T-test found no significant difference between 
EGM2 (34.41, SD=2.6) and EBM2 (31.27, SD=1.4) P=0.0775 using the EdU analysis. The same test 
found a significant decrease in cell number in EBM2 (178.8, SD=13.48) compared to EGM2 (206.7, 
SD=8.394) P=0.0126. N=3 for each of these experiments. 
A B 
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methods of quantitation both used the same images. When using the EdU proliferation assay 
analysis there is no significant difference in proliferation between HUVECs cultured in EGM2 
compared to EBM2 using an unpaired t-test (34.41% for EGM2 vs 31.27% for EBM, the 
difference was 3.141 ± 1.477, P=0.07775,). However, when using the simpler system of 
counting the cells in each field of view, there is a statistical difference between the two 
conditions using the same t-test (*P=0.0126, 206.7 cells for EGM2 vs 178.8 cells for EBM2, the 
difference is 27.93 ± 7.938). The differences could be seen by eye in the tissue culture dish, so 
it is interesting that they do not show up on the EdU analysis. EdU appears to be a less sensitive 
method for determining differences in cell proliferation and so in future should be used in 
conjunction with a second proliferation assay. Due to time constraints and the fact that 
differences in proliferation were negligible when using integrin inhibitors or integrin KD, this 
was not pursued further. 
 In conclusion, the data here suggests that inhibition of α1β1 and α2β1 has no effect on 
HUVEC proliferation over a 24-hour time point as measured by EdU incorporation. Inhibition 
of α1β1 was not expected to decrease proliferation as the α2β1 integrin will compensate for 
any loss of adhesion incurred by α1β1 Inhibition. Inhibition of α2β1 and α1β1 together with 
TC-I-15 was shown in chapter 4 to impede HUVEC adhesion but this deficit in adhesion is not 
translated to a change in cell proliferation. This is possibly due to other adhesion receptors 
anchoring the cell to the ECM to stabilise the cell and allow proliferation such as αvβ3. Cells 
that do not adhere at all will not undergo apoptosis but clearly these cells overcome α1β1 and 
α2β1 inhibition and do attach to the collagen coated plates through other means. Perhaps over 
the 24-hour time period the HUVECs that attach weakly to the collagen coated surface will 
secrete their own extracellular matrix. This would allow the cells to adhere more strongly. 
Additionally, the HUVECs may overcome the TC-I-15-induced inhibition by another means, for 
example breaking down the TC-I-15 inhibitor over time. 
6.4 Effects of Integrin Inhibition or siRNA Knockdown on Apoptosis 
 To study the effects of integrin signalling on cell death, HUVECs were cultured in the 
presence of TNFα to simulate chronic inflammation associated with EC dysfunction. 
Additionally, HUVECs were cultured in low serum conditions (0.2%) to create cell stress in 
response to a pro-apoptotic environment. Assays were either carried out in the presence of 
inhibitors or 48 hours post siRNA KD of integrins. Zeocin was used as a positive control to 
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induce apoptosis in HUVECs. Annexin V was used to detect phosphatidylserine (PS) exposure 
on the membranes of early-stage apoptotic cells using both flow cytometry and microscopy. 
The Helix NIR far-red nuclear stain, or propidium iodide (PI) was used also to detect dead cells 
in flow cytometry, but not in microscopy because the Leica microscope available in the 
laboratory did not contain the correct filter for far red detection.  
 Figure 6.5 shows the quantification of cell death in HUVECs 24 hours after inhibition of 
integrins in the presence of TNFα in serum starved conditions. None of the inhibitors 
significantly increased the Annexin V binding to the surface of HUVECs. Only Zeocin 
upregulated Annexin V detection of PS on the cell membranes compared to the control (10.9%, 
30.79%, *P=0.0125). As described earlier, adherent cells will undergo apoptosis if adhesion is 
prevented. While TC-I-15 and 6F1 impede adhesion assays over one-hour time frames, they do 
not block all adhesion over longer time periods. As with the migration assays, the cells do 
adhere to the collagen surface over time and so would not undergo apoptosis due to anoikis. 
However, it is surprising that the inhibition of α2β1 adhesion does not affect cell survival at all. 
It is possible the cells overcome the inhibition either by receptor turnover or by destabilising 
the inhibitor. Once the cells have overcome the inhibition they would adhere to collagen and 
Figure 6.5. Quantification of Apoptosis after Integrin Inhibition 
Graphs quantifying the percentage of annexin V positive cells after A) integrin inhibition and B) the 
percentage of PI positive cells after integrin inhibition. The mean percentage of three experiments 
is plotted with error bars indicating SD.  
A B 
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start to secrete their own ECM proteins and remodel their environment, facilitating adhesion 
and cell survival. It is important to note that the Zeocin positive control also did not significantly 
upregulate the percentage of PI positive cells and so this indicates that the experimental set-
up was not optimised. Unfortunately, due to time constraints this could not be addressed 
further. Additionally, the flow cytometry experiments used here involved first detaching cells 
from the ECM before staining with Annexin V and PI and its possible that apoptotic and dead 
cells are being missed in this step. If cells have already undergone apoptosis or necrosis, they 
would not be picked up by the flow cytometer. Similarly, late stage apoptotic cells may be more 
fragile than live, healthy cells and may not survive the detachment and subsequent 
centrifugation steps required for the assay. 
Table 6.3. Statistical analysis of apoptosis in HUVECs after integrin inhibition  
 Percentage of Annexin V positive cells Percentage of PI positive cells 
 Mean % SD N P Mean % SD N P 
Control 10.9 5.622 3  8.37 5.48 3  
Obtustatin 9.077 5.218 3 0.9955 7.83 4.325 3 >0.9999 
6F1 14.04 8.907 3 0.9665 12.21 9.139 3 0.9132 
TC-I-15 
Control 11.28 3.572 
3 
 9.247 3.252 3  
TC-I-15 8.56 4.796 3 0.9801 7.847 5.022 3 0.9978 
Zeocin 30.79 9.427 3 0.0125 20.88 7.562 3 0.1069 
One-way ANOVA and Sidak’s multiple comparison test was used to compare the percentage means 
of each condition with the percentage mean of the appropriate control. Significant P values are 
shown in bold 
  
 Next, the effects of integrin KD on HUVEC cell survival were tested. Flow cytometry and 
fluorescent Annexin V was used to detect exposed PS on the membranes of apoptotic cells and 
Helix NIR was used to stain dead cells instead of PI in these experiments. Additionally, annexin 
V was also used to detect exposed PI on the membranes of apoptotic cells in fluorescence 
microscopy experiments and this was quantified using ImageJ as fluorescence intensity. A 
colorimetric LDH assay was also carried out to detect LDH secreted into the media by apoptotic 
or necrotic cells 24 hours after the addition of TNFα in EBM media. Figure 6.6 shows the 
quantification of cell death after siRNA KD of each integrin in the presence of 20ng/ml TNFα 
and 0.2% FBS. One-way ANOVA and Dunnett’s multiple comparison tests were used to analyse 
all the data presented in Figure 6.6, showing the effects of siRNA KD of each integrin on cell 
death in each condition. The statistical analysis is summarised in Table 6.4 and compares the 
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mean percentage of Annexin V/NIR positive cells of each condition compared to the control 
mean. 
A) to D) Annexin V binding to PS exposed on the membranes of HUVECs undergoing apoptosis was 
quantified using flow cytometry at 6 and 24 hours. E) microscopic analysis of annexin V using ImageJ 
relative fluorescence intensity at 24 hours. F) LDH release in the media of HUVECs was quantified 
using a colorimetric LDH cytotoxicity kit. 
Figure 6.6. Quantification of Cell Death After siRNA Knockdown of Integrins 
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 Table 6.4 – Statistical Analysis of Annexin V and NIR staining after siRNA 
 Percentage of Annexin V positive cells % Percentage of NIR positive cells % 
 6 hour 6 hour 
 Mean % SD N P Mean % SD N P 
ITGA1 45.19 7.021 3 0.4841 5.243 1.136 4 0.7083 
ITGA2 45.82 9.878 3 0.5315 7.098 0.6417 4 0.9999 
ITGA10 56.93 2.598 3 0.9999 6.368 1.121 4 0.9888 
All 63.74 8.1 3 0.9488 7.875 1.979 4 0.9980 
Control 57.84 2.477 3  7.263 0.4424 4  
Zeo 70.64 22.33 3 0.4729 11.05 5.726 4 0.1610 
EGM2 55.54 1.68 3 0.9996 5.62 1.304 4 0.8456 
 24 hour 24 hour 
ITGA1 72.53 19.39 4 0.9980 12.38 5.311 4 0.9944 
ITGA2 69.77 21.81 4 0.9788 18.19 9.134 4 0.9841 
ITGA10 69.63 11.72 4 0.9767 17.99 8.421 4 0.9886 
All 64.67 22.17 4 0.8039 13.33 6.552 4 0.9996 
Control 76.67 11.51 4  14.98 8.202 4  
Zeo 83.91 9.368 4 0.9733 40.94 12.61 4 0.0011 
EGM2 58.13 14.8 4 0.4351 6.883 3.931 4 0.5513 
 Relative Fluorescence Intensity Detection of LDH – Absorbance 490nm 
 24 hour 24 hour 
ITGA1 14547 4775 3 >0.9999 0.8165 0.03106 3 0.1596 
ITGA2 13009 3391 3 0.9997 0.9489 0.05045 3 0.4978 
ITGA10 14533 4936 3 >0.9999 0.9245 0.04724 3 0.9147 
All 15252 5690 3 0.9998 0.8835 0.03562 3 0.9979 
Control 14254 7197 3 >0.9999 0.8961 0.03807 3  
Zeo     0.8546 0.06502 3 0.7059 
EGM2 11500 15142 3 0.9899 0.5391 0.01867 3 <0.0001 
One-way ANOVA and Dunnett’s multiple comparison tests were used to compare each siRNA 
condition to the control for percentage of annexin V and NIR positive cells, for mean fluorescence 
intensity calculated in ImageJ, and for the mean absorbance in LDH detection assays 
 
 For the six-hour time point none of the siRNA conditions tested had any effect on the 
percentage of Annexin V positive cells or NIR positive cells as quantified by flow cytometry. At 
24 hours only the Zeocin significantly increased the percentage of NIR positive cells, but not 
the percentage of Annexin V positive cells. When annexin V was quantified by microscopy a 
similar situation was seen, none of the siRNA conditions resulted in an increase in Annexin V 
detection.  
 Figure 6.6 also shows the quantification of LDH released into the media after siRNA KD 
and treatment with TNFα in serum starved media (EBM). The statistical analysis for this is also 
shown in table 6.4. None of the siRNA conditions resulted in an increase or decrease of LDH 
detected in the media of HUVECs. However, when the cells were left in EGM2, instead of EBM 
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and TNFα there was a significant decrease in the amount of LDH detected in the media. This 
indicates a decrease in cell death. This is expected as the cells in this condition are not 
subjected to TNFα or serum starved conditions and have not undergone siRNA transfection.  
 In hindsight, the transfection method used to transport siRNA inside the cells could 
have a pro-apoptotic affect. When HUVECs were left overnight in the transfection media there 
was a huge amount of cell death. Therefore, the transfection time was limited to eight hours 
only. These experiments are carried out 48-72 hours after siRNA transfection, but this may still 
not be enough time for cells to fully recover from the transfection process. The positive control 
for these apoptosis assays, Zeocine, used untreated cells that had not undergone siRNA 
transfection and so may not be appropriate as a positive control in these conditions. These 
results show no difference in cell death between the siRNA KD conditions and Zeocine but in 
reality, these two measures are not comparable. With more time, these apoptosis assays 
would have been further optimised to give a more relevant comparison. However, there is still 
no increase of cell death when comparing the integrin KD siRNA to the negative control siRNA 
and so it can be concluded that the KD of integrin receptors does not increase cell death as 
measured by Annexin V staining or NIR staining after TNFα stimulation and serum starving 
HUVECs. 
6.5 Conclusions 
 Integrin inhibition or KD has no effect on HUVEC proliferation as quantified by cell 
number quantification or EdU incorporation analysis. This is likely due to the fact that the cells 
are still adhered for the duration of this experiment and so the process by which non-adhered 
cells stop proliferating does not occur here. Obtustatin was not expected to impede HUVEC 
proliferation severely due to the low expression levels of α1β1 compared to α2β1, in this 
condition the α2β1 integrin would adhere to the collagen. It is possible that the inhibition of 
α2β1 and α1β1 by TC-I-15 or the inhibition of α2β1 by 6F1 is cleared over time. This would 
facilitate the return of integrin mediated adhesion and subsequent proliferation. Further 
studies to elucidate the exact mechanism and stability of integrin inhibition would be needed 
to clarify this. 
 Similarly, knockdown or inhibition of integrins has no effect on the apoptosis or 
necrosis of HUVECs in response to TNFα stimulation and serum starvation. However, the 
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positive control, Zeocine, also did not always increase the apoptosis of these cells and so this 
study may have not been optimised fully to measure cell death in this set-up. The results were 
also variable, suggesting that the experimental protocol was not sufficiently optimised. 
Additionally, the siRNA transfection protocol may have increased apoptosis in HUVECs, 
clouding the results. Due to time constraints, further experiments could not be carried out to 
further investigate this.   
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7.1 Chapter Summary 
 This chapter focusses on quantifying the effects of integrin inhibition or siRNA KD of 
integrins on HUVEC cell spreading and migration on collagen I coated surfaces. Migration is 
quantified as random migration over a substrate, in time lapse assays. This project aims to 
study the roles of collagen-binding integrins and their inhibition in the regulation of HUVEC 
migration on collagen surfaces with a focus on α10β1 as this integrin is the second most 
abundant in HUVECs but has not been characterised in these cells. 
7.2 Introduction 
Cell migration is an essential function in embryonic development, wound healing, 
immune response and angiogenesis[194] but can also be pathological when deregulated, for 
example when cancer cells become highly motile and metastasise[196]. Pathological migration 
is also seen in chronic inflammatory diseases, vascular diseases, multiple sclerosis, 
osteoporosis and mental retardation[194]. Cell migration relies on the careful regulation of 
detachment, actin cytoskeleton reorganisation and cell adhesion in response to external 
stimuli like chemotactic gradients[194]. Different areas of the cell need to be coordinated so that 
the leading edge moves forward and the rear detaches and moves with it. This is achieved by 
cell polarisation[194]. The generation of polarity involves vesicle trafficking and cytoskeletal 
organisation, thought to be regulated partly by Cell Division Control Protein 42 (Cdc42). Cdc42 
localises to the leading edge; inhibition or global activation of Cdc42 will disrupt directional 
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migration[307]. Phosphatidylinositol (PI)P3 and PIP2 are signalling molecules that help to polarise 
cells exposed to a chemoattractant. PI3 kinase phosphorylates PIP2 to PIP3, which binds to 
proteins with a pleckstrin homology (PH) domain. Phosphatase and Tensin homolog protein 
(PTEN) dephosphorylates PIP3 back to PIP2, negatively regulating the pathway. PI3 Kinase 
accumulates at the leading edge while PTEN is found in abundance at the trailing edge, and 
this contributes to the polarity seen in migrating cells[308]. 
Cell migration is a complicated process involving many steps. In response to 
chemotactic, haptotactic or other migratory stimuli, the cell polarises and the membrane at 
the leading edge protrudes outwards, fuelled by actin filament polymerisation from a cellular 
pool of profilin-bound ATP-actin monomers[309-312]. Actin filaments are polarised double helical 
structures wherein the actin monomers are arranged head-to-tail. They have a barbed end, 
oriented at the leading edge onto which ATP-bound actin monomers are added, and a pointed 
end at the trailing side of the filament[312]. The filaments are disassembled over time and 
recycled to form new filaments at the leading edge; hydrolysis of ATP, to ADP, held in the actin 
filament signals that filament for disassembly[312]. Actin polymerisation is regulated by a large 
number of proteins, including the Rho family of GTPases[251]. The life cycle of actin filaments is 
as follows (reviewed in[194, 312]): 
1) Extracellular stimuli activate Rho GTPases, such as Rac, Cdc42, RhoA and RhoG which 
activate the WASP/Scar pathway 
2) WASP/Scar activates the Arp2/3 complex which initiates actin polymerisation into 
filaments from ATP-actin monomers, branching from an existing filament 
3) Barbed ends of actin filaments elongate as actin is polymerised in lamellipodia to push 
membrane forwards, until capping proteins bind the barbed ends to block 
polymerisation 
4) ATP hydrolysis in the filament occurs as the filament ages, signalling the filament for 
depolymerisation. The ATP hydrolysis is fairly quick, but the phosphate takes much 
longer to disassociate, and the phosphate disassociation step signals the filament for 
degradation 
5) ADF/Cofilin depolymerises the actin at the pointed end, creating monomers of ADP-
actin 
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6) Profilin exchanges the ADP for ATP and actin monomers are recycled. They move to the 
barbed ends again, until profilin is inhibited by LIM-kinase/PAK pathway 
Proteins that modify any one of these steps will affect the rate of actin filament 
polymerisation, altering the rate of protrusion and cell migration. The rate of actin 
polymerisation depends partly on the concentration of Actin-ATP and so a constant pool must 
be available. This is maintained by constant depolymerisation of actin filaments into actin 
monomers and capping of barbed ends in cells[312]. Capping ensures filaments are shorter and 
stiffer while ensuring growth of filaments only occurs in necessary areas, i.e. in protrusions[309, 
311]. There are two main types of cell protrusions: filopodia and lamellipodia. Filopodia are thin 
cylinders that contain a tight bundle of orientated actin filaments held together by crosslinking 
proteins such as fascin, fimbrin, α-actinin and filamin[310]. Lamellipodia are wide sheets of 
membrane and cytoplasm that protrude out from the leading edge consisting of webs of actin 
filaments created by activated Arp2/3[312]. Arp2/3 is a complex of Actin-Related Protein (Arp) 2 
and Arp3 that binds actin filaments to initiate the branching of a new filament from the existing 
one. In vitro, the branching angle of Arp2/3 is 70°, but in vivo data have suggested a wider 
range of angles are seen from 15-90°[312, 313]. Cortactin, filamin A and α-actinin all stabilise actin 
networks by crosslinking branches[194]. The actin filaments themselves flow away from the 
leading edge in the opposite direction of cell movement at a variable rate, termed the 
retrograde flow rate[252, 314]. The rate of protrusion is the difference between the rate of actin 
polymerisation and the retrograde flow rate; if the retrograde flow rate is inhibited, the 
protrusions will form faster and the velocity of the subsequent cell migration is faster[252, 315]. 
Actin polymerisation is regulated by proteins that affect the available pool of actin-ATP 
monomers, the rate of polymerisation, the stability of the filaments, the rate of retrograde 
flow or the depolymerisation of filaments into monomers[309, 311]. 
Membrane protrusions that are formed must then adhere to the ECM. Strong adhesions 
and contractile forces will create traction and strong adhesions in the leading edge will inhibit 
retrograde flow by helping to stabilise the protrusions and anchor the actin cytoskeleton to the 
ECM[197]. Conversely, retrograde flow can be stimulated to decrease protrusion rate and 
migration[252]. The influence of adhesion proteins on migration vary: vinculin and talin have 
been shown to allow slippage[316] relative to the ECM whereas integrins are thought to adhere 
strongly and do not move with the actin filament retrograde flow[252]. Finally, the rear tail of 
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the cell must detach and retract from the ECM to allow the cell to move forward[194, 317]. 
Strongly adherent cells, like cultured fibroblasts, may exhibit reduced tail de-adhesion and 
instead leave a trail of membrane and cytoplasmic fragments in their wake[311]. Similarly, 
neuronal growth cones lack tail retraction completely, as they produce axons as they 
migrate[318]. Tail de-adhesion involves the severing of integrin-ECM adhesion or integrin-
cytoskeletal association and may involve the endocytosis and turnover of integrin receptors[194, 
197]. Rho/ROCK signalling is involved in adhesion disassembly and tail retraction; inhibition of 
Rho kinase results in impaired tail detachment in monocytes and accumulation of β2 in the 
still-attached tails[317]. 
 Myosins are a family of motor proteins that have functions in cell movement, 
intracellular transport and adhesion[319]. Myosin molecules, fuelled by ATP, move along actin 
filaments. Depending on their function, this movement can result in transport of molecules 
along actin filaments, contractile tension in actin filaments or the pushing and sliding of 
filaments relative to myosin[320]. They contain N-terminal ATPase domains that are activated 
on actin-binding and C-terminal helical domains which either bind cellular cargo or associate 
into filaments with other myosin monomers[320]. Myosin dimers can then attach to actin 
filaments to form large myosin-crosslinked contractile bundles. Myosin II is a bipolar protein 
that associates with actin to form contractile bundles. It is found as myosin IIA and myosin 
IIB[319]. Myosin II can affect the rate of retrograde flow and can also affect tail-retraction and 
adhesion stability[319]. Myosin IIA and IIB deficient cells show increased, continuous protrusion 
with immature adhesions whereas wildtype cells exhibit pauses in protrusion that allow 
adhesion complexes to mature[319, 321]. In ECs, myosin II is responsible for maintaining stress 
fibres. The myosin II inhibitor blebbistatin promotes stress fibre disassembly and ablates EC 
tension without inhibiting actin polymerisation[322]. In bovine aortic ECs, myosin IIA localises at 
the leading edge while myosin IIB is found in the retracting tail[319, 323]. The localisation of 
myosin IIB is regulated by Rho and inhibition of Rho leads to impeded tail retraction while 
leaving protrusion unaffected, resulting in elongated cells[323]. 
Adhesion proteins, such as integrins, regulate adhesion between the ECM and the 
cytoskeleton and so are implicated in the regulation of cell migration. Integrins at the leading 
edge will be adherent whereas integrins at the rear must detach to allow the cell to move 
forward[194, 197]. Upon ligand binding, activated integrins cluster to form complexes that link the 
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ECM to the cytoskeleton, termed focal adhesions for the large adhesions and nascent 
adhesions or focal complexes if they are newer and smaller[194]. Nascent adhesions form 
initially and they either form and disassemble with rapid turnover or they mature into focal 
complexes and much later, focal adhesions[324]. Early nascent adhesions rely on Rac1 signalling 
and suppression of RhoA but as the adhesions mature into large focal adhesions Rac1 becomes 
supressed and RhoA is stimulated, possibly mediated by ROCK-induced myosin activity that 
encourages stress fibre formation[324]. Focal adhesions contain over 150 associated molecules 
and are complex signalling hubs[197]. Nascent adhesions and focal complexes are both smaller, 
dynamic adhesion structures located at the leading edge to promote actin polymerisation[314], 
they are generally present in very motile cells and form less organised adhesions. Larger, highly 
organised adhesions like focal adhesions correlate with slower migration and vice versa as they 
are very adhesive and will not allow much cell movement[197]. Nascent adhesions, focal 
complexes and focal adhesions vary in size and complexity but contain many of the same 
proteins such as clustered integrins, signalling molecules and structural proteins such as 
vinculin, talin, filamin and α-actinin[325] that link integrins to the cytoskeleton where actin 
filaments converge. They have been characterised in ECs[326], skeletal muscle[253] and neuronal 
growth cones[254]. Vinculin can transiently recruit Arp2/3 to the adhesions to locally stimulate 
actin polymerisation. Ablation of vinculin-Arp2/3 binding results in diminished lamellipodial 
protrusion[327].  Signalling proteins found in adhesions include Src, FAK, PAK, paxillin and ILK 
(integrin linked kinase) and the Rho family of GTPases which regulate actin polymerisation, 
adhesion formation and facilitate crosstalk between integrins[197, 328]. The affinity of integrins 
for the ECM proteins can be regulated by integrin activation: activation of αvβ3 is seen in 
lamellipodia at the leading edge of ECs[197, 329]. Talin and kindlins are examples of regulators of 
integrin activation[330, 331], talin binds the cytoplasmic tails of several β-subunits including β1, 
β2 and β3[332]. There is a wealth of evidence linking integrin adhesion to the regulation of cell 
migration, summarised in bullet points below for simplicity: 
• The integrin expression profile can change the migrative potential of a cell, for example 
αvβ3 expression in melanomas correlates with increased tumour invasion[333]  
• α2β1 integrin upregulation in rhabdomyosarcoma is associated with higher levels of 
metastasis, but not an increased growth rate[334] 
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• Localised activation of Protein Kinase A (PKA) and Focal Adhesion Kinase (FAK) induced 
by integrin ligation happens early in the migration process[335]  
• Integrins are thought to help regulate actin polymerisation and therefore localise 
protrusion[336]  
• Endothelial β1 integrin is essential for migration, adhesion and angiogenesis, β1-null ECs 
showed deficient adhesion and migration on collagen and laminin, while cell adhesion 
to fibronectin was unaffected[35].  
• In HMVECs both α1β1 and α2β1 regulate haptotactic migration towards collagen I and 
VEGF dependent chemotaxis through a collagen matrix. Inhibition of both integrins 
results in reduced tumour growth and angiogenesis of human squamous cell carcinoma 
xenografts[160].  
• In HUVECs, α2β1 has been shown to regulate EC attachment, spreading and migration 
on collagen while αvβ3 mediates attachment spreading and migration on vitronectin[337]  
• In platelets, α2β1 activation is dependent on cdc42 and actin polymerisation[338]  
• DDR1 activation supresses cell spreading by inhibiting α2β1-dependent Cdc42 activation 
in MDCK cells[339]. 
• The α1β1 inhibitor lebestatin decreases HMEC-1 adhesion and migration, and reduces 
angiogenesis in chick chorioallantoic membrane model[340] 
• Decorin, expressed preferentially in sprouting ECs, activates IGF-IR and Rac in ECs and 
this promotes α2β1 dependent cell adhesion and migration on collagen I[341]  
• Integrin α10β1 regulates migration, proliferation and cell survival in glioblastoma. 
α10β1 KD results in decreased migration and increased cell death. α10Β1 is upregulated 
in glioblastoma[169].  
• Integrin α10β1 is also upregulated in malignant melanoma and reduced α10β1 indicates 
reduced migratory potential[170] 
Invasive cancer cells can form invadopodia, which are integrin-mediated actin-rich 
adhesions that can degrade matrix proteins. They contain rapid actin-polymerisation 
machinery to promote localised membrane protrusion and migration. They contain β1, β2, and 
β3 integrins and actin regulatory proteins like cortactin, gelsolin, WASP, Rho GTPases, and the 
actin nucleating Arp 2/3 complex[196]. Contact inhibition, the cessation of cell migration and 
membrane protrusion on contact with other cells, is also lost in cancer cells[342].  
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7.3 Effects of Integrin Inhibition or siRNA Knockdown on HUVEC Cell Spreading 
 KD of ITGA2 had a profound effect on HUVEC adhesion to collagen in Chapter 5, Figure 
5.6, but KD of ITGA1 and ITGA10 did not. However, adhesion is just one measure of cell 
function, HUVECs form a tight monolayer by adhering and then spreading out on collagen to 
form contacts with neighbouring cells. Integrins are adhesion receptors that help the cells 
anchor, spread and migrate on the ECM so next, the effects of integrin inhibition or KD on cell 
spreading was tested. The cells were placed on collagen or THP coated plates and left for 45 
minutes to spread, either 48-72 hours after siRNA or in the presence of inhibitors. Cells were 
fixed with 4% PFA and stained with Hoechst, to stain the nuclei and determine cell number, 
and rhodamine phalloidin to stain the actin filaments. Fluorescent images were taken on a 
Leica DM6000 microscope at 10x magnification and ImageJ was used to quantify the area of 
the cells to measure cell spreading. Figure 7.1 shows the quantification of cell spreading as the 
average area per cell, in pixels. One-way ANOVA and Sidak’s multiple comparison test was used 
to analyse the effects of integrin inhibition on cell spreading. Obtustatin and 6F1 are compared 
Quantification of cell spreading after A) inhibition of integrins or B) siRNA KD of integrins (right). 
Cells were seeded on collagen I and left to spread for 45 minutes before fixing and staining with 
Hoechst and rhodamine phalloidin. ImageJ was used to quantify the cell area in pixels and count 
the cell number. Data is shown as average area per cell. Experiments were performed in triplicate 
and repeated three times 
Figure 7.1: Quantification of HUVEC Cell Spreading on Collagen I 
Chapter 7 – Effects of Integrin Inhibition or siRNA Knockdown on Migration 
158 
 
to the control and TC-I-15 is compared to the TC-I-15 control. One-way ANOVA and Dunnett’s 
multiple comparisons test was used to analyse the effects of siRNA KD of each integrin on cell 
spreading, with condition compared to the control. Table 7.1 summarises the statistical 
analysis of each of these tests. The P values shown in the table are comparisons between the 
inhibitor or siRNA KD and the appropriate control mean. The P value for TC-I-15 control is 
compared to the control. Figure 7.2 shows representative images of inhibition of HUVEC cell 
spreading on collagen I. These images were used to quantify cell spreading as the area (in 
pixels) per cell. 




SD N P  
Mean area 
(pixels/cell) 
SD N P 
Control 2124 92.54 3  ITGA1 2175 202 3 0.2269 
Obtustatin 1888 149.9 3 0.4501 ITGA2 1004 69.99 3 <0.0001 








TC-I-15 1073 246.6 3 0.0005 Control 1956 169.3 3  
 HUVEC spreading on collagen I was significantly impeded by TC-I-15 (1073 µm2) 
compared with the TC-I-15 control (1964 µm2) ***P0.0005, and by 6F1 (876 µm2) compared 
to the control with no inhibitor or antibody (2124 µm2) ****P<0.0001. There was no further 
inhibition of cell spreading using TC-I-15 than using 6F1, suggesting that the inhibition of α2β1 
is enough to impede cell spreading, and that the additional inhibition of α1β1 and possibly 
other receptors does not affect cell spreading further. Obtustatin had no significant effect on 
cell spreading compared to the control (1888 µm2 compared to 2124 µm2, P=0.4501), 
demonstrating that α1β1 is not required in HUVECs for cell spreading, possibly because these 
cells express α2β1 in high levels to facilitate cell spreading. Additionally, inhibition of α2β1 via 
6F1 or α2β1 and α1β1 via TC-I-15 resulted in a change in cell morphology to irregularly shaped 
cells with many small membrane protrusions compared to obtustatin and control cells which 
were rounded and flat (Figure 7.2). Inhibition of α2β1 could be impeding the adhesion of 
membrane protrusions. The weaker adhesions may be unable to stabilise lamellipodia in these 
conditions, leading to an irregular shape where filopodia continue to extend but cannot 
properly adhere.  
  





Fluorescence Images used to quantify cell spreading after integrin inhibition. The left column shows 
rhodamine phalloidin (red) staining on fixed cells after one hour of attachment and spreading on 
collagen I. The middle column shows Hoechst nuclear staining (blue) of the same cells and the right 
column shows a merge of the two channels. 
Figure 7.2: Effect of Integrin Inhibition on HUVEC Cell Spreading.  
 




Fluorescence Images used to quantify cell spreading after siRNA KD of integrins. The left column 
shows rhodamine phalloidin (red) staining on fixed cells after one hour of attachment and spreading 
on collagen I. The middle column shows Hoechst nuclear staining (blue) of the same cells and the 
right column shows a merge of the two channels. 
Figure 7.3: Effect of Integrin siRNA Knockdown on HUVEC Cell Spreading 
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Similarly, siRNA KD of ITGA1 or ITGA10 had no effect on cell spreading compared to the 
negative control siRNA (2175 µm2 vs 1956 µm2, P=0.2269 and 1920 µm2 and 1956 µm2, 0.9921 
respectively), as α2β1 can compensate for any loss of these integrins. However, siRNA KD of 
ITGA2 or of all the collagen-binding integrins at once, severely impedes cell spreading on 
collagen I (1004 µm2 for ITGA2 and 1085 µm2 for All, vs 1956 µm2, ****P<0.0001 for both 
conditions), suggesting α2β1 is the main integrin used for adhesion and spreading of these cells 
on collagen. Again, KD of α2β1 is enough to impede cell spreading and further KD of α1β1 and 
α10β1 achieves no further inhibition of cell spreading. The same change in cell morphology 
was seen in ITGA2 KD and KD of all integrins, these cells were irregular in shape while the 
control and ITGA1 or ITGA10 KD cells were spread into more rounded, regular shapes. The 
irregular shape could be a result of the filopodia protruding from the cell but not then adhering 
to the collagen surface enough to stabilise the adhesion and inhibit actin retrograde flow. The 
protrusions may be constantly forming and then flowing back to the cell after failing to adhere 
to the substrate due to a lack of α2β1 adhesion. 
7.4 Effects of Integrin Inhibition on Migration 
Showing the TrackMate analysis of migration images. A time lapse video is uploaded into the TrackMate 
ImageJ plug-in and the image on the left shows the TrackMate plug-in identifying “blobs” or cells. These 
cells are then linked from frame-to-frame and a track is displayed showing the distance moved by each cell. 
This image shows untreated cells migrating over collagen I coated surfaces. 
Figure 7.4: Representation of TrackMate analysis 
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The involvement of integrins α1β1 and α2β1 in regulating EC migration has been 
characterised well. However, the role of α10β1, which is the second most abundant integrin in 
HUVECS, has not been characterised in ECs. The integrin inhibitor TC-I-15 has also not been 
characterised in HUVECs and so migration experiments were carried out to investigate the 
effect of this inhibitor. Ibidi 4-well μ-slides Ph+ were coated with collagen I or peptides 
overnight and blocked with BSA, before seeding a low density (17,000 cells/ml) of HUVECs, 
either 48h post-siRNA or in the presence of inhibitors. Cells were left to attach for 4 hours 
before taking time-lapse images over a 9-hour period to track cell movement. The TrackMate 
ImageJ plugin was used to quantify cell migration over this time period, quantified as Track 
Displacement. This is the average distance (in μm) from the starting position and the finish 
position of each cell. Figure 7.4 shows a representative image of the TrackMate program 
tracking untreated HUVECs migrating over collagen I coated surfaces. At the time, it was not 
possible to calculate total track length using TrackMate and so track displacement was used as 
a measure of cell migration. Mean, minimum and maximum velocity were also calculated by 
TrackMate and are shown here. Figure 7.5 shows the quantification of cell migration after the 
addition of obtustatin or TC-I-15. One-way ANOVA and Sidak’s multiple comparison test was 
used to analyse the effects of integrin inhibition on cell migration. Obtustatin was compared 
to the control and TC-I-15 was compared to the TC-I-15 control. Table 7.2 summarises the 
statistical analysis for these tests. 
Table 7.2 – Statistical Analysis of HUVEC migration after integrin inhibition 
 Average Distance Migrated (μm) Mean velocity (μm/5min) 
 Mean SD N P Mean SD N P 
Control 89.62 8.371 3  3.814 0.2854 3  
Obtustatin 87.68 1.939 3 0.8790 3.714 0.2838 3 0.8997 
TC-I-15 Control 90.83 5.156 3  3.696 0.3465 3  
TC-I-15 61.34 1.47 3 0.0002 3.131 0.2221 3 0.0843 
 Maximum velocity (μm/5min) Minimum velocity (μm/5min) 
Control 19.04 0.9312 3  0.2283 0.02542 3  
Obtustatin 18.09 1.562 3 0.6852 0.2231 0.0152 3 0.9235 
TC-I-15 Control 18.55 1.951 3  0.2247 0.008779 3  
TC-I-15 17.39 0.9768 3 0.5736 0.1756 0.01587 3 0.0169 
One-way ANOVA and Sidak’s multiple comparison test was used to compare the means to the control 
mean 




Inhibition of α2β1 and α1β1 by TC-I-15 resulted in a significant decrease in track 
displacement compared to the TC-I-15 vehicle control (61.34μm vs 90.83 μm, ***P=0.0002). 
Conversely, inhibition of α1β1 by obtustatin had no effect on track displacement compared to 
the control (87.68 μm vs 89.62 μm, P=0.8790), as the more abundant α2β1 is present to 
facilitate cell adhesion and migration. TC-I-15 is likely to the disrupt adhesion complexes at the 
leading edge. α2β1 stabilises protrusions, effectively decreasing the retrograde flow of actin 
filaments away from the leading edge. In the presence of TC-I-15 α2β1 and α1β1 can no longer 
adhere to the collagen or anchor the cytoskeleton to the ECM, resulting in decreased adhesion 
Figure 7.5: Quantification of HUVEC Migration After Integrin Inhibition 
Quantification of the effects of integrin inhibition on HUVEC migration as measured by A) distance 
migrated, B) mean velocity, C) maximum velocity and D) minimum velocity. Migration is quantified 
below as distance migrated (track displacement) mean, maximum and minimum velocity of HUVEC 
migration. Means are shown with error bars depicting SD. 
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and increased retrograde flow. This would impede protrusion formation and subsequent 
migration 
The maximum velocity and mean velocity were unaffected by TC-I-15 or obtustatin 
(Table 7.2). However, the minimum velocity was reduced in the presence of TC-I-15 compared 
to the TC-I-15 control (0.01587μm/5min vs 0.008779μm/5min *P=0.0169). The maximum 
velocity takes the fastest speed reached by any cell at any point in the 9-hour period and can 
be dramatically affected on a single fast-migrating cell. This suggests that some cells were able 
to overcome the α2β1 inhibition to migrate normally across the collagen I. The minimum speed 
is lowered, suggesting that at least some cells were unable to move as quickly as normal, which 
fits with the notion that α2β1 inhibition impedes the ability of the adhesion complexes to 
stabilise actin filaments and protrusions at the leading edge. The TC-I-15 vehicle control, added 
to the media as NaOH, had no effect on cell migration and so it can be assumed that TC-I-15 is 
responsible for the decrease in migration distance seen here. 
  The signalling pathways downstream of integrin activation and clustering involve 
GTPase exchange factors (GEFs) and GTPase activating proteins (GAPs), the regulators of 
GTPase activity[197]. Integrins do not harbour any intrinsic catalytic activity, but their 
cytoplasmic tails provide a scaffold for the localisation of other proteins such as FAK and 
Src[197]. After integrin adhesion and clustering in nascent adhesions, FAK associates with the β-
subunit cytoplasmic tail, leading to the autophosphorylation of FAK on Y397 which in turn binds 
Src to form an activated FAK/Src complex[197]. This FAK/Src complex phosphorylates the 
adhesion protein paxillin, among other signalling molecules, and results in the downstream 
recruitment of the GEF β-Pix at the nascent adhesion and subsequent activation of Rac, which 
in turn regulates actin polymerisation via WASP/Scar/Arp2/3[343]. Paxillin is essential for the 
formation of focal adhesions and reorganisation of the actin cytoskeleton[344, 345]. ILK (integrin 
linked kinase) is also an integrin-mediated signalling protein, it associates with the β1 and β3 
cytoplasmic tails to form signalling complexes with other adaptor proteins like PINCH and α- 
and β-parvin that also result in the activation of the GEFs α- and β-Pix, again resulting in the 
regulation of the actin cytoskeleton[324]. The inhibitor TC-I-15 stabilises the β1-subunit in the 
inactive conformation in α2β1, and presumably α1β1, inhibiting the adhesion of these integrins 
to collagen[2]. This presumably results in reduced integrin clustering which diminishes the 
density of cytoplasmic β-subunit tails that are available to facilitate the cytoplasmic co-
localisation of signalling molecules described earlier. As a result, the Rac pathway is not 
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activated downstream of integrin activation and the associated upregulation of the actin 
polymerisation cannot happen, resulting in impaired EC migration. However, the cells still 
express a number of other collagen binding adhesion receptors such as DDR1 and DDR2, and 
so while migration is impeded, it is not completely abolished in HUVECs. Other cells, like 
leukocytes, can exhibit integrin-independent migration[346]. In one study, pan-integrin KO or 
talin KO did not result in migratory deficiency in dendritic cells on 2D surfaces, but did abolish 
migration through 3D matrices[346], so it is also possible that HUVECs are employing an integrin-
independent migration mechanism.  
7.5 Knockdown of ITGA2 inhibits HUVEC Migration 
The same experiments were repeated with HUVECs that had undergone siRNA silencing 
of integrins 48 hours previously. Ibidi 4-well μ-slides Ph+ were coated with collagen I overnight 
and blocked with BSA, before seeding a low density (17,000 cells/ml) of post-siRNA HUVECs. 
Phase images were taken every 5 minutes over a 9-hour period and analysed with TrackMate 
as before. One-way ANOVA and Dunnett’s multiple comparisons test was used to analyse the 
effects of siRNA KD of each integrin on cell migration. Table 7.3 summarises the statistical 
analysis of these tests, the means of each condition were compared to the means from the 
control condition.  
Figure 7.6 shows the quantification of the effects of siRNA KD of integrins on the 
migration of HUVECs over collagen I coated surfaces. of ITGA2 using siRNA significantly reduced 
the track displacement (57μm vs 92.81μm, *P=0.0095 for ITGA2 and 57.61μm vs 92.81μm 
*P=0.0106 for All), which represents the average distance moved by each cell, compared to 
the negative control. Neither ITGA1 or ITGA10 knockdown had any effect on the migration 
distance of HUVECs, and knockdown of all three integrins had no cumulative effects on 
integrin-mediated migration. There was no significant difference in the track displacement of 
ITGA2 KD compared to KD of all three integrins. There were also no significant differences in 
migration velocity in any condition. This suggests HUVECs use α2β1 as the main integrin 
adhesion receptor in the regulation of migration, and the expression of ITGA1 or ITGA10 does 
not contribute further to the regulation of HUVEC migration as a function of random walk 
across collagen I coated surfaces. Again, this can be explained as α2β1 is the most abundant 
integrin on the surface of HUVECs. In the event of ITGA1 or ITGA10 KD, the α2β1 integrin will 
adhere to collagen, become activated, cluster in nascent adhesions and facilitate the co-
Chapter 7 – Effects of Integrin Inhibition or siRNA Knockdown on Migration 
166 
 
localisation and activation of FAK and Src. This leads to the downstream activation of Rac and 
the promotion of actin polymerisation at the leading edge, ultimately leading to increased 
migration. Conversely, in the event of an ITGA2 KD, there is not enough ITGA1 or ITGA10 to 
compensate and overcome the loss of integrin-mediated adhesion and nascent adhesions are 
not formed as efficiently, resulting in impaired FAK and Src activation and decreased Rac 
activation, ultimately resulting in reduced migration.  
 
Table 7.3 – Statistical analysis of HUVEC migration after siRNA 
Figure 7.6: Quantification of HUVEC Migration After Integrin siRNA Knockdown 
Effects of siRNA knockdown of each integrin on HUVEC migration as measured by A) distance 
migrated, B) mean velocity, C) maximum velocity and D) minimum velocity. Migration is quantified 
below as distance migrated (track displacement) mean, maximum and minimum velocity of HUVEC 
migration. Means are shown with error bars depicting SD. 
A B 
C D 
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 Average Distance Migrated (μm) Mean velocity (μm/5min) 
 Mean SD N P Mean SD N P 
Control 92.81 15.39 3  3.724 0.3488 3  
ITGA1 88.88 13.02 3 0.9772 3.725 0.3263 3 >0.9999 
ITGA2 57 11.95 3 0.0095 3.307 0.4762 3 0.6508 
ITGA10 88.94 7.752 3 0.9784 3.74 0.5985 3 >0.9999 
All 57.61 4.265 3 0.0106 3.528 0.5043 3 0.9563 
 Maximum velocity (μm/5min) Minimum velocity (μm/5min) 
Control 14.31 0.9111 3  0.2934 0.04001 3  
ITGA1 15.17 1.347 3 0.8055 0.2839 0.05266 3 0.9981 
ITGA2 14.16 0.6987 3 0.9993 0.2469 0.05181 3 0.6742 
ITGA10 14.13 1.581 3 0.9990 0.2886 0.04914 3 0.9998 
All 14.2 1.348 3 0.9998 0.2539 0.06846 3 0.7762 
One-way ANOVA and Dunnett’s multiple comparisons test was used to compare the mean values to 
the control mean 
 
 
7.6 Effect of Peptide Affinity on HUVEC Migration 
In VSMCs maximal velocity is seen when cell attachment is intermediate, where 
adhesion and detachment can both happen efficiently[347]. Similarly, a study using Chinese 
Hamster Ovary (CHO) cells expressing α5β1 and αIIbβ3 found that the velocity of migration is 
dependent on integrin expression levels, ligand concentration and integrin-ligand affinity; the 
optimal ligand concentration for maximal velocity decreases with increased integrin expression 
levels and increased integrin-ligand affinity[348], suggesting that an equilibrium is formed 
between attachment and detachment to facilitate cell migration. We therefore tested HUVEC 
migration as random movement on a range of different affinity peptides to test the function 
of collagen-binding integrins in affinity-related migration. 
To test the effect of substrate affinity on the ability of HUVECs to migrate across 2D 
coated surfaces, different peptides were coated onto 4-well μ-slides Ph+ overnight. After 
blocking with BSA, HUVECS were seeded at 17,000 cells/ml. Adhesion studies were undertaken 
(Chapter 3) to determine the adhesion affinities of different peptides. GFOGER and GLOGEN 
were used as high affinity peptides, GMOGER was used as a low affinity peptide, VWF III is a 
low affinity peptide that binds to DDR1 and DDR2, and GPP10 was used as a negative control 
Chapter 7 – Effects of Integrin Inhibition or siRNA Knockdown on Migration 
168 
 
peptide. BSA was used as a control for the BSA blocking procedure. One-way ANOVA and 
Dunnett’s multiple comparisons tests were used to compare the migration of HUVECs across 
each peptide surface. Table 7.4 summarises the statistical analysis. Figure 7.7 shows the 
quantification of HUVEC migration over different peptides.  
There were no significant differences in the migration of HUVECs across the integrin-
binding peptides over the course of the experiment. However, both GFOGER and GNRGER 
supported a small but significant increase in migration distances compared to  BSA. In addition, 
Figure 7.7: Quantification of HUVEC migration of different peptides 
Quantification of the effects of peptide affinity of each integrin on HUVEC migration as measured by 
A) distance migrated, B) mean velocity, C) maximum velocity and D) minimum velocity. Migration is 
quantified below as distance migrated (track displacement) mean, maximum and minimum velocity of 
HUVEC migration. Means are shown with error bars depicting SD. 
A B 
C D 
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GFOGER supported significantly longer migration distances than GPP10, again the difference 
was small. This suggests that integrin ligation could have a modest effect on the ability of 
HUVECs to migrate over peptide surfaces. However, the affinity of the peptides did not 
influence HUVEC migration. This could be due to the intrinsic ability of HUVECs to secrete their 
own matrix over time, although the experiment was performed over a relatively short time 
frame (four hours to adhere and nine hours to migrate). The differences in affinities between 
the integrin-binding peptides may not be sufficiently important to induce differential migration 
across these surfaces. With the exception of VWF III, these peptides all ligate α2β1. Perhaps 
even low affinity peptides are sufficient to cause the formation of nascent adhesion complexes 
and the associated integrin clustering that leads to FAK/Src activation and eventual Rac 
signalling that mediates actin filament elongation and migration. BSA does not support HUVEC 
adhesion in static adhesion binding assays but here it supports adhesion and subsequent 
migration here. This is likely due to the differences in timeframe for adhesion assays (one hour) 
compared to these migration assays (13-15 hours). In one hour, BSA cannot support cell 
adhesion, but over the longer time frames the BSA coating may not completely obscure the 
tissue culture surface underneath and the cells maybe be able to degrade the BSA to attach to 
this surface. Additionally, HUVECs secrete their own ECM and so could, over time, adhere to 
the BSA non-specifically and then secrete their own ECM proteins onto this.  
Interestingly, the track displacement (distance migrated) is decreased when the surface 
is coated with peptides compared to collagen I coated surfaces. The control conditions for both 
the inhibitors and siRNA experiments were around 90μm whereas the peptide coatings all 
result in a migration distance of around 50μm. Additionally, the mean velocity is slower in these 
peptide migration assays than with surfaces coated with collagen I, (3.7 vs 2.9). Both the 
peptides and the collagen are coated at 10μg/ml, meaning that the peptides will exhibit a far 
higher concentration of integrin binding sites than the collagen I due to a huge difference in 
size between the two molecules. This indicates a concentration dependent effect where an 
increase of integrin binding sites slows down the migration of HUVECs across the substrate. 








Table 7.4 – Statistical analysis of migration across different THPs 








 Mean SD N Mean SD N Mean SD N Mean  SD N 
GFOGER 55.38 4.934 3 2.917 0.1101 3 12.71 0.1101 3 0.2055 0.01844 3 
GLOGEN 48.75 7.87 3 2.879 0.1783 3 13.23 0.4278 3 0.2035 0.02644 3 
GMOGER 48.6 5.516 3 2.973 0.1924 3 13.56 0.3347 3 0.2155 0.01761 3 
GNRGER 51.61 4.722 3 2.85 0.1083 3 12.71 0.6607 3 0.1943 0.02423 3 
VWFIII 44.51 1.5 3 2.927 0.09836 3 13.82 0.6888 3 0.2017 0.02209 3 
GPP10 39.87 2.759 3 2.769 0.1271 3 13.65 0.457 3 0.1836 0.00895 3 
BSA 36.5 6.412 3 2.704 0.0421 3 14.29 0.6639 3 0.1788 0.00896 3 
P values obtained using Dunnett’s multiple comparison test comparing the means above 
 
P value for 
Average Distance 
Migrated 
P value for 
Mean velocity  
P value for 
Maximum 
velocity  
P value for 
Minimum 
velocity 
GFOGER vs. GLOGEN 0.7087 0.9998 0.8639 >0.9999 
GFOGER vs. GMOGER 0.6882 0.998 0.449 0.9943 
GFOGER vs. GNRGER 0.9691 0.9948 >0.9999 0.989 
GFOGER vs. VWFIII 0.2119 >0.9999 0.19 >0.9999 
GFOGER vs. GPP10 0.033 0.8015 0.3368 0.7954 
GFOGER vs. BSA 0.0078 0.4618 0.0278 0.6248 
GLOGEN vs. GMOGER >0.9999 0.9708 0.985 0.9853 
GLOGEN vs. GNRGER 0.9922 >0.9999 0.8695 0.9961 
GLOGEN vs. VWFIII 0.9464 0.9992 0.8042 >0.9999 
GLOGEN vs. GPP10 0.4082 0.9373 0.9485 0.8552 
GLOGEN vs. BSA 0.1259 0.6632 0.2327 0.6987 
GMOGER vs. GNRGER 0.9898 0.9026 0.4563 0.8168 
GMOGER vs. VWFIII 0.9546 0.9994 0.9952 0.9704 
GMOGER vs. GPP10 0.4269 0.5062 >0.9999 0.4396 
GMOGER vs. BSA 0.1336 0.2263 0.6094 0.2929 
GNRGER vs. VWFIII 0.6444 0.989 0.194 0.9988 
GNRGER vs. GPP10 0.153 0.9852 0.343 0.9919 
GNRGER vs. BSA 0.039 0.8104 0.0285 0.9495 
VWFIII vs. GPP10 0.9205 0.7513 0.9996 0.9007 
VWFIII vs. BSA 0.5204 0.4104 0.913 0.7627 
GPP10 vs. BSA 0.9821 0.9956 0.7379 >0.9999 
 




 Cell spreading is impeded by inhibition of α2β1 using TC-I-15 or 6F1. This inhibition 
results in irregularly shaped cells, possibly due to the lack of integrin adhesion in the membrane 
protrusions at the leading edge. Adhesions formed at the leading may be weaker in the 
absence of α2β1 leading to less stable cytoskeletal-ECM linkages. These weaker adhesions may 
be less capable of inhibiting actin retrograde flow, leading to decreased membrane protrusion 
in filopodia or lamellipodia and decreased cell spreading. 
Inhibition or siRNA KD of integrin α2β1 inhibits HUVEC migration over a collagen I 
substrate as measured by track displacement. Inhibition or KD of α2β1 is sufficient to impede 
HUVEC migration and further KD of α1β1 or α10β1 does not decrease migration further. This 
is likely due to the increased prevalence of α2β1 compared to α1β1 and α10β1. Again, the 
inhibition or siRNA KD of integrin α2β1 may result in weaker adhesions that lead to increased 
actin retrograde flow and decreased membrane protrusions. If the protrusions cannot adhere 
to the ECM, they cannot create traction and pull the cell forward. 
HUVEC migration over collagen peptides is not dependent on the affinity of HUVECs for 
the peptide, but there could be a concentration dependent effect where peptide coating 
supports slower migration than collagen I coated surfaces. The concentration of integrin 
binding sites is much higher with peptide coated surfaces than with collagen coated surfaces 
as the peptides consist of integrin binding sequence plus some GPP repeats whereas collagen 
I one has a far lower density of integrin binding sites per µg. Peptides were coated here at 
10µg/ml and the integrin binding sites could have reached saturation at this concentration. A 
range of concentrations, with 10µg/ml as the maximum, should have been tested to more 
closely resemble physiological settings. Future experiments using different concentrations of 
peptide could be carried out to investigate this. 
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8.1 Chapter Summary 
 This chapter focusses on using integrin inhibitors and siRNA to modulate integrin 
function before quantifying the effects on angiogenesis in tube formation assays using Geltrex 
as a substrate. Tube formation is quantified using the Angiogenesis Analyzer plug-in for ImageJ.  
8.2 Introduction 
Angiogenesis is the growth of new blood vessels from existing vasculature and is an 
important process in tissue repair, embryonic development and tumour progression[18, 179, 200]. 
Whereas vasculogenesis describes the formation of the first blood vessels from the mesoderm 
in the embryo and is an important process in embryonic development, described in chapter 1. 
Embryos cannot develop without a healthy, functioning vasculature to transport essential 
metabolites, nutrients, growth factors and hormones to and from tissues[31, 32]. Insufficient 
blood-supply results in ischaemia and tissue necrosis due to a lack of oxygen and nutrients and 
a build-up of toxic metabolic end-products. Most blood vessels form via angiogenesis from 
existing vasculature; in response to certain stimuli a new vessel will ‘sprout’ from an existing 
one. Angiogenesis is a tightly regulated process involving many signalling pathways that control 
EC proliferation, apoptosis, migration and adhesion. It is driven through angiogenic signalling 
molecules such as VEGF, bFGF or TNFα[31, 32, 195, 349, 350]. The regulation of cellular responses to 
VEGF is tightly regulated depending on the cell type and location. Different cells will express 
different VEGF receptors, VEGFR1, VEGFR2 being the most common[195]. Some VEGF molecules 
will also bind neuropilins (NRPs) which are receptors originally found in neurons that help 
regulate neuronal migration[351]. 
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The VEGF family (VEGFA, VEGFB, VEGFC, VEGFD, viral VEGFE and placental growth 
factor (PLGF))[349] all have conserved cysteine-knot structures that share homology with 
platelet derived growth factors (PDGFs)[195, 352]. VEGFA is the most critical and is highly 
conserved between species, showing high homology between fish and mammals. Tiger 
pufferfish (Fugu rubripes) VEGFA shares 68% homology with human VEGF189[353]. VEGF 
homologs are even observed in non-vertebrates without vasculature such as nematode worms 
and jellyfish, where they regulate neurogenesis and cell migration[195]. VEGFA has 8 exons, 
while the rest of the family have 7. VEGFA has several isoforms arising from alternative splicing 
of the VEGFA gene, each isoform has a different function, summarised in Table 8.1. VEGF 
generally exists as a head-to-tail homodimer with VEGFR binding sites at each pole and each 
monomer contains the cysteine-knot structure held together by disulphide bonds[354]. VEGFA 
binds to NRP-1 through exon 6, the heparin binding domain, plus exons 7 and 8. Heparin 
binding domains help to localise VEGF molecules and sequester VEGF in the ECM, and this 
contributes to the formation of the VEGF gradients that drive cell migration. The VEGF isoforms 
that bind to the ECM and are not diffusible will concentrate close to where they are secreted, 
whereas the smaller, soluble VEGF120 will diffuse through tissues resulting in action over a 
longer distance but a shallower VEGF gradient[355]. Additionally, VEGF isoforms that are 
sequestered in the ECM via their heparin binding domains can be released by proteolytic 
degradation of the ECM.  
Table 8.1 – Summary of different VEGFA isoforms.  
Isoform Exons Characteristics 
VEGF121 1-5 and 8 
Soluble and diffusible  
Secreted as covalently linked homodimer 
Does not bind heparin 
VEGF145  1-6 and 8 Binds NRP2 but not NRP1 
VEGF165 1-5, 7 and 8 
Most abundant and biologically active 
Soluble and diffusible, binds NRP1 and NRP2 
Contains a heparin binding domain 
Glycosylated on N74 
VEGF165b  1-5, 7 and alternate 8 Inhibitory form of VEGF165 
VEGF183 1-5, short exon 6, 7 and 8 Sequestered in ECM 
VEGF189 1-8 Cell surface or bound to ECM, not readily diffusible 
VEGF206 
1-8 plus extra exon 6 
sequence 
Cell surface or bound to ECM  
Not readily diffusible 
Adapted from Holmes, D. I, Zachary, I, 2005. The vascular endothelial growth factor (VEGF) family: 
angiogenic factors in health and disease[195] 
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Tumours without their own surrounding vasculature are growth-limited to less than 2-
3mm[356, 357] presumably by a nutrient deficit as metabolites must diffuse and transport 
through surrounding tissues before reaching the tumour cells. Whereas tumours that have 
acquired a vasculature can transport metabolites and waste products directly to and from the 
blood stream and can grow much more quickly as a result[358-360]. Additionally, tumours require 
vasculature or the lymph system for efficient metastasis. Therefore, eliminating or preventing 
tumour angiogenesis is a useful tool for fighting cancer progression[361]. Tumours can recruit 
vasculature by encouraging angiogenesis of nearby blood vessels or by the capture of rare 
circulating EC progenitors[362]. Generally, the vasculature is quiescent: it maintains tissue 
homeostasis and helps regulates platelet aggregation until signals downstream of EC damage, 
hypoxia, infection or inflammation signal a change in EC state to a more proliferative or 
angiogenic phenotype[87]. Tumours must promote a change in the EC state from quiescent to 
pro-proliferative and pro-angiogenic before they can recruit their own vasculature. This is 
termed the angiogenic switch[360]. The turnover of non-tumour ECs has been estimated to be 
47-23000 days compared to 2.4-13 days for tumour endothelium, so there is clearly an 
upregulation of EC proliferation in tumour vasculature[363]. Both VEGF and bFGF have been 
found elevated in cancers as well as in the urine and serum of cancer patients; 47% of patients 
with metastatic cancer showed elevated bFGF[357, 364].  
Angiogenesis can occur by two methods. Sprouting angiogenesis is the branching of 
ECs in the existing vessel wall into tubes that invade the surrounding tissue and then mature 
into new vessels[179]. Intussusceptive angiogenesis involves the splitting of a single vessel into 
two and involves reorganisation of existing vasculature[365]. The basic process of sprouting 
angiogenesis first involves an increase in VEGFA signalling in the surrounding tissue; ECs that 
receive the VEGFA signal at high enough amounts become tip cells that degrade the basement 
membrane and start to migrate into the tissue towards the VEGFA source[350]. ECs adjacent to 
this tip cell then proliferate to facilitate the growth of a stalk behind the migrating tip cell. This 
then becomes a tube which grows until it fuses with a second tip cell branching from an 
opposite vessel towards the same VEGFA gradient (Figure 8.1). Once the sprouting tubes have 
converged and fused, oxygenated blood can be perfused through the new lumen and the new 
vessel is stabilised with pericytes. Hypoxia will drive some cells to secrete VEGFA, which will 
encourage the formation of tip cells and attract them to chemotactically migrate towards the 
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hypoxic environment. Once a network of vessels has formed the unwanted, immature vessels 
are ‘pruned’ and degraded leaving an efficient, mature vascular tree behind. Immature vessels 
depend on VEGF for survival and so pruning is mediated by the withdrawal of VEGF, often 
induced by hyperoxia[366, 367].  
A diagram showing the progression of tip cells in sprouting angiogenesis. A) shows the quiescent 
vessel with ECs and surrounding pericytes. B) shows the formation of multiple filopodia on the tip 
cell. C) Shows the migration of the tip cell outwards and the following stalk cells. D) describes the 
column of cells forming a lumen through which blood will perfuse and E) shows the mature new 
blood vessel after connecting with an opposite vessel. Once a new blood vessel is formed the tip 





Figure 8.1: Diagram of Sprouting Angiogenesis. 
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Tip cells are specialised, highly polarised ECs containing protease-secreting filopodia 
that degrade the ECM and pave the way for the sprouting cell to migrate[350]. These filopodia 
are induced by VEGFA and contain increased levels of VEGFR2 to ‘sense’ increasing VEGFA 
concentrations by chemotaxis[350]. Tip cells also express higher levels of PDGF-B than their 
neighbouring ECs[350]. As the tip cell migrates into the ECM the ‘stalk’ ECs behind it proliferate 
and move with the tip cell creating a sprout. Tip cells essentially guide the sprouting stalk of 
ECs towards VEGFA. As many sprouts are likely to be converging on the source of the VEGFA, 
the tip cells of two sprouts will meet and fuse together to create a continuous lumen through 
which blood is then perfused. It is important that the migration of tip cells ceases when two 
converge and fuse together. The shear stress created by blood flow through the newly formed 
lumen will contribute to vessel maturation, as will the recruitment of pericytes and the 
deposition of ECM components[179]. Tip cell formation is highly regulated as tip cells are 
essential for angiogenesis. However, if all the surrounding ECs turn into tip cells there would 
be no stalk to form the new vessel. Notch signalling is thought to help supress VEGFR2 
expression in stalk cells to supress the tip cell phenotype. Tip cells express delta-like-4 (DL4) in 
response to VEGFA. This DL4 then interacts with and activates Notch on neighbouring cells[368, 
369]. The activated Notch supresses VEGFR2 expression and the tip cell phenotype. Inhibition 
or knockdown of DL4 results in increased numbers of tip cells[369]. VEGFA expression is tightly 
controlled and deletion of one VEGFA allele is embryonic lethal since the vasculature is unable 
to form correctly[32, 370]. Excess VEGFA seen in tumour angiogenesis results in overproduction 
of tip cells and disorganised vasculature[371]. Different VEGF isoforms will induce different 
cellular reactions. For example VEGF188 induces many long filopodia and a highly branched, 
thin vessel network in mouse hindbrains whereas filopodia are much shorter in the presence 
of VEGF120 resulting in a poorly branched network with larger vessels[355]. Mice expressing only 
VEGF165, which is soluble and diffuses through tissues freely, displayed no vessel abnormalities. 
Heparin binding VEGF tends to build up steep gradients whereas VEGF120, which is diffusible, 
travels over large distances to stimulate EC proliferation[355].  As well as regulating the tip cell 
specialisation and migration, VEGF also upregulates the stalk cell proliferation[350].  
Intussusceptive angiogenesis (Figure 8.2) is much faster than sprouting angiogenesis, 
mainly because it does not rely on the proliferation of ECs and instead only requires vessel wall 
reorganisation as the vessel wall extends into the lumen and splits the vessel[372]. 
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Intussusceptive angiogenesis is important in the bifurcation of veins and arteries and the 
pruning of larger microvessels[372]. Firstly, ECs opposite each other in the capillary wall develop 
membrane folds that protrude across the lumen of a capillary to contact the opposite side 
creating tissue pillars. These pillars eventually split the vessel in two creating two capillaries[372]. 
 After blood vessels are formed, they are stabilised by pericytes that proliferate and 
migrate along the vessels in a VEGF dependent manner[373, 374]. The association of newly 
formed capillaries with pericytes protects the vessel from hyperoxia-induced degradation in 
the pruning process of vascular remodelling. Pericyte coverage of vessels happens days after 
the formation of blood vessels in the mouse retina, allowing time for the remodelling process 
to occur before vessel stabilisation[373]. Pericytes express α-smooth muscle actin and are 
thought to be related to VSMCs. Both VSMCs and pericytes interact with ECs and GJ exist 
between ECs and pericytes[374].  
There is significant crosstalk between neurons and ECs. Sprouting vessels in the retinas 
of new-born mice are guided by a network of astrocytes which forms days before the blood 
vessels sprout. The filopodia of tip cells then migrates exclusively along the existing astrocyte 
network and disruption of the astrocyte network impedes angiogenesis[375]. The astrocytes also 
Figure 8.2 – Diagram of Intussusceptive Angiogenesis.  
Diagram showing the stages of intussusceptive angiogenesis. Pr = pericytes, BM = basement 
membrane, Fb = fibroblast, EC = endothelial cell, Co = collagen. A shows the vessel before 
intussusceptive angiogenesis starts. B shows the vessel wall starting to protrude into the lumen. C 
describes protrusions coming together and cell-cell junctions forming at the point of contact. D 
shows the final vessel splitting and a fibroblast moving into the space created by the vessel splitting 
in two. Image taken from: https://thoracickey.com/arteriogenesis-and-angiogenesis/ 
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respond to EC tip cells and mature on contact with tip cells[375]. Astrocytes produce VEGF in 
response to hypoxia and culturing primary astrocytes in an oxygen rich environment abolishes 
VEGF production[376]. Blood vessels and axons often align, and they share some of the same 
regulatory pathways. For example, Unc5b and netrin1 are both involved in axon guidance and 
EC migration[377, 378]. Unc5b is expressed in the EC tip cells; loss of Unc5b leads to excessive 
branching of vessels in mice. EphrinB, a neural cell migration regulator, is also involved in both 
axon guidance and angiogenesis and mice lacking ephrinB2 die in utero at embryonic day 11.5 
due to vascular remodelling defects[379]. Also, VEGF165 binds to NRP1 which is a receptor that 
guides axons in neurons but is also expressed in ECs and is also thought to enhance the 
interaction between VEGF165 and VEGFR2[351]. The same study found that Inhibition of NRP1-
VEGF165 interaction decreases VEGF165 binding to VEGFR2 and subsequent HUVEC 
proliferation. Additionally, mice overexpressing NRP1 die at embryonic day 17.5 due to 
vascular defects and abnormal capillaries[380], suggesting a role for the neuronal guidance 
receptor NRP in the regulation of EC behaviour. 
Angiogenin is an upregulator of angiogenesis expressed in some tumour cells. It is 
associated with poor prognosis as it increases cell survival, proliferation and tumour 
angiogenesis which in turn facilitates metastasis[199]. Angiogenin is a member of the RNase A 
superfamily that stimulates MMP-2 expression through ERK1/2 phosphorylation[199]. 
Endogenous regulators of angiogenesis also include fragments of basement membrane 
proteins that are released by proteolysis. The main component of the endothelial ECM is 
collagen IV, which exists as 6 α-chain isoforms, α1-α6. The α1 and α2 isoforms are ubiquitously 
expressed whereas the other chains are distributed in a tissue specific manner. The non-
collagenous domains of some collagens, and other ECM proteins, exhibit angiogenic properties 
summarised as bullet points below: 
• Arresten is a 26kDA fragment of the non-collagenous domain of collagen IV α1 chain that 
inhibits squamous cell carcinoma invasion and angiogenesis via α1β1 inhibition and 
induction of EC apoptosis[185, 381, 382] 
• Tumstatin is produced by MMP-9 proteolysis of the α3 chain of type IV collagen and inhibits 
angiogenesis and proliferation on vitronectin, fibronectin and collagen I via αvβ3[383-385]. 
Overexpression of tumstatin in tumour cells inhibits their growth in B16F1 melanoma 
cells[386] 
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• Canstantin is a fragment of the non-collagenous domain of the α2 chain of collagen IV. It 
induces apoptosis though mitochondrial damage induced via αvβ3 and αvβ5 and inhibits 
angiogenesis and migration in ECs[387-389] 
• Endostatin is a fragment of collagen XVIII. It potently inhibits angiogenesis and tumour 
growth through interaction with α5 and αv integrins on ECs[390] 
• The α6 chain of type IV collagen inhibits angiogenesis and tumour growth[391] 
• Angiostatin, a proteolytic fragment of plasminogen, inhibits tumour metastasis by blocking 
angiogenesis[392] 
 Angiogenesis involves many cell processes including migration, adhesion, apoptosis 
and proliferation and so many receptors, including integrins, are involved[18, 160, 179, 180, 200]. The 
αvβ3 and αvβ5 integrins are known to regulate angiogenesis and many collagen fragments 
described above exert their angiogenic properties through these integrins. Additionally, 
fibronectin ligation of α5β1 induces angiogenesis in chick embryos in a VEGF-independent 
manner and α5β1 is upregulated in human tumour biopsies, suggesting that this integrin is 
important in angiogenesis[393]. Peptide, antibody and small molecule inhibition of α5β1 blocked 
bFGF, TNFα and IL-8 driven angiogenesis but not VEGF-mediated angiogenesis. In contrast, 
fibronectin blocking inhibited both bFGF and VEGF induced angiogenesis, suggesting other 
fibronectin receptors could play a role in regulating angiogenesis[393]. Fibronectin itself is 
upregulated in blood vessels during wound healing[394] and has been shown to regulate 
proliferation in CHOα5 cells[395]. Fibronectin KO in mice is embryonic lethal due to defects in 
vascular development as well as mesoderm and neural tube development[396]. KO of the αv 
subunit, eliminating αβv1, αvβ3, αvβ5, αvβ6 and αvβ8, in mice results in 80% embryonic 
lethality with 20% surviving until birth but displaying intestinal and intracerebral haemorrhages 
and cleft palates[397]. 
 A number of studies have found roles for α1β1 and α2β1 in angiogenesis. For example, 
α2β1 has been implicated in the regulation of lumen formation in HUVECs[398] and the α1β1 
inhibitor, arresten, inhibits VEGF driven angiogenesis[185]. VEGF has been shown to exert 
angiogenic properties partially through upregulation of α1β1, α2β1[157] and αvβ3 surface 
expression. An in vivo study has also shown that antibodies blocking α1β1 and α2β1 inhibit 
VEGF mediated angiogenesis[157]. The same study found that VEGF-driven α1β1 and α2β1 
upregulation correlated with an increase in cell spreading in Human Dermal Microvascular 
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Endothelial Cells[157]. HUVECs are cultured in EMG2 which contains low levels of VEGF165 but 
only very weak α1β1 expression was observed. The effects of VEGF on integrin expression in 
HUVECs was tested here, in Chapter 3, and no upregulation of α2β1 or α1β1 was observed 
after addition of increased VEGF. The expression of integrins is expected to vary with the cell-
type: for instance, HUVECs are large vein ECs and will show a different expression profile to 
microvascular ECs. It is also worth noting that with in vivo experiments involving antibody 
inhibition of α1β1 and α2β1, these receptors would be inhibited in all cell types. Therefore, the 
decrease in angiogenesis seen after α1β1 or α2β1 inhibition could conceivably be due to α1β1 
or α2β1 inhibition on other cell types, for example VSMCs or pericytes, rather than on ECs 
specifically.   
 The effects of TC-I-15 induced α2β1 and α1β1 inhibition on HUVEC migration have been 
described in Chapter 7. Since angiogenesis involves migration of the tip cells and the stalk cells 
to create a new vessel, TC-I-15 is expected to exert some effects on angiogenesis as well. In 
this Chapter, the effects of TC-I-15 mediated inhibition of α2β1 and α1β1 on angiogenic 
capability are presented, using tube formation assays using HUVECs on Geltrex. The effects of 
siRNA KD on tube formation are also tested. 
8.3 The Effects of Integrin Inhibition on Tube Formation  
 Geltrex was plated into Ibidi Angiogenesis μ-slides and incubated at 37°C for one hour 
to induce gelation. Once a gel had formed, 4500 HUVECs were added per well in EGM2 in the 
presence or absence of Obtustatin or TC-I-15 inhibitors, as well as the 6F1 antibody, and 
incubated at 37°C for 24 hours. Phase contrast images, ten fields of view per well, were taken 
on a DM6000 Leica microscope at 10x magnification at 6 hours and 24 hours and three repeat 
experiments were quantified using the Angiogenesis Analyser plugin for ImageJ created by 
Giles Carpentier. This program quantifies angiogenesis by analysing many parameters and the 
most relevant were chosen here. Nodes and junctions are both points at which branches of 
the vascular network converge and so are taken as a measure of vascular complexity. Junctions 
are quantified as groups of nodes. A mesh describes an area completely closed by branches of 
the network and so measures the connectedness of the network. Isolated segments are cells 
or branches that have not connected to the rest of the network and so indicate unconnected 
cells and disorganised networks.  
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Figure 8.3 shows representative phase images taken at the six-hour time point after 
integrin inhibition and the corresponding ImageJ Angiogenesis Analyzer program analysis. 
From these images there is clearly a difference in the number of connections in the networks 
between the controls and 6F1 or TC-I-15. The networks formed in the presence of TC-I-15 and 
6F1 seem less complete, with some cells not connected to the network at all. Figure 8.4 shows 
the quantification of the analysis and Table 8.2 shows the statistical analysis of the data using 
one-way ANOVA and Sidak’s multiple comparisons test to compare each condition to the 
appropriate control. P values in bold signify statistical significance. 
Figure 8.3. Phase contrast images of 
tube formation assays after 6 hours of 
integrin inhibition 
Representative phase images of 
angiogenesis experiments alongside 
the Angiogenesis Analyzer Plug-in 
quantification of parameters. Yellow 
and green denote branches, purple 
denotes junctions, which are made up 
of nodes. Light blue shows the meshes 
and dark blue shows twigs (branches 
that are a dead-end). Images were 
taken on a 10x objective using a Leica 
microscope. The scale bar indicates 
100µm (bottom left panel) 
 
Figure 8.3. Tube Formation After Integrin Inhibition 
TC-I-15 




Quantitation of the effects of integrin inhibition on angiogenesis as measured by the number of 
nodes (A, B), junctions (C, D), Meshes (E, F) and isolated segments (G, H). Means are plotted with 
error bars indicating SD. The left column shows the quantification of images taken at six hours and 
the right column indicates the 24-hour time point.  
Figure 8.4: Quantification of Tube Formation After Integrin Inhibition. 
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Table 8.2 – Statistical analysis of tube formation after integrin inhibition 
 6 hours 24 hours 
 Number of Nodes per field of view 
 Mean SD N P Mean SD N P 
Control 118.3 15.11 4  51.44 12.83 4  
Obtustatin 94.5 15.38 4 0.0371 55.94 23.6 4 0.9861 
6F1 73.89 11.6 4 0.0003 47.93 24.2 4 0.9932 
TC-I-15 Control 111.5 3.735 4  45.15 4.875 4  
TC-I-15 82.68 9.48 4 0.0110 33.16 14.28 4 0.8066 
 Number of Junctions per field of view 
Control 33.75 4.138 4  14.33 3.571 4  
Obtustatin 27.47 4.31 4 0.0542 16.33 7.625 4 0.9587 
6F1 22.06 3.543 4 0.0005 14.2 7.34 4 >0.9999 
TC-I-15 Control 32.58 0.7335 4  12.93 1.326 4  
TC-I-15 24.48 2.749 4 0.0115 9.831 3.703 4 0.8677 
 Number of Meshes per field of view 
Control 10.06 1.259 4  3.037 1.326 4  
Obtustatin 7.417 2.245 4 0.0930 3.454 2.427 4 0.9825 
6F1 5 1.443 4 0.0012 2.176 1.452 4 0.8732 
TC-I-15 Control 9.583 0.5 4  2.519 0.6415 4  
TC-I-15 6.063 1.873 4 0.0195 1.55 1.027 4 0.8309 
 Number of Isolated Segments per field of view 
Control 1.611 0.467 4  1.741 1.389 4  
Obtustatin 2.278 1.503 4 0.8330 2.569 1.856 4 0.8364 
6F1 2.528 1.578 4 0.6604 2.736 1.782 4 0.9710 
TC-I-15 Control 1.694 0.7665 4  1.222 0.1925 4  
TC-I-15 3 1.346 4 0.3836 2.942 1.899 4 0.9888 
one-way ANOVA and Sidak’s multiple comparisons test were used to compare the means of each 
condition to the appropriate control mean. P values in bold signify statistical significance 
 
After quantification and statistical analysis, Obtustatin (94 compared to 118.3 nodes 
per field of view, *P=0.0371), 6F1 (73.89 compared to 118.3 nodes per field of view 
***P=0.0003) and TC-I-15 (82.68 compared to 111.5 nodes per field of view*P=0.0110) all 
significantly decreased the number of nodes per field of view at 6 hours compared to the 
appropriate control, but no significant differences were seen for the number of nodes at 24 
hours for any condition tested. However, only 6F1 (22.06 compared to33.75 junctions per field 
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of view, ***P=0.0005) and TC-I-15 (24.48 compared to 32.58 junctions per field of view, 
*P=0.02) significantly decreased the number of junctions at 6 hours, with no significant 
differences seen with obtustatin (P=0.0542). Similarly, these differences were not seen at 24 
hours. In terms of meshes, both 6F1 (**P=0.0012) and TC-I-15 (*P=0.0195) impeded mesh 
formation at 6 hours but that difference was not significant at 24 hours. Lastly, there were no 
significant differences in the number of isolated segments, due to the high variability of this 
parameter in the acquired images. The tubes formed quickly, and networks were becoming 
visible after only 2 hours in the control conditions. By 6 hours the networks were well defined 
in control conditions but not so well defined in the presence of 6F1 and TC-I-15. However, by 
24 hours the tubes were beginning to disintegrate in all conditions. .  
Overall, this suggests that inhibition of α2β1 using 6F1 or TC-I-15 impedes the 
formation of a vascular network in tube formation assays at early time points. These results 
also raise the possibility that obtustatin could also affect tube formation despite the α1β1 
integrin being expressed in extremely low mRNA levels in HUVECs. The inhibition of tube 
formation seen with TC-I-15 and 6F1 is likely due, in part, to the effects of α2β1 inhibition on 
cell migration seen in Chapter 7. The cells will migrate more slowly in the presence of α2β1 
inhibitors and this would impede the formation of the network. However, there is likely 
another process by which α2β1 inhibition impedes tube formation as these cells did not simply 
form the same networks more slowly, but instead never reached the complexity of the control 
networks seen at 6 hours. The fact that there are no significant differences seen at 24 hours is 
more indicative of the tubes in all conditions disintegrating than the 6F1 and TC-I-15 conditions 
catching up to the controls. The case for α1β1 is more complicated as differences are seen 
when comparing the number of nodes in the presence of obtustatin compared to the control, 
but not the number of junctions, despite both of these functions evaluating very similar 
characteristics. This is likely explained by slight differences in the sensitivities of these two 
measurements in that the effect of Obtustatin is very small and is minimally picked up when 
quantifying the number of nodes but is just missed when quantifying the number of junctions. 
It is highly likely that repeating this experiment with ECs that express higher levels of α1β1 
would see greater differences in tube formation inhibition in the presence of Obtustatin[165]. 
As seen before, there is a similar inhibition of angiogenesis seen when inhibiting α2β1 with 6F1 
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and inhibition of both α1β1 and α2β1 simultaneously with TC-I-15, suggesting that inhibition 
of α2β1 is the main avenue by which TC-I-15 inhibits angiogenesis in HUVECs.  
8.4 Effects of Integrin siRNA Knockdown on Tube Formation 
 A role has clearly been established for α2β1 and α1β1 in the regulation of angiogenesis 
in ECs, both in this chapter and in the literature described earlier[160, 165]. However, no role has 
been established for α10β1. To study the effects of integrin KD on HUVEC tube formation, 
HUVECs were cultured in EGM2 and subjected to siRNA KD of each integrin, and all three 
together. 48-72 hours following the transfection, tube formation assays were repeated as 
before on Geltrex substrates. 4500 cells were added to each well and left to form tubes for 24 
hours. Phase contrast images, five fields of view per well, were taken at 6 hours and 24 hours 
and three experimental repeats were quantified using the Angiogenesis analyser as before. 
One-way ANOVA and Dunnett’s multiple comparison test was used to analyse the data 
obtained from the Angiogenesis Analyzer plug-in. Table 8.3 summarises the statistical analysis. 
Figure 8.5 shows the quantification of tube formation after siRNA KD of each integrin. 
The tube formation was variable, as a consequence the SDs for each condition are 
larger here than with the integrin inhibitors. Due to time constraints, only three repeats of this 
experiment were carried out. It’s possible this was not enough to properly investigate the 
effects of siRNA KD of integrins on HUVEC tube formation. The only parameter that returned 
a statistically significant difference was the KD of ITGA10 on the quantification of isolated 
segments. KD of ITGA10 resulted in significantly (0.5481 per field of view vs 1.07 per field of 
view *P=0.0057) less isolated segments compared to the control at the six-hour time point. 
This decrease in isolated segments was not seen when all integrins were knocked down with 
siRNA simultaneously. There were no significant differences in any of the other parameters 
tested (nodes, junctions, meshes or isolated segments), even with siRNA knockdown of all 
collagen-binding integrins expressed in HUVECs. This was surprising as the role of α2β1 in EC 
migration and angiogenesis has been established in this study and is well documented in the 
literature described earlier. As such, KD of all integrins was expected to impede tube formation. 
Previously, siRNA KD of ITGA2 significantly decreased cell migration over collagen substrates in 
a manner similar to the inhibition of α2β1 by 6F1 and TC-I-15. KD of ITGA2 was thus expected 
to impede angiogenesis in a similar way to 6F1 and TC-I-15 but this was not the case. Instead, 
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the inhibitors were more potent at impeding angiogenesis than the siRNA. There are several 
possible explanations for this. 
 
 
Representative phase contrast 
images taken six-hours after seeding 
siRNA treated HUVECs. Experiments 
were carried out 48 hours post-siRNA 
treatment. The left hand column 
shows the phase images obtained at 
the six-hour time point and the right-
hand column shows the Angiogenesis 
Analyser analysis of the images. 
Images were taken on a 10x objective 
using the Leica microscope as before. 
Yellow and green denote branches, 
purple denotes junctions, which are 
made up of nodes. Light blue shows 
the meshes and dark blue shows 
twigs (branches that are a dead-end). 
The scale bar on the bottom right 
panel represents 100µm. 
Figure 8.5: Tube Formation After siRNA Knockdown of Integrins 




Quantitation of the effects of integrin inhibition on angiogenesis as measured by the number of 
nodes (A, B), junctions (C, D), Meshes (E, F) and isolated segments (G, H). Means are plotted with 
error bars indicating SD. The left column shows the quantification of images taken at six hours and 
the right column indicates the 24-hour time point.  
Figure 8.6: Quantification of Tube Formation After siRNA Knockdown of Integrins 
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Table 8.3 – Statistical Analysis of Tube Formation After siRNA 
 6 hours 24 hours 
 Mean SD N P Mean SD N P 
 Number of Nodes per field of view 
Control 55.25 12.61 3  22.25 8.685 3  
ITGA1 65.48 14.43 3 0.7719 26.21 7.165 3 0.9464 
ITGA2 57.04 14.21 3 0.9993 26.73 7.304 3 0.9205 
ITGA10 58.67 13.15 3 0.9934 24.79 7.752 3 0.9886 
All 49.81 14.02 3 0.9650 26.26 12.06 3 0.9442 
 Number of Junctions per field of view 
Control 16.56 3.852 3  6.759 2.531 3  
ITGA1 19.33 3.878 3 0.8079 7.82 1.862 3 0.9566 
ITGA2 16.78 4.131 3 >0.9999 7.893 2.08 3 0.9462 
ITGA10 16.94 3.677 3 0.9998 7.426 2.132 3 0.9916 
All 14.83 4.302 3 0.9528 7.878 3.568 3 0.9485 
 Number of Meshes per field of view 
Control 5.696 1.042 3  1.207 0.7626 3  
ITGA1 6.422 0.7374 3 0.6788 1.87 0.3699 3 0.6208 
ITGA2 5.423 0.5771 3 0.9822 1.956 0.4904 3 0.5281 
ITGA10 5.794 0.3256 3 0.9997 1.807 0.577 3 0.6909 
All 4.757 1.196 3 0.4840 2.019 1.089 3 0.4636 
 Number of Isolated Segments per field of view 
Control 1.07 0.1091 3  1.233 0.3168 3  
ITGA1 1.019 0.2364 3 0.9795 0.709 0.2174 3 0.2789 
ITGA2 0.9529 0.1778 3 0.7479 0.9074 0.3528 3 0.6461 
ITGA10 0.5481 0.08981 3 0.0057 0.8778 0.2502 3 0.5816 
All 0.8794 0.07973 3 0.3885 0.8185 0.5545 3 0.4600 
One-way ANOVA and Dunnett’s multiple comparisons tests were used to compare the means of each 
condition to the control mean. P values indicating a significant difference and shown in bold 
  
Firstly, the inhibitors TC-I-15 and 6F1 act with immediate effect and impede integrin 
binding just before adding cells to the Geltrex substrate without allowing for the cells to 
compensate in any way. In contrast, siRNA is a much slower process involving gene regulation 
over two to three days, giving the HUVECs time to upregulate other compensatory receptors 
and thus allowing the cells to form tubes adequately in the absence of ITGA2. No upregulation 
of other collagen binding integrins was seen here with ITGA2 KD (Chapter 5.6), but there are 
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many other integrins, as well as non-integrin receptors, that could be upregulated to facilitate 
adhesion, migration and angiogenesis in the absence of α2β1. For example, the αvβ3, αvβ5 
and α5β1 described above would all contribute to angiogenesis and could be upregulated to 
compensate for the loss of ITGA2-mediated adhesion. 
 Secondly, the differences in cell migration in the presence and absence of inhibitors 
and in siRNA KD were witnessed over collagen I substrates. In this setting, collagen-binding 
receptors such as α2β1 and α1β1 play crucial roles in cell behaviours, whereas Geltrex is made 
up of a vast array of basal lamina proteins including laminin, collagen IV, entactin, fibronectin, 
fibrinogen, dynein, desmin, myosin, transferrin and heparin sulphates proteoglycans, as well 
as some low levels of growth factors like bFGF, TGFβ, PDGF, IGF and EGF[192, 193]. The complexity 
of Geltrex will affect the behaviour of ECs. There are many other protein-protein interactions 
taking place in the angiogenesis experiments presented here, that would not be occurring in 
an EC-collagen I interface. For example, laminin receptor like α3β1, α6β1, αvβ3 could all bind 
laminin in Geltrex and facilitate adhesion, promoting angiogenesis[399, 400]. Fibronectin 
receptors like α5β1 have also been implicated in the regulation of angiogenesis[401]. These 
receptors would all be highly active on a Geltrex substrate but not on collagen I, and so can 
compensate for the loss of collagen-binding integrins after siRNA knockdown. Additionally, 
even the low levels of growth factors seen in the growth-factor-reduced Geltrex could be 
affecting numerous signalling pathways to ablate the effects of siRNA KD on HUVEC behaviour.  
 Lastly, there is a difference between inhibition of an existing receptor and the complete 
absence of this receptor. The presence of an non-ligated integrin receptor could signal 
downstream processes that register the cell as ‘not adhered’ whereas the absence of these 
receptors cannot signal their non-ligated state, forcing the cell to instead rely on signals from 
other receptors which are unaffected by siRNA KD. In this case, where there is redundancy in 
function, for example adhesion, the cell may be not sensitive to the lack of α2β1, α1β1 or 
α10β1 at all if there are other signals that mark the cell as adherent and functioning. TC-I-15 
stabilises the inactive conformation of α2β1, and presumably α1β1, and so would result in non-
ligated signals being transduced into the cell. The inactive, non-ligated integrin may actively 
inhibit cell migration and angiogenesis whereas an absent receptor would not.  
 




 TC-I-15 and 6F1 inhibition of α2β1 in HUVECs inhibits tube formation on a Geltrex 
substrate at six-hour time points. This could be partially due to the TC-I-15 and 6F1 mediated 
inhibition of adhesion and migration seen previously in Chapter 7 whereby the HUVECs 
migrated more slowly over collagen substrates. The TC-I-15 treated cells are less capable of 
migrating into the tube formation network and this could explain why the networks were not 
as complex.   
 Conversely, siRNA KD of integrins in HUVECs had no effect on the HUVECs ability to 
form tubes on a Geltrex substrate. This could partially be due to a lack of non-ligated signal 
downstream of the absent receptor. Additionally, the HUVECs could be upregulating other 
receptors involved in adhesion, migration and angiogenesis to compensate for the loss of 
α2β1. While no upregulation of collagen binding integrins was seen with siRNA KD of each 
integrin, other non-integrin or other integrin receptors were not studied in detail downstream 
of integrin siRNA KD.    
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9.1 Chapter Summary 
 In this chapter I aim to summarise my findings with an emphasis on the physiological 
relevance of each finding. 
9.2 Discussion 
 The work described here set out to study and characterise the roles of the four 
collagen-binding integrins (α1β1, α2β1, α10β1 and α11β1) in the regulation of EC behaviour. 
In the literature described in the introduction, α1β1 and α2β1 have both been shown to 
contribute to the regulation of EC proliferation, migration and angiogenesis. This work aims to 
build on this knowledge with the intention of additionally characterising the roles of α10β1 and 
α11β1.  
This project began by studying the binding preferences of the four collagen-binding 
integrins in Chapter 3. The αI-domains of α1β1 and α2β1 were expressed in bacteria as GST-
tagged constructs, by Dr Samir Hamaia, and purified using GST-affinity columns. These 
recombinant αI-domains were tested in static adhesion assays with THPs containing integrin-
binding motifs from the triple helical domains of different collagens. The expression of the 
recombinant α10β1 and α11β1 αI-domains was problematic and no functional proteins were 
recovered. For the αI-domains of α1β1 and α2β1, all adhesion was Mg2+-dependent and no 
non-specific binding was seen in the presence of the metal ion chelator EDTA, implying that 
the observed adhesion was integrin-specific and occurred through the αI-domains functioning 
as in the full-length α-β heterodimer. The αI-domain of α1β1 showed a far more active binding 
profile than that of α2β1 on the collagen peptides tested. The α2β1 αI-domain bound relatively 
few THPs while the αI-domain for α1β1 bound to the majority of THPs. This was unexpected, 
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as the αI-domains of these integrins are proposed to behave similarly due to their high 
homology. Integrins exist in varying states of activation. It is possible that the expression of the 
recombinant αI-domains results in varying states of activation: the recombinant α1β1 αI-
domain may be inadvertently expressed in a more active state whereas the α2β1 αI-domain is 
expressed in a less active state in comparison. There are conformational changes that take 
place in the αI-domain and β1-subunit upon adhesion to collagen and it is possible that the αI-
domains of each integrin, when expressed in this manner, exist in different conformations. This 
would result in varying affinities for these two αI-domains to collagen. Additionally, the β1-
subunit that would be present in the full-length receptor is absent here. The β1-subunit 
interacts with the α-subunit and this interaction could be important for adhesion. It is also 
important to note that these αI-domains are expressed as GST-tagged constructs and GST will 
dimerise[402], resulting in an increased signal. A significant limitation of the work presented here 
is the absence of a GST-only control. This should have been included to rule out binding of the 
GST construct to the peptides. Therefore, the αI-domain adhesion assays are not the best 
method for studying integrin adhesion and it is important to validate findings in full-length 
heterodimers. 
 To study the integrin binding preferences in a more physiologically relevant setting, 
C2C12 cells that express the α-subunit from one of the four integrins were used to test the full-
length receptor adhesion to THPs. C2C12 cells are a mouse myofibroblast cell line and were 
chosen because they do not express any native collagen-binding receptors. Any subsequent 
adhesion to collagen in the transfected cells can be attributed to the transfected integrin α-
subunit . The C2C12 cells have been transfected with one of the integrin α-subunits and these 
associate with the native mouse β1-subunit to form the functional full integrin heterodimer. 
The adhesion profiles of all four integrin receptors on THPs proved to be very similar. 
Similarities were expected, but the extent of homology was surprising. There were three 
peptide motifs that were specific for α2β1 (GNRGER, GNOGER and GKOGER). There were also 
other THPs that were selective for some integrins over others, for example GFQGEK, found in 
collagen IV, bound only to α1β1 and α2β1. GROGER, (found in collagens I, III, VII and X) did not 
bind to α10β1, as described in a publication I co-authored[243]. The homology seen in the 
binding profiles of the four integrins meant that THPs could not be used to ligate each integrin. 
The differences between the adhesion profiles of the I-domains and the full-length receptors 
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for α1β1 and α2β1 can be partially attributed to the absence of the β1-subunit and any 
regulatory function it might serve. Similarly, the rest of the α-subunit is also absent and could 
potentially modulate the function of the αI-domain. 
 The C2C12 adhesion profiles revealed integrin binding motifs are widely distributed 
across the collagens (Table 3.2). The motifs GFOGEK, GFOGER and GLOGEK bound to all 
integrins, these motifs are found in abundance in collagen IV, the main collagen component of 
the EC basal lamina. Collagen IV also contains some α2β1 specific motifs, GAOGER, and 
GSOGEK alongside the selective motifs GFQGEK (α1β1 and α2β1 only), GLKGER (α10β1 and 
α2β1 only) and GLOGEA (not α11β1). Many of the collagen types contain several integrin-
binding motifs. For example, collagen I contains GFOGER and GLOGER (binds all four integrins), 
GKOGER and GMOGER (α2β1 only) and GROGER (binds all but α10β1). Other collagens did not 
contain any of the integrin binding motifs that were tested. The motifs found in collagens VIII, 
XV, XIX, XX, XXIII, XXV and XXVIII did not return any positive binding peptides. However, this 
does not mean that these collagens would not bind integrins through other motifs not 
identified here. This highlights the complexity of the collagen-integrin interactions and the 
abundance of integrin-binding sites found across the collagen family. 
 Next, the mRNA expression profiles of the four collagen-binding integrins were 
explored using qPCR. At the mRNA transcript level, α2β1 was the most abundant transcript by 
far, followed by α10β1, and then α1β1. α11β1 was barely detectable. The low expression of 
α1β1 was surprising as this integrin has been studied in ECs in the literature[157, 160]. Both α1β1 
and α2β1 have been shown to be upregulated by VEGF[156], which is present in EGM2 in low 
levels. Addition of further VEGF did not increase the expression of α1β1 mRNA. Four different 
pools of HUVECs were tested and the results were consistent, confirming that mRNA 
corresponding to α1β1 is expressed in low levels in HUVECs. However, low levels of mRNA do 
not necessarily translate to a non-existent receptor at the protein level and vice versa. It was 
not possible during this project to detect or quantify the presence of these integrins at the 
protein level due to problems with antibody specificity. Therefore, the assumption was made 
that α1β1 and α10β1 are present and functional on the HUVECs’ cell surface and could regulate 
EC behaviour. The endothelial phenotype of HUVECs was characterised using several EC-
specific markers and each pool of HUVECs was found to be positive for VWF, PECAM, CD146 
and VE-Cadherin, confirming that HUVECs used throughout this project are indeed endothelial 
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cells. HUVECs also displayed typical endothelial behaviour. For example, when HUVECs were 
stimulated with TNFα or IL-1α overnight, they increased expression of inflammatory markers 
VCAM, ICAM and E-Selectin. Surprisingly, the addition of LPS at 1μg/ml did not affect the 
expression of inflammatory markers. It is possible that LPS may take longer to induce an 
inflammatory phenotype, or higher concentrations may have been required. 
 The adhesion profile of HUVECs on the collagen THPs is very similar to C2C12 cells 
expressing α2β1. This was expected because α2β1 is the most abundant collagen-binding 
receptor in HUVECs and displays the most active binding profile to THPs. The prevalence of 
α2β1 in HUVECs indicates that this integrin is the main collagen receptor HUVECs, and α2β1-
mediated binding is likely to mask the adhesion of the other integrins. HUVECs showed a 
slightly more active adhesion profile than the C2C12 cells expressing α2β1. In addition to the 
C2C12-α2β1 positive motifs, HUVECs also adhered to GASGER, GHDGEK and GSQGEK. 
Additional attachment to these THPs could be due to a more active conformation of α2β1 in 
HUVECs than in C2C12 cells expressing the α2β1 receptor. HUVECs will also express the human 
β1-subunit whereas C2C12 express a mouse β1-subunit, which could affect the specificity of 
the αI-domain. Lastly, HUVECs could express a number of other receptors or signalling 
molecules that could co-localise with integrins and modulate integrin activity. These might not 
be present in C2C12 cells. 
 Due to the lack of integrin specific motifs in THPs, these could not be used to modulate 
integrin function. Instead, inhibitors for the integrins were sought out and tested. TC-I-15, a 
commercially available α2β1 inhibitor and obtustatin, an α1β1 inhibitor, were characterised 
using I-domains, C2C12 cells, HT1080s and HUVECs. TC-I-15 was promiscuous and inhibited 
adhesion of both α1β1 and α2β1, but not recombinant α3β1 adhesion to collagen, laminin or 
THPs. Meanwhile, obtustatin was found to be specific for α1β1.  Neither TC-I-15 nor obtustatin 
had any effect on the adhesion of αI-domains to THPs, suggesting that the mode of inhibition 
also involves the rest of the receptor. This finding agrees with the literature proposing that TC-
I-15 adheres to the β1-subunit to stabilise the inactive conformation of the αI-domain[2]. 
Obtustatin is proposed to bind to the αI-domain via a KTS motif located within an integrin-
binding motif[4, 255]. However, the isolated αI-domain from α1β1 was unaffected by Obtustatin. 
This suggests that the mode of Obtustatin inhibition might also employ the β1-subunit, or the 
rest of the α-subunit. TC-I-15 also had varying potencies depending on the THP motif used. The 
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THPs may have different affinities for the integrin receptors which could affect the efficacy of 
the receptor. In C2C12 cells expressing ITGA2, TC-I-15 attenuated adhesion on GLOGEN at very 
low concentrations, the IC50 was 0.39μM compared to 26.77μM for GFOGER. This was not seen 
for C2C12 cells expressing ITGA1 where the inhibition of adhesion to GFOGER and GLOGEN 
was similar with IC50s at 23.55μM and 24.43μM respectively. The reason for these differences 
is unclear. α2β1 has a lower affinity for GLOGEN than GFOGER and it is possible that a lower 
concentration is necessary to attenuate adhesion, whereas the affinity for α1β1 to GFOGER 
and GLOGEN is similar, leading to an equally similar mode of inhibition. However, in static 
adhesion assays the C2C12-ITGA1 adhesion to GLOGEN has a lower mean absorbance than for 
GFOGER (1.342 +/- 0.085 compared to 2.116 +/- 0.090) suggesting that there could be a 
difference in affinity here that does not translate to a difference in inhibition by TC-I-15. 
Further studies would be necessary to determine the cause for these differences of TC-I-15 
IC50s in C2C12 cells. Nevertheless, these newly characterised inhibitors were used throughout 
the project to investigate the functions of these integrins in the regulation of EC behaviour as 
measured by changes in proliferation, apoptosis, migration and tube formation.  
 There were no commercially available inhibitors for α10β1 and so a lentiviral CRISPR 
system was created to KO each integrin in HUVECs. However, the transduction efficiencies of 
the lentiviral delivery system were disappointing. Liposomal transfection methods were also 
tested but to no avail. Primary cells cannot be cultured indefinitely, as they lose their 
phenotype and de-differentiate. HUVECs were not used beyond passage 5 in this project. 
Therefore, it would not have been possible to isolate the few successfully transfected cells and 
expand them for use in downstream assays. CRISPR was abandoned due to the low 
transduction and transfection efficiency and siRNA was optimised instead. Using Silencer Select 
siRNAs, 85-90% KDs were achieved for ITGA1, ITGA2 and ITGA10. These KDs were reproducible 
and efficient. The ITGA2 KD was stable over 5 days at the protein level in quantitative western 
blots. Due to problems with antibody cross-reactivity, only ITGA2 could be detected in western 
blots and it was assumed that the ITGA1 and ITGA10 KDs would occur similarly. Downstream 
experiments were all carried out 24-72 hours post siRNA KD.   
 In adhesion assays, both the inhibition of α2β1 and siRNA KD of the ITGA2 transcript 
severely impeded HUVEC attachment to collagen, THPs and laminin, with no effect on the 
adhesion of HUVECs to fibronectin. Inhibition or siRNA KD of α1β1 or α10β1 had no effect on 
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HUVEC adhesion to any substrate tested. This suggests that HUVECs use α2β1 as their main 
collagen and laminin adhesion receptor. Laminin is a major constituent of the endothelial basal 
lamina. Therefore, other endothelial laminin receptors were expected to compensate for the 
loss of α2β1 adhesion, but this was not the case. Although it is outside the scope of this project 
to further investigate laminin receptors, it would be interesting to characterise the expression 
levels of other laminin-binding integrins, such as α3β1 α6β1 α7β1 and α6β4. Additionally, TC-
I-15 inhibition of these receptors could also have been tested. Interestingly, the interaction 
between laminin and α2β1 has been implicated in the progression of endothelial 
quiescence[403].  
 In proliferation assays, none of the inhibitors tested had any effect on the ability of 
HUVECs to proliferate as measured in EdU incorporation assays. This was surprising as there 
are several studies outlining the effects of integrin signalling on cell proliferation[7, 197, 302, 303, 
404]. Similarly, no effect on proliferation was seen after integrin siRNA KD. Cell number 
quantification assays also detected no change in proliferation over 72 hours for each integrin 
siRNA KD condition compared to the negative control siRNA. Although a positive control for 
cell-cycle arrest should have been included. Lastly, Integrin inhibition or siRNA KD also had no 
effect on apoptosis, as measured by Annexin V detection of PS exposed on the membranes of 
apoptotic cells and PI or NIR nuclear labelling of membrane compromised dead cells.  
Adherent cells, such as HUVECs, must attach to the ECM for proliferation to occur. A 
complete loss of attachment will initiate apoptosis. Over the 24-hour experiment, HUVECs did 
adhere to collagen despite integrin inhibition, which could account for the lack of effect on 
proliferation or apoptosis. Perhaps other adhesion pathways compensate for the loss of α1β1 
and α2β1 adhesion seen after inhibition with obtustatin, TC-I-15 or 6F1. Similarly, HUVECs may 
be able to overcome α1β1 and α2β1 inhibition over the 24-hour period to facilitate adhesion 
and subsequent proliferation or cell survival. It is also possible that the HUVECs attach weakly 
to the collagen coated surface and secrete their own ECM proteins, thus allowing them to 
adhere through non-collagen receptors. HUVECs also adhered to BSA coated wells overnight. 
It is possible that the surface coatings are eroded over the 24-hour time period of the 
experiment and that HUVECs are then able to attach to the tissue culture treated surface 
underneath independent of collagen-binding integrins. The collagen structure is also less stable 
at 37°C and the triple helical structure may dissociate over 24 hours at this temperature leading 
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to exposure of other adhesion motifs, like the RGD motif seen in the collagen II and III toolkits. 
These exposed, non-helical sequences may facilitate adhesion of other integrins such as αvβ3, 
which can facilitate EC proliferation. 
  Both integrin inhibition and siRNA KD of α2β1 decreased HUVEC cell spreading and 
migration across collagen I coated surfaces. This was expected as integrin-mediated adhesion 
stabilises the actin cytoskeletal-ECM interaction at membrane protrusions leading to 
decreased actin retrograde flow and increased protrusion in filopodia and lamellipodia[197]. 
When integrins adhere to the ECM they cluster with each other and with other adhesion 
receptors to form adhesion complexes, such as nascent adhesions that eventually mature into 
focal adhesions[194, 252]. These adhesion receptor clusters associate with the actin cytoskeleton 
and contribute to the regulation of actin polymerisation[197]. Integrin-mediated adhesion at the 
leading edge will also facilitate traction between the cell and the ECM which pulls the rest of 
the cell forward, thus promoting cell migration. α2β1 inhibition or KD translated into a 
destabilisation of adhesion in membrane protrusions which ultimately resulted in decreased 
cell spreading and migration. Inhibition or siRNA KD of α1β1 and α10β1, however, did not 
affect adhesion, and subsequent cell spreading or migration, because α2β1 could compensate 
for the loss of the less abundant α1β1 and α10β1 adhesion. Simultaneous KD of all three 
integrins expressed in HUVECs did not add any cumulative inhibition, suggesting that ECs do 
not rely on α1β1 or α10β1 to migrate. 
Inhibition of α2β1 using TC-I-15 or 6F1 reduced the complexity of networks formed in 
tube formation assays, possibly due to the inhibition of α2β1-mediated adhesion and 
subsequent cell migration. Inhibition of α1β1 using Obtustatin led to a significant decrease in 
the number of nodes per field of view. In all other parameters tested, Obtustatin had a small 
but not significant effect. Once again, α2β1-mediated adhesion and migration still present in 
this condition was speculated to be the driving force for tube formation. Obtustatin should also 
be tested in ECs that express higher levels of the α1β1 integrin to study the effects on α1β1 in 
ECs. Conversely, siRNA KD of α2β1 had no effect on tube formation. This could be due to 
upregulation of compensatory receptors in response to integrin absence. The KD of integrins 
using siRNA takes place over several days, which would allow the HUVECs to upregulate any 
compensatory receptors. In contrast, the inhibition of receptors is instantaneous, and this does 
now allow time for the cells to compensate. Additionally, in the presence of inhibitors, the cell 
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could be receiving an active non-ligated signal which conveys the non-adhered state of the cell. 
In the absence of the receptor altogether after siRNA KD, this non-ligated signal would not be 
created. This could affect the downstream processes involved in tube formation, in that 
HUVECs could just rely on other receptors to facilitate adhesion, migration and tube formation. 
Overall, modulation of collagen binding integrins did not affect their ability to 
proliferate or survive in response to TNFα and serum starvation. Inhibition or siRNA KD of α2β1 
resulted in decreased adhesion, migration and cell spreading. Inhibition, but not siRNA KD, of 
α2β1 decreased angiogenesis as measured by tube formation. Inhibition of α1β1 only impaired 
tube formation, while α1β1 KD had no effect on cellular response. The lesser influence of α1β1 
compared to α2β1 can be explained by the lower levels of α1β1 mRNA expression compared 
to α2β1. α10β1 did not seem to play an active role in the regulation of EC behaviour in these 
experiments. However, due to the lack of a specific inhibitor for α10β1, we could not 
thoroughly investigate the impact of α10β1 inhibition on HUVEC behaviour.  
Lastly, the data presented here highlights a role for TC-I-15 in the inhibition of 
endothelial α2β1 to decrease EC migration and angiogenesis. TC-I-15 could have therapeutic 
value in limiting tumour angiogenesis. Further studies should be carried out to characterise the 
effects of TC-I-15 in co-culture experiments or in vivo. Similarly, TC-I-15 could be used to inhibit 
α2β1 on other cell types where this integrin plays a major role in adhesion. For example, TC-I-
15 could be tested on platelets to investigate whether inhibition of platelet α2β1 could have 
therapeutic value in preventing inappropriate platelet adhesion such as that seen in stroke or 
atherosclerosis. With respect to cardiovascular research in general, the work presented here 
contributes to the fundamental understanding of the interactions between ECs and their 
surrounding ECM and highlights the importance of integrin α2β1, but not α1β1 or α10β1, in 
the regulation of EC behaviour. TC-I-15 is shown to be an effective inhibitor of EC migration 
and angiogenesis and α10β1 is shown to be present but ineffective in ECs. The work presented 
here helps to characterise the roles that these collagen-binding integrins play in regulating EC 
behaviour and rules out integrin α10β1 as a potential target for anti-angiogenic therapeutics.  
9.3 Limitations of the Current Work 
 The techniques used in this work were limited due to the difficulty in obtaining specific 
antibodies for targeting the four collagen-binding integrins. Several antibodies were purchased 
and tested but proved to be non-specific, probably due to the high homology seen between 
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these four receptors. C2C12 cells were used to test integrin antibodies for flow cytometry and 
western blots but nearly all the antibodies tested displayed cross-reactivity for the other 
integrin receptors and so could not be used. This highlights the importance of rigorous 
antibody testing before use in downstream experiments.  
 The collagen used here is soluble, meaning it has been digested with pepsin to remove 
the non-helical telopeptides and so exists as single triple helices. In contrast, collagen found in 
the basal lamina would be fibrillar, containing the telopeptide sequences. The tertiary structure 
of fibrillar collagen could behave differently to that of soluble collagen as integrin binding 
motifs could be hidden or revealed in the fibres. Therefore, these experiments do not entirely 
reflect the physiological EC-ECM interaction. 
 With respect to presentation, most of the data shown here is displayed in bar charts 
that show the mean with error bars representing standard deviation. In hindsight, dot plots 
would have been a more informative way of showing this data as they also convey the spread 
of the data by showing each data point. This is especially important when the data obtained 
doesn’t follow a normal distribution.  
 ECs display heterogeneity dependant on the age and gender of the donor and 
cardiovascular diseases are far less prevalent in premenopausal women than in men of the 
same age[405]. For example, reproductive-age women display higher numbers of CEPCs than 
men[406]. A lower number of CEPCs has been linked to a higher prevalence of cardiovascular 
disease because the CEPCs will help regenerate existing vasculature by replacing damaged and 
dysfunctional ECs[99, 407]. Additionally, female CEPCs show better functionality than those found 
in males, due to the EC protecting function of oestrogen[406]. Oestrogen receptors are present 
in ECs and oestrogen encourages increased production and secretion of NO, which contributes 
to a more relaxed vascular tone and decreased atherogenesis[408]. Oestrogen has also been 
shown to promote EC proliferation, migration and angiogenesis (reviewed in[408]). In this work, 
pools of HUVECs obtained from a mixture of male and female donors were chosen to attempt 
to mitigate the effects of gender on EC function. This also means no gender specific effects 
would be picked up here.  
The HUVECs used for the duration of this project were isolated from new-born 
umbilical cords and so no age-dependant characteristics could be studied. Age is a major 
contributor to EC dysfunction and cardiovascular disease, so it is important to also study EC 
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dysfunction in ECs obtained from older patients. ECs undergo constant damage and stress, 
accelerated by unhealthy lifestyle choices, that contribute to EC dysfunction and damage[409]. 
This damage accumulates over time leading to an increase in EC dysfunction and associated 
cardiovascular disease. ECs are also more likely to undergo senescence as time goes on[409]. 
Many factors contribute to the accumulation of damage to the endothelium including oxidative 
stress, decreased NO bioavailability, increased glucose and lipid blood concentrations, 
decreased prostacyclin expression, increased genomic instability and sustained chronic 
inflammation (reviewed in[409]). Oxidative stress can change NO to ONOO-·, which in turn 
irreversibly converts tyrosine to nitrotyrosine, which can be used as a marker for oxidative 
stress; nitrotyrosine is associated with aged arteries[410]. None of these age-related changes 
would be present in HUVECs obtained from new-borns and this must be taken into 
consideration when interpreting data. Understandably, ECs are not as readily available from 
older patients as they are from umbilical cords and HUVECs were chosen in part due to their 
wide-spread use and easy availability. Additionally, it is likely that ECs obtained from adult 
patients could display varying degrees of EC damage and dysfunction related to the lifestyle of 
the donor, resulting in less reproducible data. In conclusion, neither gender nor age-specific 
conditions could be studied in the scope of this project. 
Migration was quantified as track displacement, which is an oversimplification of 
migration distance. This is the linear distance, in μm, between the starting point of the cell in 
the first frame of a time lapse video and the end point of the same cell in the last frame of the 
video. HUVEC migration did not occur in a linear straight line and the cells tended to move 
around randomly, back and forth, in these experiments. Track displacement does not measure 
this back-and-forth movement and therefore may not be an accurate measurement of cell 
migration. Track displacement may underestimate the migration of many cells and it’s possible 
that bigger differences would be seen in these experiments if total track length was quantified 
instead. Additionally, ECs exist in monolayers surrounding the blood vessels and are generally 
quiescent and non-migratory unless stimulated by chemoattractants such as VEGF, therefore 
it would have been more physiologically relevant to track the migration of EC monolayers in 
response to a VEGF gradient in chemotaxis assays. The optimisation of these chemotaxis assays 
was started but, due to time constraints, was not completed.  
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 The tube formation assays performed here are used as a measure of angiogenesis but 
bear little resemblance to physiological angiogenesis which occurs in a 3D matrix alongside 
other cell types. Tube formation is a simplification of this process and as such, the tubes may 
not form a lumen. There is no blood flow and no shear stress, which has been shown to 
regulate EC differentiation. Additionally, fibroblasts have been reported to form networks on 
Matrigel. The tube formation assays carried out for this project are therefore an indicator of 
HUVECs’ angiogenic potential, but do not provide a complete measure of angiogenesis. To truly 
measure angiogenesis, in vivo assays must be carried out and these were outside the scope of 
this project. 
 Finally, ECs exist in a monolayer that lines blood vessels. None of the experiments here 
were carried out using EC monolayers and so care must be taken when extrapolating this data 
to physiological settings. The cell-cell interactions seen in monolayers are important in 
maintaining the barrier function of ECs. This barrier function varies depending on the type and 
location of the ECs in question. For example, blood-brain barrier ECs will have a much more 
stringent barrier function than ECs found in the liver or kidney as solutes that pass into the 
brain must be restricted. However, using a monolayer of HUVECs would require ECs to reach 
confluency before experiments. In standard cell culture conditions this is generally not 
recommended as cell-cell contacts induce quiescence. Comparisons between confluent and 
non-confluent ECs could be tested to investigate this. 
9.4 Future Work 
 If more time was available, other EC characteristics could have been explored. For 
example, the barrier function of ECs is integral to their function. Studies exploring the effects 
of integrin inhibition or siRNA KD on the permeability of EC monolayers could also be carried 
out. ECs grown to confluence on collagen coated semi-permeable membranes would be 
probed for any increases in permeability using fluorescently tagged high molecular weight 
dextran molecules. A range of different collagens could be used in future experiments. For 
example, fibrillar collagens or 3D collagen scaffolds could be used as a better approximation of 
physiological settings. 
 Chemotaxis experiments using VEGF, bFGF and other chemoattractants could also be 
carried out. All future migration experiments should quantify total cell migration rather than 
the track displacement, as this is a more accurate measure of cell movement across a 
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substrate. Additionally, co-cultures of ECs with VSMCs or pericytes imbedded in collagen 
scaffolds or gels would include the interactions between different cell types in a 3D setting, 
creating a more physiologically relevant environment. 
 Lastly, the compensation that may be taking place to facilitate the tube formation seen 
with integrin KD would be investigated. The effects of integrin KD on the expression of other 
ECM adhesion receptors will be tested using qPCR, RNA sequencing and quantitative western 
blots to determine which, if any, receptors are up or downregulated in response to a loss of 
integrin signalling.  
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